B7-H1, a third member of the B7 family, co-stimulates T secretion

Nature Medicine

5, 1365-1369

DOI: 10.1038/70932

Citation Report

#	Article	IF	Citations
1	T-cell stimulation: an abundance of B7s. Nature Medicine, 1999, 5, 1345-1346.	15.2	58
2	Developmental seizures induced by common early-life insults: Short- and long-term effects on seizure susceptibility. Mental Retardation and Developmental Disabilities Research Reviews, 2000, 6, 253-257.	3.5	63
3	Epilepsy genes: The link between molecular dysfunction and pathophysiology. Mental Retardation and Developmental Disabilities Research Reviews, 2000, 6, 281-292.	3.5	13
4	Long-term consequences of early postnatal seizures on hippocampal learning and plasticity. European Journal of Neuroscience, 2000, 12, 2252-2264.	1.2	165
5	Costimulatory wars: the tumor menace. Current Opinion in Immunology, 2000, 12, 589-596.	2.4	69
6	What is GABAergic Inhibition? How Is it Modified in Epilepsy?. Epilepsia, 2000, 41, S90-S95.	2.6	104
7	T cells: A proliferation of costimulatory molecules. Current Biology, 2000, 10, R227-R230.	1.8	45
8	4-1BB: Still in the Midst of Darkness. Molecules and Cells, 2000, 10, 119-126.	1.0	60
9	Costimulation ofâ€‰ T cells by B7-H2, a B7-like molecule that binds ICOS. Blood, 2000, 96, 2808-2813.	0.6	236
10	Hyperthermic Spreading Depressions in the Immature Rat Hippocampal Slice. Journal of Neurophysiology, 2000, 84, 1355-1360.	0.9	59
11	Selective Depolarization of Interneurons in the Early Posttraumatic Dentate Gyrus: Involvement of the Na⁺/K⁺-ATPase. Journal of Neurophysiology, 2000, 83, 2916-2930.	0.9	119
12	Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 2000, 192, 1027-1034.	4.2	4,394
13	Costimulation of T Cells. American Journal of Respiratory and Critical Care Medicine, 2000, 162, S164-S168.	2.5	63
14	The B7/CD28/CTLA4 T-Cell Activation Pathway. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 261-264.	1.4	41
15	Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. International Immunology, 2000, 12, 1439-1447.	1.8	126
16	Neuronal activity and stress differentially regulate hippocampal and hypothalamic corticotropin-releasing hormone expression in the immature rat. Neuroscience, 2000, 101, 571-580.	1.1	51
17	Cytokines in airway inflammation. International Journal of Biochemistry and Cell Biology, 2000, 32, 833-853.	1.2	25
18	Soluble CD86 Is a Costimulatory Molecule for Human T Lymphocytes. Immunity, 2000, 13, 303-312.	6.6	114

#	Article	IF	Citations
19	Cell fate decision: T-helper 1 and 2 subsets in immune responses. Arthritis Research, 2000, 2, 179.	2.0	113
20	T lymphocyte costimulatory molecules in host defense and immunologic diseases. Annals of Allergy, Asthma and Immunology, 2000, 85, 164-176.	0.5	6
21	Dendritic cell-related immunoregulation: signals and mediators. , 2001, , 51-cp2.		2
22	Identification of an Alternatively Spliced Variant of Human CD86 mRNA. Biochemical and Biophysical Research Communications, 2001, 280, 1211-1215.	1.0	9
23	Human ERMAP: An Erythroid Adhesion/Receptor Transmembrane Protein. Blood Cells, Molecules, and Diseases, 2001, 27, 938-949.	0.6	24
24	Costimulation of Memory T-Cells by ICOS: A Potential Therapeutic Target for Autoimmunity?. Clinical Immunology, 2001, 100, 263-269.	1.4	29
25	Overview of the Current Animal Models for Human Seizure and Epileptic Disorders. Epilepsy and Behavior, 2001, 2, 201-216.	0.9	153
26	The Cluster of BTN Genes in the Extended Major Histocompatibility Complex. Genomics, 2001, 71, 351-362.	1.3	129
27	ICOS Ligand Costimulation Is Required for T-Cell Encephalitogenicity. Clinical Immunology, 2001, 100, 277-288.	1.4	73
28	Suppression of immune surveillance in melanoma. Medical Hypotheses, 2001, 56, 648-652.	0.8	16
29	The expanding world of co-stimulation: the two-signal model revisited. Trends in Immunology, 2001, 22, 217-223.	2.9	180
30	The effects of GABAB receptor activation on spontaneous and evoked activity in the dentate gyrus of kainic acid-treated rats. Neuropharmacology, 2001, 40, 193-202.	2.0	21
31	PATHOGENESIS OF RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America, 2001, 27, 317-334.	0.8	96
32	Manipulation of costimulatory pathways in autoimmune diseases. Modern Rheumatology, 2001, 11, 184-191.	0.9	1
33	Costimulatory Molecules in T Cell Activation. , 2001, 31, 217-221.		0
34	Kindling, Neural Basis of. , 2001, , 8094-8098.		0
35	The process of epileptogenesis: a pathophysiological approach. Current Opinion in Neurology, 2001, 14, 187-192.	1.8	175
36	T-lymphocyte coactivator molecules. Current Opinion in Hematology, 2001, 8, 5-11.	1.2	18

#	Article	IF	Citations
37	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood, 2001, 97, 1809-1816.	0.6	201
38	RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-Î°B. Blood, 2001, 97, 2702-2707.	0.6	59
39	Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood, 2001, 97, 2750-2757.	0.6	79
40	Dendritic cells and immunotherapy for malignant disease. British Journal of Haematology, 2001, 112, 874-887.	1.2	58
41	Maturational Aspects of Epilepsy Mechanisms and Consequences for the Immature Brain. Epilepsia, 2001, 42, 577-585.	2.6	181
42	Resistance of immature hippocampus to morphologic and physiologic alterations following status epilepticus or kindling. Hippocampus, 2001, 11, 615-625.	0.9	150
43	Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Annals of Neurology, 2001, 50, 366-372.	2.8	131
44	Long-term hyperexcitability in the hippocampus after experimental head trauma. Annals of Neurology, 2001, 50, 708-717.	2.8	225
45	Annotated References by Year. , 2001, , 651-770.		0
46	Systematic review of the role of prostaglandins and their synthetase inhibitors with respect to febrile seizures. Epilepsy Research, 2001, 46, 251-257.	0.8	16
48	The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nature Immunology, 2001, 2, 203-209.	7.0	372
49	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology, 2001, 2, 261-268.	7.0	2,504
50	B7-H3: A costimulatory molecule for T cell activation and IFN-Î³ production. Nature Immunology, 2001, 2, 269-274.	7.0	856
51	Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunology, 2001, 2, 725-731.	7.0	1,145
52	Development and applications of surface-linked single chain antibodies against T-cell antigens. Journal of Immunological Methods, 2001, 248, 77-90.	0.6	25
53	B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo. Journal of Experimental Medicine, 2001, 194, 1339-1348.	4.2	111
54	B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells. Journal of Experimental Medicine, 2001, 193, 839-846.	4.2	794
55	Functional Expression of a Costimulatory B7.2 (CD86) Protein on Human Salivary Gland Epithelial Cells that Interacts with the CD28 Receptor, but Has Reduced Binding to CTLA4. Journal of Immunology, 2001, 166, 3107-3113.	0.4	83

#	Article	IF	Citations
56	Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production. International Immunology, 2001, 13, 181-191.	1.8	24
57	CD4+CD25high Regulatory Cells in Human Peripheral Blood. Journal of Immunology, 2001, 167, 1245-1253.	0.4	1,655
58	IL-3 Induces B7.2 (CD86) Expression and Costimulatory Activity in Human Eosinophils. Journal of Immunology, 2001, 167, 6097-6104.	0.4	49
59	RANTES Potentiates Antigen-Specific Mucosal Immune Responses. Journal of Immunology, 2001, 166, 162-169.	0.4	108
60	Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice. Journal of Immunology, 2001, 166, 5578-5584.	0.4	43
61	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13866-13871.	3.3	732
62	Assessing the behavioral and cognitive effects of seizures on the developing brain. Progress in Brain Research, 2002, 135, 377-390.	0.9	76
63	Targeting T cell costimulation in autoimmune disease. Expert Opinion on Therapeutic Targets, 2002, 6, 275-289.	1.5	46
64	Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 1393-1398.	4.2	96
65	Animal Models for Febrile Seizures. , 2002, , 189-201.		5
66	Expression of Programmed Death 1 Ligands by Murine T Cells and APC. Journal of Immunology, 2002, 169, 5538-5545.	0.4	831
67	A Novel Costimulation Pathway Via the 4C8 Antigen for the Induction of CD4+ Regulatory T Cells. Journal of Immunology, 2002, 169, 3710-3716.	0.4	28
68	B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis. Journal of Immunology, 2002, 169, 3581-3588.	0.4	300
69	Inducible Costimulator Costimulates Cytotoxic Activity and IFN-Î³ Production in Activated Murine NK Cells. Journal of Immunology, 2002, 169, 3676-3685.	0.4	72
70	Programmed Death-1 Targeting Can Promote Allograft Survival. Journal of Immunology, 2002, 169, 6546-6553.	0.4	219
71	Immunomodulatory Effects of Antigen-Pulsed Macrophages in a Murine Model of Allergic Asthma. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 257-264.	1.4	24
72	Is neuronal death required for seizure-induced epileptogenesis in the immature brain?. Progress in Brain Research, 2002, 135, 365-375.	0.9	45
73	Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity. Journal of Immunology, 2002, 168, 4914-4919.	0.4	153

#	Article	IF	Citations
74	Basic Electrophysiology of Febrile Seizures. , 2002, , 231-247.		1
75	CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function. Journal of Experimental Medicine, 2002, 195, 1407-1418.	4.2	96
76	New concepts in neonatal seizures. NeuroReport, 2002, 13, A3-A8.	0.6	86
77	Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood, 2002, 99, 3326-3334.	0.6	106
78	Do occasional brief seizures cause detectable clinical consequences?. Progress in Brain Research, 2002, 135, 221-235.	0.9	20
79	A Cell-Based Artificial Antigen-Presenting Cell Coated with Anti-CD3 and CD28 Antibodies Enables Rapid Expansion and Long-Term Growth of CD4 T Lymphocytes. Clinical Immunology, 2002, 105, 259-272.	1.4	84
80	THEB7 FAMILY OFLIGANDS ANDITSRECEPTORS: New Pathways for Costimulation and Inhibition of Immune Responses. Annual Review of Immunology, 2002, 20, 29-53.	9.5	792
81	The Combination of Chemotherapy and Systemic Immunotherapy and the Concept of Cure in Murine Leukemia and Lymphoma. Leukemia and Lymphoma, 2002, 43, 2075-2082.	0.6	6
82	Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. Journal of the American Academy of Dermatology, 2002, 47, 692-700.	0.6	36
83	H-channels in epilepsy: new targets for seizure control?. Trends in Pharmacological Sciences, 2002, 23, 552-557.	4.0	39
84	Mossy cells in epilepsy: rigor mortis or vigor mortis?. Trends in Neurosciences, 2002, 25, 140-144.	4.2	135
85	Cognitive Outcome of Febrile Seizures. , 2002, , 53-61.		6
86	T cells and aging january 2002 update. Frontiers in Bioscience - Landmark, 2002, 7, d1056-1183.	3.0	347
87	B7 Family Molecules: Novel Immunomodulators at the Maternal-Fetal Interface. Placenta, 2002, 23, S95-S101.	0.7	101
88	Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. , 2002, 94, 185-211.		63
89	T-cell activation: a multidimensional signaling network. Current Opinion in Cell Biology, 2002, 14, 575-580.	2.6	69
90	PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. European Journal of Immunology, 2002, 32, 634.	1.6	612
91	Hyperthermia induces age-dependent changes in rat hippocampal excitability. Annals of Neurology, 2002, 52, 318-326.	2.8	43

#	Article	IF	Citations
92	Negative co-receptors on lymphocytes. Current Opinion in Immunology, 2002, 14, 391-396.	2.4	152
93	New regulatory co-receptors: inducible co-stimulator and PD-1. Current Opinion in Immunology, 2002, 14, 779-782.	2.4	221
94	T cell-mediated immune responses in melanoma: implications for immunotherapy. Critical Reviews in Oncology/Hematology, 2002, 43, 1-11.	2.0	26
95	Epileptogenesis During Development: Injury, Circuit Recruitment, and Plasticity. Epilepsia, 2002, 43, 47-53.	2.6	23
96	Keeping Pace with Pacemaker Channels. Epilepsy Currents, 2002, 2, 155-156.	0.4	0
97	Childhood febrile convulsionsâ€"which factors determine the subsequent epilepsy syndrome? A retrospective study. Epilepsy Research, 2002, 50, 283-292.	0.8	39
98	Microanatomical localization of PD-1 in human tonsils. Immunology Letters, 2002, 83, 215-220.	1.1	69
99	The pathogenesis of febrile seizures: Is there a role for specific infections?. Reviews in Medical Virology, 2002, 12, 93-106.	3.9	23
100	Protect the killer: CTLs need defenses against the tumor. Nature Medicine, 2002, 8, 787-789.	15.2	22
101	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 2002, 8, 793-800.	15.2	4,217
102	The B7â€"CD28 superfamily. Nature Reviews Immunology, 2002, 2, 116-126.	10.6	1,513
103	Spinning molecular immunology into successful immunotherapy. Nature Reviews Immunology, 2002, 2, 227-238.	10.6	341
104	Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney International, 2002, 62, 1291-1300.	2.6	66
105	ANTIGENPRESENTATION ANDT CELLSTIMULATION BYDENDRITICCELLS. Annual Review of Immunology, 2002, 20, 621-667.	9.5	1,577
106	Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation. Immunologic Research, 2003, 28, 49-60.	1.3	32
107	MOLECULARMECHANISMSREGULATINGTH1 IMMUNERESPONSES. Annual Review of Immunology, 2003, 21, 713-758.	9.5	839
108	Immunology of B7-H1 and Its Roles in Human Diseases. International Journal of Hematology, 2003, 78, 321-328.	0.7	34
109	B7-H1 pathway and its role in the evasion of tumor immunity. Journal of Molecular Medicine, 2003, 81, 281-287.	1.7	249

#	Article	IF	Citations
110	Mossy fiber plasticity and enhanced hippocampal excitability, without hippocampal cell loss or altered neurogenesis, in an animal model of prolonged febrile seizures. Hippocampus, 2003, 13, 399-412.	0.9	160
111	Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. European Journal of Immunology, 2003, 33, 2773-2782.	1.6	119
112	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. European Journal of Immunology, 2003, 33, 2706-2716.	1.6	551
113	Gabapentin Increases the Hyperpolarizationâ€activated Cation Current I h in Rat CA1 Pyramidalâ€ƒCells. Epilepsia, 2003, 44, 150-156.	2.6	117
114	T-cell costimulatory pathways in allograft rejection and tolerance. Immunological Reviews, 2003, 196, 85-108.	2.8	202
115	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunology, 2003, 4, 670-679.	7.0	768
116	Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cellâ€“dependent B cell responses. Nature Immunology, 2003, 4, 765-772.	7.0	185
117	The B7 family member B7-H3 preferentially down-regulates T helper type 1â€“mediated immune responses. Nature Immunology, 2003, 4, 899-906.	7.0	479
118	Blockade of B7-H1 improves myeloid dendritic cellâ€“mediated antitumor immunity. Nature Medicine, 2003, 9, 562-567.	15.2	1,157
119	Temporal Lobe Epileptogenesis and Epilepsy in the Developing Brain: Bridging the Gap Between the Laboratory and the Clinic. Progression, But in What Direction?. Epilepsia, 2003, 44, 51-59.	2.6	45
120	DOES THEIMMUNESYSTEMSEETUMORS ASFOREIGN ORSELF?. Annual Review of Immunology, 2003, 21, 807-839.	9.5	688
121	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Allergy and Clinical Immunology, 2003, 112, 837-849.	1.5	50
122	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. Journal of Experimental Medicine, 2003, 198, 851-862.	4.2	1,002
123	B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1. Biology of Reproduction, 2003, 68, 1496-1504.	1.2	189
124	BTLA: a new inhibitory receptor with a B7-like ligand. Trends in Immunology, 2003, 24, 524-527.	2.9	83
125	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. Journal of Experimental Medicine, 2003, 198, 63-69.	4.2	697
126	Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochemical and Biophysical Research Communications, 2003, 307, 672-677.	1.0	181
127	Informatics and the immune system: the expanding IL-1 and B7 protein families. Seminars in Immunology, 2003, 15, 225-231.	2.7	2

#	Article	IF	Citations
128	B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation. Immunity, 2003, 18, 863-873.	6.6	386
129	B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity. Immunity, 2003, 18, 849-861.	6.6	623
130	Long-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures. Neuron, 2003, 39, 599-611.	3.8	189
131	Regulation of immune and autoimmune responses by ICOS. Journal of Autoimmunity, 2003, 21, 255-260.	3.0	86
132	Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation. Journal of Immunology, 2003, 171, 4156-4163.	0.4	163
133	B7DC/PDL2 Promotes Tumor Immunity by a PD-1â€“independent Mechanism. Journal of Experimental Medicine, 2003, 197, 1721-1730.	4.2	130
134	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. Journal of Experimental Medicine, 2003, 197, 1083-1091.	4.2	259
135	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5336-5341.	3.3	536
136	Human muscle cells express a B7â€related molecule, B7â€H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB Journal, 2003, 17, 1-16.	0.2	95
137	B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy. Journal of Immunology, 2003, 170, 3637-3644.	0.4	242
138	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. Journal of Experimental Medicine, 2003, 198, 31-38.	4.2	144
139	Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-Î³-Dependent Mechanism. Journal of Immunology, 2003, 171, 1272-1277.	0.4	305
140	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2003, 198, 71-78.	4.2	461
141	PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver. Journal of Experimental Medicine, 2003, 198, 39-50.	4.2	353
142	B7x: A widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10388-10392.	3.3	362
143	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. Journal of Immunology, 2003, 170, 1257-1266.	0.4	842
144	Molecular Biology and Ontogeny of Î³-Aminobutyric Acid (GABA) Receptors in the Mammalian Central Nervous System. Journal of Child Neurology, 2003, 18, 39-48.	0.7	53
145	Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-Dependent Mechanism. Journal of Immunology, 2003, 171, 6929-6935.	0.4	100

#	Article	IF	Citations
146	Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells. Journal of Immunology, 2003, 171, 4574-4581.	0.4	99
147	Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family. Journal of Immunology, 2003, 171, 4650-4654.	0.4	233
148	Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses. Journal of Immunology, 2003, 170, 711-718.	0.4	248
149	The global transcriptional maturation program and stimuli-specific gene expression profiles of human myeloid dendritic cells. International Immunology, 2003, 15, 491-503.	1.8	50
150	Evaluation of Inducible Costimulator/B7-Related Protein-1 as a Therapeutic Target in a Murine Model of Allergic Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 722-730.	1.4	37
151	Keratinocytes Induce Local Tolerance to Skin Graft by Activating Interleukin-10â€“Secreting T Cells in the Context of Costimulation Molecule B7-H11. Transplantation, 2003, 75, 1390-1396.	0.5	28
152	BOOSTING T CELL COSTIMULATION IN CANCER: THE POSSIBILITIES SEEM ENDLESS. International Reviews of Immunology, 2003, 22, 173-194.	1.5	10
153	Role of novel T-cell costimulatory pathways in transplantation. Current Opinion in Organ Transplantation, 2003, 8, 25-33.	0.8	0
154	Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys1. Transplantation, 2003, 75, 2106-2113.	0.5	39
155	Impaired germinal center formation and recall T-cellâ€“dependent immune responses in mice lacking the costimulatory ligand B7-H2. Blood, 2003, 102, 1381-1388.	0.6	72
156	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood, 2003, 101, 2514-2520.	0.6	157
157	Microarray analysis of lipopolysaccharide-treated human neutrophils. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L663-L670.	1.3	74
158	Impact of Heterogeneous Perisomatic IPSC Populations on Pyramidal Cell Firing Rates. Journal of Neurophysiology, 2004, 91, 2849-2858.	0.9	20
159	Genetic Susceptibility and Immunological Synapse in Type 1 Diabetes and Thyroid Autoimmune Disease. Experimental and Clinical Endocrinology and Diabetes, 2004, 112, 407-415.	0.6	15
160	PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. International Immunology, 2004, 17, 133-144.	1.8	413
161	B7-H1-targeted immunotherapy for head and neck cancer. Expert Opinion on Biological Therapy, 2004, 4, 1577-1583.	1.4	3
162	Induction of Tolerance by Porphyromonas gingivalis on APCs: a Mechanism Implicated in Periodontal Infection. Journal of Dental Research, 2004, 83, 429-433.	2.5	39
163	The genetic basis of systemic lupus erythematosus--knowledge of today and thoughts for tomorrow. Human Molecular Genetics, 2004, 13, 143R-148.	1.4	49

#	Article	IF	Citations
164	Murine B7-H3 Is a Negative Regulator of T Cells. Journal of Immunology, 2004, 173, 2500-2506.	0.4	299
165	Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8RÎ² interactions. Journal of Leukocyte Biology, 2004, 76, 1240-1247.	1.5	4
166	Human Recombinant B7-H3 Expressed in <italic>E. coli</italic> Enhances T Lymphocyte Proliferation and IL-10 Secretion <italic>in Vitro</italic>. Acta Biochimica Et Biophysica Sinica, 2004, 36, 430-436.	0.9	25
167	B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clinical Cancer Research, 2004, 10, 5094-5100.	3.2	633
168	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17174-17179.	3.3	723
169	Refolding and Characterization of Recombinant Human GST-PD-1 Fusion Protein Expressed in Escherichia coli. Acta Biochimica Et Biophysica Sinica, 2004, 36, 141-146.	0.9	9
170	B7-DC Regulates Asthmatic Response by an IFN-Î³-Dependent Mechanism. Journal of Immunology, 2004, 172, 2530-2541.	0.4	136
171	B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells. Journal of Immunology, 2004, 173, 5445-5450.	0.4	163
172	Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2057-2062.	1.1	88
173	Schistosoma mansoni Worms Induce Anergy of T Cells via Selective Up-Regulation of Programmed Death Ligand 1 on Macrophages. Journal of Immunology, 2004, 173, 1240-1248.	0.4	180
174	Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine. Journal of Immunology, 2004, 173, 4919-4928.	0.4	111
175	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. Journal of Immunology, 2004, 173, 945-954.	0.4	989
176	Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains. Journal of Immunology, 2004, 172, 2352-2359.	0.4	228
177	The Ability of Two Listeria monocytogenes Vaccines Targeting Human Papillomavirus-16 E7 to Induce an Antitumor Response Correlates with Myeloid Dendritic Cell Function. Journal of Immunology, 2004, 172, 6030-6038.	0.4	45
178	Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway. Journal of Immunology, 2004, 172, 5774-5781.	0.4	24
179	PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. Cancer Research, 2004, 64, 1140-1145.	0.4	679
180	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10691-10696.	3.3	556
181	Accessory cell function of airway epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L318-L331.	1.3	32

#	Article	IF	Citations
182	Epithelial responses in airway inflammation and immunity. Clinical and Experimental Allergy Reviews, 2004, 4, 176-182.	0.3	6
183	NBQX or Topiramate Treatment after Perinatal Hypoxia-induced Seizures Prevents Later Increases in Seizure-induced Neuronal Injury. Epilepsia, 2004, 45, 569-575.	2.6	132
184	Co-inhibitory molecules of the B7â€“CD28 family in the control of T-cell immunity. Nature Reviews Immunology, 2004, 4, 336-347.	10.6	1,110
185	Functional and phenotypic variations in human T cells subjected to retroviral-mediated gene transfer. Gene Therapy, 2004, 11, 474-482.	2.3	10
186	Interferon-Î² enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Journal of Neuroimmunology, 2004, 155, 172-182.	1.1	249
187	Fever, genes, and epilepsy. Lancet Neurology, The, 2004, 3, 421-430.	4.9	179
188	New B7 Family Members with Positive and Negative Costimulatory Function. American Journal of Transplantation, 2004, 4, 8-14.	2.6	33
189	Inducible-costimulator-mediated suppression of human immunodeficiency virus type 1 replication in CD4+ T lymphocytes. Virology, 2004, 325, 252-263.	1.1	8
190	On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochemical Pharmacology, 2004, 68, 1691-1698.	2.0	175
191	PD-1 ligands, negative regulators for activation of naÃ¯ve, memory, and recently activated human CD4+ T cells. Cellular Immunology, 2004, 230, 89-98.	1.4	64
192	Immunology of Pregnancy: Implications for the Mother. Clinical Reviews in Allergy and Immunology, 2004, 26, 161-170.	2.9	117
193	Reflections on CD8 T-Cell Activation and Memory. Immunologic Research, 2004, 29, 151-160.	1.3	50
194	Regulation of Recombinant and Native Hyperpolarization-Activated Cation Channels. Molecular Neurobiology, 2004, 30, 279-306.	1.9	48
195	The role of ICOS and other costimulatory molecules in allergy and asthma. Seminars in Immunopathology, 2004, 25, 349-359.	4.0	53
196	Costimulation-based immunotherapy for head and neck cancer. Current Treatment Options in Oncology, 2004, 5, 27-33.	1.3	12
197	Diversity beyond variance: modulation of firing rates and network coherence by GABAergic subpopulations. European Journal of Neuroscience, 2004, 19, 119-130.	1.2	29
198	Paradoxical role of programmed death-1 ligand?2 in Th2 immune responsesin vitro and in a mouse asthma modelin vivo. European Journal of Immunology, 2004, 34, 3326-3336.	1.6	47
199	Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. European Journal of Immunology, 2004, 34, 2089-2099.	1.6	90

#	Article	IF	Citations
200	Commentary: Regulated equilibrium between opposite signals: a general paradigm for Tâ€„cell function?. European Journal of Immunology, 2004, 34, 2084-2088.	1.6	10
201	Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology, 2004, 40, 1312-1321.	3.6	277
202	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes and Infection, 2004, 6, 759-766.	1.0	112
203	Microparticulate Î²-glucan upregulates the expression of B7.1, B7.2, B7-H1, but not B7-DC on cultured murine peritoneal macrophages. Immunology Letters, 2004, 93, 71-78.	1.1	21
204	The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunology Letters, 2004, 94, 215-222.	1.1	67
205	The regulation of lymphocyte activation by inhibitory receptors. Current Opinion in Immunology, 2004, 16, 328-336.	2.4	90
206	New Advances and Potential Therapies for the Treatment of Asthma. BioDrugs, 2004, 18, 211-223.	2.2	20
207	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes and Infection, 2004, , .	1.0	0
208	The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology, 2004, 126, 1347-1357.	0.6	141
209	Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clinical Immunology, 2004, 111, 28-37.	1.4	40
210	The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone, 2004, 35, 1059-1068.	1.4	28
211	Cognitive impairment following status epilepticus and recurrent seizures during early development: support for the â€œtwo-hit hypothesisâ€• Epilepsy and Behavior, 2004, 5, 873-877.	0.9	38
212	Plasticity of interneuronal species diversity and parameter variance in neurological diseases. Trends in Neurosciences, 2004, 27, 504-510.	4.2	38
213	Cooperative translational control of gene expression by Ras and Akt in cancer. Trends in Molecular Medicine, 2004, 10, 607-613.	3.5	51
214	Altered GABAB receptor immunoreactivity in the gerbil hippocampus induced by baclofen and phaclofen, not seizure activity. Neuroscience Research, 2004, 49, 405-416.	1.0	10
215	B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes. Immunity, 2004, 20, 327-336.	6.6	352
216	Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. Immunity, 2004, 20, 337-347.	6.6	331
217	The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity. Immunity, 2004, 20, 529-538.	6.6	202

#	Article	IF	Citations
218	Requirement for CD28 in the Effector Phase of Allergic Airway Inflammation. Journal of Immunology, 2004, 173, 632-640.	0.4	23
219	Shaping Phenotype, Function, and Survival of Dendritic Cells by Cytomegalovirus-Encoded IL-10. Journal of Immunology, 2004, 173, 3383-3391.	0.4	122
220	Programmed death-1â€“programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation, 2004, 77, 6-12.	0.5	34
221	Suppressed T-cell activation by IFN-Â-induced expression of PD-L1 on renal tubular epithelial cells. Nephrology Dialysis Transplantation, 2004, 19, 2713-2720.	0.4	84
222	Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood, 2004, 103, 1747-1754.	0.6	99
223	In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood, 2004, 104, 2124-2133.	0.6	156
224	B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. NeuroReport, 2005, 16, 1081-1085.	0.6	93
225	Role of Mossy Fiber Sprouting and Mossy Cell Loss in Hyperexcitability: A Network Model of the Dentate Gyrus Incorporating Cell Types and Axonal Topography. Journal of Neurophysiology, 2005, 93, 437-453.	0.9	240
226	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood, 2005, 105, 13-21.	0.6	276
227	NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood, 2005, 105, 2428-2435.	0.6	112
228	The Many Sounds of T Lymphocyte Silence. Immunologic Research, 2005, 33, 135-148.	1.3	7
229	Existence and Theoretical Aspects of Homomeric and Heteromeric Dopamine Receptor Complexes and Their Relevance for Neurological Diseases. NeuroMolecular Medicine, 2005, 7, 061-078.	1.8	21
230	THE B7 FAMILY REVISITED. Annual Review of Immunology, 2005, 23, 515-548.	9.5	2,104
231	Gender Differences in Febrile Seizure-induced Proliferation and Survival in the Rat Dentate Gyrus. Epilepsia, 2005, 46, 1603-1612.	2.6	58
232	Febrile Convulsions Induced by the Combination of Lipopolysaccharide and Low-dose Kainic Acid Enhance Seizure Susceptibility, Not Epileptogenesis, in Rats. Epilepsia, 2005, 46, 1898-1905.	2.6	60
233	Rearranging Receptors. Epilepsia, 2005, 46, 29-38.	2.6	51
234	Changes of Cortical Interhemispheric Responses after Status Epilepticus in Immature Rats. Epilepsia, 2005, 46, 31-37.	2.6	6
235	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney International, 2005, 68, 2091-2102.	2.6	44

#	Article	IF	Citations
236	Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression analysis of 2IgB7-H3 on dendritic cells and tumor cells. Tissue Antigens, 2005, 66, 83-92.	1.0	31
237	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. British Journal of Haematology, 2005, 130, 809-824.	1.2	46
238	Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease. Clinical and Experimental Allergy, 2005, 35, 1521-1534.	1.4	18
239	Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clinical and Experimental Immunology, 2005, 139, 189-201.	1.1	38
240	Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer, 2005, 5, 263-274.	12.8	1,858
241	PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes and Immunity, 2005, 6, 430-437.	2.2	42
242	Epileptiform activity triggers long-term plasticity of GABABreceptor signalling in the developing rat hippocampus. Journal of Physiology, 2005, 568, 951-966.	1.3	9
243	Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain1. Acta Pharmacologica Sinica, 2005, 26, 462-468.	2.8	59
244	The B7/CD28 costimulatory family in autoimmunity. Immunological Reviews, 2005, 204, 128-143.	2.8	129
245	Alternative splice variants of the human PD-1 gene. Cellular Immunology, 2005, 235, 109-116.	1.4	171
246	Time courses of B7 family molecules expressed on activated T-cells and their biological significance. Cellular Immunology, 2005, 236, 146-153.	1.4	26
247	Antagonism between MyD88- and TRIF-dependent signals in B7RP-1 up-regulation. European Journal of Immunology, 2005, 35, 1918-1927.	1.6	18
248	Switching from a restricted to an effective CD4 Tâ€„cell response by activating CD8+ murine dendritic cells with a Toll-like receptorâ€„9 ligand. European Journal of Immunology, 2005, 35, 3209-3220.	1.6	9
249	Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. European Journal of Immunology, 2005, 35, 3545-3560.	1.6	28
250	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer, 2005, 104, 2084-2091.	2.0	166
251	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology, 2005, 58, 50-57.	2.8	203
252	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunology, Immunotherapy, 2005, 54, 307-314.	2.0	509
253	Dendritic cell-mediated T cell polarization. Seminars in Immunopathology, 2005, 26, 289-307.	4.0	296

#	Article	IF	Citations
254	The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine, 2005, 83, 193-202.	1.7	69
255	Mini-I on Epilepsy. Focus on â€œChanges in mIPSCs and sIPSCs After Kainate Treatment: Evidence for Loss of Inhibitory Input to Dentate Granule Cells and Possible Compensatory Responsesâ€. Journal of Neurophysiology, 2005, 94, 903-904.	0.9	2
256	Immune Modulations. , 2005, , 475-490.		0
257	Immunity at the Maternal-Fetal Interface. , 2005, , 1735-1745.		1
258	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Frontiers in Bioscience - Landmark, 2005, 10, 2856.	3.0	55
259	Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 3408-3415.	0.4	164
260	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1747-1767.	1.8	56
261	Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer. Clinical Cancer Research, 2005, 11, 2947-2953.	3.2	714
262	In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. Journal of Experimental Medicine, 2005, 201, 1531-1541.	4.2	140
263	Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 280-289.	1.4	129
264	PD-1/PD-L pathway and autoimmunity. Autoimmunity, 2005, 38, 353-357.	1.2	85
265	Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-Î³-Induced Nitric Oxide Production. Journal of Immunology, 2005, 175, 1586-1592.	0.4	129
266	Prevention of Experimental Autoimmune Encephalomyelitis by Transfer of Embryonic Stem Cell-Derived Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein Peptide along with TRAIL or Programmed Death-1 Ligand. Journal of Immunology, 2005, 174, 1888-1897.	0.4	122
267	Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 6648-6656.	0.4	139
268	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. Journal of Neuroscience, 2005, 25, 2537-2546.	1.7	150
269	Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia. Clinical Cancer Research, 2005, 11, 5708-5717.	3.2	111
270	Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential. Journal of Immunology, 2005, 174, 4706-4717.	0.4	94
271	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. Journal of Immunology, 2005, 175, 7372-7379.	0.4	122

#	Article	IF	Citations
272	A critical role for the programmed death ligand 1 in fetomaternal tolerance. Journal of Experimental Medicine, 2005, 202, 231-237.	4.2	375
273	The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling. Advances in Immunology, 2005, 87, 163-208.	1.1	218
274	Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells. International Immunopharmacology, 2005, 5, 1446-1457.	1.7	22
275	Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. Biochemical and Biophysical Research Communications, 2005, 330, 263-270.	1.0	40
276	PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clinical Immunology, 2005, 115, 184-191.	1.4	86
277	B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). FEBS Letters, 2005, 579, 6259-6264.	1.3	35
278	Effects of Seizures on Brain Development: Lessons from the Laboratory. Pediatric Neurology, 2005, 33, 1-11.	1.0	134
279	The h-channel: A potential channelopathy in epilepsy?. Epilepsy and Behavior, 2005, 7, 51-56.	0.9	34
280	Multiple facets of GABAergic neurons and synapses: multiple fates of GABA signalling in epilepsies. Trends in Neurosciences, 2005, 28, 108-115.	4.2	292
281	Impaired and repaired inhibitory circuits in the epileptic human hippocampus. Trends in Neurosciences, 2005, 28, 334-340.	4.2	185
282	Various Costimulatory Pathways Are Essential for Induction of Regulatory Cells by Intratracheal Delivery of Alloantigen. Transplantation Proceedings, 2005, 37, 1934-1936.	0.3	8
283	B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology, 2005, 66, 10-14.	0.5	48
284	Immunologic aspect of ovarian cancer and p53 as tumor antigen. Journal of Translational Medicine, 2005, 3, 34.	1.8	31
285	IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. Journal of Dermatological Science, 2005, 40, 95-103.	1.0	112
286	Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Research and Therapy, 2006, 8, R163.	1.6	70
287	Checkpoint Blockade in Cancer Immunotherapy. Advances in Immunology, 2006, 90, 297-339.	1.1	498
288	Immunology of Pregnancy. , 2006, , .		11
289	The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors. Neoplasia, 2006, 8, 190-198.	2.3	505

#	Article	IF	Citations
290	Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opinion on Biological Therapy, 2006, 6, 63-72.	1.4	10
291	Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine, 2006, 203, 883-895.	4.2	1,042
292	Mechanisms of Immune Evasion by Tumors. Advances in Immunology, 2006, 90, 51-81.	1.1	580
293	Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochemica, 2006, 108, 19-24.	0.9	446
294	Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clinical Immunology, 2006, 118, 258-267.	1.4	55
295	Characterization of rebound depolarization in hippocampal neurons. Biochemical and Biophysical Research Communications, 2006, 348, 1343-1349.	1.0	25
296	No cancer in cancers: Evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. Medical Hypotheses, 2006, 66, 888-897.	0.8	21
297	PD-L1 is induced in hepatocytes by viral infection and by interferon-Î± and -Î³ and mediates T cell apoptosis. Journal of Hepatology, 2006, 45, 520-528.	1.8	331
298	Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. Journal of Hepatology, 2006, 45, 468-472.	1.8	46
299	Triptolide inhibits B7-H1 expression on proinflammatory factor activated renal tubular epithelial cells by decreasing NF-ÎºB transcription. Molecular Immunology, 2006, 43, 1088-1098.	1.0	25
300	Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends in Molecular Medicine, 2006, 12, 244-246.	3.5	30
301	Immune Accessory Functions of Human Endothelial Cells Are Modulated by Overexpression of B7-H1 (PDL1). Human Immunology, 2006, 67, 568-578.	1.2	25
302	The PD-1â€“PD-L pathway in immunological tolerance. Trends in Immunology, 2006, 27, 195-201.	2.9	632
303	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics, 2006, 88, 841-845.	1.3	12
304	Acute Seizures and Status Epilepticus. , 2006, , 81-124.		1
305	CD4+PD-1+T Cells Acting as Regulatory Cells during the Induction of Anterior Chamber-Associated Immune Deviation. , 2006, 47, 4444.		40
306	Immunobiology of Human Pregnancy. , 2006, , 2759-2785.		8
307	Interferon-Î³-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood, 2006, 107, 2570-2577.	0.6	290

#	Article	IF	Citations
309	Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance. Cell Transplantation, 2006, 15, 105-119.	1.2	65
310	Suppression of Human T-Cell Responses to Î²-Cells by Activation of B7-H4 Pathway. Cell Transplantation, 2006, 15, 399-410.	1.2	41
311	Selective impairment of GABAergic synaptic transmission in the flurothyl model of neonatal seizures. European Journal of Neuroscience, 2006, 23, 1559-1566.	1.2	58
312	Decrease of Hippocampal GABAB Receptor-Mediated Inhibition after Hyperthermia-induced Seizures in Immature Rats. Epilepsia, 2006, 47, 277-287.	2.6	36
313	Decreased IH in Hippocampal Area CA1 Pyramidal Neurons after Perinatal Seizure-inducing Hypoxia. Epilepsia, 2006, 47, 1023-1028.	2.6	38
314	B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. Journal of Viral Hepatitis, 2006, 13, 725-733.	1.0	32
315	PD-1 blockade: rescue from a near-death experience. Nature Immunology, 2006, 7, 227-228.	7.0	25
316	Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006, 439, 682-687.	13.7	3,471
317	Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells. Kidney International, 2006, 70, 2092-2099.	2.6	23
318	CD28 and ICOS: Similar or separate costimulators of T cells?. Immunology Letters, 2006, 105, 115-122.	1.1	63
319	Adverse psychiatric effects of antiepileptic drugs. Epilepsy Research, 2006, 68, 67-69.	0.8	20
320	Placenta-Derived Multipotent Cells Exhibit Immunosuppressive Properties That Are Enhanced in the Presence of Interferon-Î³. Stem Cells, 2006, 24, 2466-2477.	1.4	246
321	Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer and Metastasis Reviews, 2006, 25, 333-356.	2.7	163
322	Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. Medical Microbiology and Immunology, 2006, 195, 125-132.	2.6	7
323	The role of leukemia-derived B7-H1 (PD-L1) in tumorâ€“T-cell interactions in humans. Experimental Hematology, 2006, 34, 888-894.	0.2	47
324	Escape from immune- and nonimmune-mediated tumor surveillance. Seminars in Cancer Biology, 2006, 16, 16-31.	4.3	58
325	Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncology, 2006, 42, 268-274.	0.8	86
326	Significance of B7-H1 Overexpression in Kidney Cancer. Clinical Genitourinary Cancer, 2006, 5, 206-211.	0.9	35

#	Article	IF	Citations
327	No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. European Journal of Immunology, 2006, 36, 1104-1113.	1.6	45
328	PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. European Journal of Immunology, 2006, 36, 58-64.	1.6	78
329	Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. European Journal of Immunology, 2006, 36, 2472-2482.	1.6	164
330	In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology, 2006, 44, 1171-1181.	3.6	145
331	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro. International Journal of Cancer, 2006, 119, 317-327.	2.3	276
332	HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. International Journal of Cancer, 2006, 118, 2657-2664.	2.3	79
333	Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway. Journal of Neuroscience Research, 2006, 84, 370-378.	1.3	205
334	Highâ€level expression of B7â€H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergenâ€primed animals. Journal of Leukocyte Biology, 2006, 79, 686-695.	1.5	35
335	Complex Febrile Seizuresâ€"An Experimental Model in Immature Rodents. , 2006, , 333-340.		9
336	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3480-3489.	0.4	122
337	Trophoblast CD274 (B7-H1) Is Differentially Expressed Across Gestation: Influence of Oxygen Concentration1. Biology of Reproduction, 2006, 74, 352-358.	1.2	60
338	Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice. Molecular and Cellular Biology, 2006, 26, 6403-6411.	1.1	72
339	B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts. Journal of Immunology, 2006, 177, 5928-5935.	0.4	190
340	Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. Cancer Research, 2006, 66, 3381-3385.	0.4	788
341	Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments. Immunological Investigations, 2006, 35, 395-418.	1.0	14
342	Expression of B7-H1 in Inflammatory Renal Tubular Epithelial Cells. Nephron Experimental Nephrology, 2006, 102, e81-e92.	2.4	39
343	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. Cancer Research, 2006, 66, 2442-2450.	0.4	129
344	Regulation of T cell activation and tolerance by PDL2. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11695-11700.	3.3	151

#	Article	IF	Citations
345	B7H1-Ig Fusion Protein Activates the CD4+ IFN-Î³ Receptor+ Type 1 T Regulatory Subset through IFN-Î³-Secreting Th1 Cells. Journal of Immunology, 2006, 177, 3606-3614.	0.4	34
346	Soluble Form of T Cell Ig Mucin 3 Is an Inhibitory Molecule in T Cell-Mediated Immune Response. Journal of Immunology, 2006, 176, 1411-1420.	0.4	111
347	Expression of B7-H1 on Gastric Epithelial Cells: Its Potential Role in Regulating T Cells during Helicobacter pylori Infection. Journal of Immunology, 2006, 176, 3000-3009.	0.4	162
348	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3360-3365.	3.3	1,308
349	Prognostic biomarkers in renal cell carcinoma. Expert Review of Molecular Diagnostics, 2007, 7, 293-307.	1.5	6
350	BTNL2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule Modulated in Intestinal Inflammation. Journal of Immunology, 2007, 178, 1523-1533.	0.4	116
351	Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells. Journal of Immunology, 2007, 178, 5552-5562.	0.4	223
352	Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine. Journal of Immunology, 2007, 179, 2860-2869.	0.4	65
353	PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver. Journal of Immunology, 2007, 178, 2714-2720.	0.4	214
354	Expression of PD-1, PD-L1, and PD-L2 in the Liver in Autoimmune Liver Diseases. American Journal of Gastroenterology, 2007, 102, 302-312.	0.2	69
355	T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity. Current Cancer Drug Targets, 2007, 7, 55-70.	0.8	43
356	Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. International Immunology, 2007, 19, 881-890.	1.8	11
357	Costimulation, Coinhibition and Cancer. Current Cancer Drug Targets, 2007, 7, 15-30.	0.8	86
358	Protease Inhibitorâ€“Associated Increased Risk of Preterm Delivery Is an Immunological Complication of Therapy. Journal of Infectious Diseases, 2007, 195, 914-916.	1.9	28
359	Master switches of T-cell activation and differentiation. European Respiratory Journal, 2007, 29, 804-812.	3.1	38
360	The Function of Donor versus Recipient Programmed Death-Ligand 1 in Corneal Allograft Survival. Journal of Immunology, 2007, 179, 3672-3679.	0.4	101
361	Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 1749-1756.	3.2	99
362	Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8 + T Cells Associated with Reversible Immune Dysfunction. Journal of Virology, 2007, 81, 9249-9258.	1.5	346

#	Article	IF	Citations
363	B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B. Journal of Immunology, 2007, 178, 6634-6641.	0.4	118
364	Effects of Specific Immunotherapy on the B7 Family of Costimulatory Molecules in Allergic Inflammation. Journal of Immunology, 2007, 178, 1931-1937.	0.4	16
365	Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy. Clinical Cancer Research, 2007, 13, 709s-715s.	3.2	191
366	Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. Clinical Cancer Research, 2007, 13, 2151-2157.	3.2	783
367	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19458-19463.	3.3	336
368	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-Î³ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 2007, 110, 296-304.	0.6	546
369	DC-HIL is a negative regulator of T lymphocyte activation. Blood, 2007, 109, 4320-4327.	0.6	109
370	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood, 2007, 110, 180-185.	0.6	209
371	Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune Responses. Transplantation, 2007, 83, 774-782.	0.5	112
372	The New B7s: Playing a Pivotal Role in Tumor Immunity. Journal of Immunotherapy, 2007, 30, 251-260.	1.2	178
373	Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections. Current Opinion in HIV and AIDS, 2007, 2, 219-227.	1.5	17
374	Fever, febrile seizures and epilepsy. Trends in Neurosciences, 2007, 30, 490-496.	4.2	196
375	Neuropeptide Y: Potential role in recurrent developmental seizures. Peptides, 2007, 28, 441-446.	1.2	14
376	Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunobiology, 2007, 212, 159-165.	0.8	26
377	Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity, 2007, 27, 111-122.	6.6	1,464
378	PD-L1 (B7-H1) regulation in zones of axonal degeneration. Neuroscience Letters, 2007, 425, 156-161.	1.0	22
379	PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology, 2007, 19, 813-824.	1.8	1,064
380	Plasmacytoid dendritic cells prime IL-10â€“producing T regulatory cells by inducible costimulator ligand. Journal of Experimental Medicine, 2007, 204, 105-115.	4.2	569

#	Article	IF	Citations
382	The B7 Family and Cancer Therapy: Costimulation and Coinhibition. Clinical Cancer Research, 2007, 13, 5271-5279.	3.2	308
384	Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. , 2007, , 257-275.		0
386	Immune Escape: Immunosuppressive Networks. , 2007, , 83-97.		2
387	Acquired Epilepsy: Cellular and Molecular Mechanisms. , 2007, , 347-370.		3
388	Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. Journal of Clinical Investigation, 2007, 117, 2974-2982.	3.9	174
389	Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape. , 2007, , 333-346.		0
390	Modification of the tumor microenvironment to enhance immunity. Frontiers in Bioscience - Landmark, 2007, 12, 3576.	3.0	43
391	Transplant tolerance through costimulation blockade - are we there yet?. Frontiers in Bioscience - Landmark, 2007, 12, 2935.	3.0	6
392	Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. International Journal of Cancer, 2007, 121, 751-758.	2.3	132
393	Programmed cell deathâ€„1 (PDâ€1) and its ligand PDâ€L1 are required for allograft tolerance. European Journal of Immunology, 2007, 37, 2983-2990.	1.6	68
394	Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology, 2008, 47, 296-305.	3.6	242
395	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer, 2007, 109, 1499-1505.	2.0	392
396	The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nature Immunology, 2007, 8, 239-245.	7.0	1,286
397	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 2007, 13, 84-88.	15.2	1,177
398	No evidence of association between genetic variants of the PDCD1 ligands and SLE. Genes and Immunity, 2007, 8, 69-74.	2.2	16
399	Absence of Cutaneous TNFÎ±-Producing CD4+ T Cells and TNFÎ± may Allow for Fibrosis Rather than Epithelial Cytotoxicity in Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma. Journal of Investigative Dermatology, 2007, 127, 1905-1914.	0.3	18
400	PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens, 2007, 69, 19-27.	1.0	68
401	Characterization and application of three novel monoclonal antibodies against human 4â€1BB: distinct epitopes of human 4â€1BB on lung tumor cells and immune cells. Tissue Antigens, 2007, 70, 470-479.	1.0	17

#	Article	IF	Citations
402	Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model. Xenotransplantation, 2007, 14, 243-248.	1.6	14
403	Age-Dependent Consequences of Status Epilepticus: Animal Models. Epilepsia, 2007, 48, 75-82.	2.6	45
404	Are Psychiatric Adverse Events of Antiepileptic Drugs a Unique Entity? A Study on Topiramate and Levetiracetam. Epilepsia, 2007, 48, 2322-2326.	2.6	96
405	Epileptogenesis in the Developing Brain: What Can We Learn from Animal Models?. Epilepsia, 2007, 48, 2-6.	2.6	50
406	From Tâ€cell activation signals to signaling control of antiâ€cancer immunity. Immunological Reviews, 2007, 220, 151-168.	2.8	69
407	Intrahepatic expression of the coâ€stimulatory molecules programmed deathâ€1, and its ligands in autoimmune liver disease. Pathology International, 2007, 57, 485-492.	0.6	54
408	Inhibitory costimulation and anti-tumor immunity. Seminars in Cancer Biology, 2007, 17, 288-298.	4.3	27
409	Immune suppression in renal cell carcinoma. Seminars in Cancer Biology, 2007, 17, 330-343.	4.3	35
410	The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. Journal of Neuroimmunology, 2007, 185, 75-86.	1.1	63
411	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunology, Immunotherapy, 2007, 56, 1173-1182.	2.0	413
412	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunology, Immunotherapy, 2007, 56, 739-745.	2.0	412
413	Polymorphisms of Genes for Programmed Cell Death 1 Ligands in Patients with Rheumatoid Arthritis. Journal of Clinical Immunology, 2007, 27, 563-567.	2.0	15
414	Hyperthermia-Induced Seizures Modify the GABAA and Benzodiazepine Receptor Binding in Immature Rat Brain. Cellular and Molecular Neurobiology, 2007, 27, 211-227.	1.7	14
415	Modulating Co-Stimulation. Neurotherapeutics, 2007, 4, 666-675.	2.1	8
416	TLR-mediated induction of negative regulatory ligands on dendritic cells. Journal of Molecular Medicine, 2008, 86, 443-455.	1.7	30
417	Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. Journal of Ocular Biology, Diseases, and Informatics, 2008, 1, 94-100.	0.2	56
418	Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. Journal of Neural Transmission, 2008, 115, 1501-1511.	1.4	50
419	B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1021-1027.	1.2	112

#	Article	IF	Citations
420	Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers. Cancer, 2008, 113, 450-460.	2.0	83
421	B7â€H1 restricts neuroantigenâ€specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. European Journal of Immunology, 2008, 38, 1734-1744.	1.6	72
422	PDâ€1 ligands expressed on myeloidâ€derived APC in the CNS regulate Tâ€cell responses in EAE. European Journal of Immunology, 2008, 38, 2706-2717.	1.6	103
423	Prognostic factors and selection for clinical studies of patients with kidney cancer. Critical Reviews in Oncology/Hematology, 2008, 65, 235-262.	2.0	73
424	Changes of cortical epileptic afterdischarges after status epilepticus in immature rats. Epilepsy Research, 2008, 78, 178-185.	0.8	6
425	PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 2008, 26, 677-704.	9.5	4,462
426	Biology of dendritic cells. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2008, 2, 296-311.	0.3	1
427	Signaling defects in antiâ€tumor T cells. Immunological Reviews, 2008, 222, 192-205.	2.8	91
428	Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological Reviews, 2008, 222, 180-191.	2.8	591
429	Cell intrinsic mechanisms of Tâ€cell inhibition and application to cancer therapy. Immunological Reviews, 2008, 224, 141-165.	2.8	207
430	Fine-Tuned Expression of Programmed Death 1 Ligands in Mature Dendritic Cells Stimulated by CD40 Ligand Is Critical for the Induction of an Efficient Tumor Specific Immune Response. Cellular and Molecular Immunology, 2008, 5, 33-39.	4.8	9
431	A critical role of IFNÎ³ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research, 2008, 18, 846-857.	5.7	355
432	Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 2008, 8, 467-477.	10.6	1,399
433	Cytogenesis in the dentate gyrus after neonatal hyperthermiaâ€induced seizures: What becomes of surviving cells?. Epilepsia, 2008, 49, 853-860.	2.6	20
434	PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transplant International, 2008, 21, ???-???.	0.8	40
435	Programmed death-1 ligands-transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response. Clinical and Experimental Immunology, 2007, 151, 86-93.	1.1	8
436	Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection. Immunology, 2008, 123, 90-99.	2.0	47
437	Soluble CD276 (B7â€H3) is released from monocytes, dendritic cells and activated TÂcells and is detectable in normal human serum. Immunology, 2008, 123, 538-546.	2.0	143

#	Article	IF	Citations
438	Microenvironment of the murine mammary carcinoma 4T1: Endogenous IFN-Î³ affects tumor phenotype, growth, and metastasis. Experimental and Molecular Pathology, 2008, 85, 174-188.	0.9	42
439	FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 2008, 8, 57.	1.1	178
440	Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clinical Immunology, 2008, 128, 306-313.	1.4	13
441	PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: Restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clinical Immunology, 2008, 129, 132-144.	1.4	63
442	B7-H1 on Hepatocytes Facilitates Priming of Specific CD8 T Cells But Limits the Specific Recall of Primed Responses. Gastroenterology, 2008, 135, 980-988.	0.6	36
443	Effects of interferon-Î² on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-Î² treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 166-176.	1.4	45
445	Trophoblast Immune Receptors in Maternal-Fetal Tolerance. Immunological Investigations, 2008, 37, 395-426.	1.0	36
447	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. Journal of Hepatology, 2008, 48, 548-558.	1.8	113
448	The complex role of B7 molecules in tumor immunology. Trends in Molecular Medicine, 2008, 14, 550-559.	3.5	84
449	Donor bone marrow cells play a role in the prevention of accelerated graft rejection induced by semi-allogeneic spleen cells in transplantation. Transplant Immunology, 2008, 18, 330-337.	0.6	1
450	Molecular markers for predicting prognosis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 113-124.	0.8	36
451	Choosing the Correct Antiepileptic Drugs: From Animal Studies to the Clinic. Pediatric Neurology, 2008, 38, 151-162.	1.0	31
452	Hyperpolarization activated cyclic-nucleotide gated (HCN) channels in developing neuronal networks. Progress in Neurobiology, 2008, 86, 129-140.	2.8	68
453	The Dialect of Immune System in the CNS: The Nervous Tissue as an Immune Compartment for T Cells and Dendritic Cells. , 2008, , 197-221.		0
454	Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Letters, 2008, 268, 98-109.	3.2	126
455	B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochemical and Biophysical Research Communications, 2008, 365, 170-175.	1.0	47
456	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet, The, 2008, 372, 145-154.	6.3	312
457	Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1â€“IgV. Cytotherapy, 2008, 10, 711-719.	0.3	16

#	Article	IF	Citations
458	B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence. Journal of Urology, 2008, 179, 1954-1960.	0.2	58
459	TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells. Cancer Investigation, 2008, 26, 816-821.	0.6	90
460	Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatology, 2008, 47, 1335-1341.	0.9	72
461	Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis. Journal of Immunology, 2008, 180, 7506-7515.	0.4	89
462	Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis. Journal of Immunology, 2008, 181, 116-125.	0.4	234
463	The Role of Negative Costimulators During Parasitic Infections. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 279-288.	0.6	11
464	Cross-Linking of B7-H1 on EBV-Transformed B Cells Induces Apoptosis through Reactive Oxygen Species Production, JNK Signaling Activation, and fasL Expression. Journal of Immunology, 2008, 181, 6158-6169.	0.4	32
465	T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival. Clinical Cancer Research, 2008, 14, 4800-4808.	3.2	238
466	Tumor-Induced Immune Suppression ofIn vivoEffector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor Î². Cancer Research, 2008, 68, 5432-5438.	0.4	66
467	Protective Role of Programmed Death 1 Ligand 1 (PD-L1)in Nonobese Diabetic Mice. Diabetes, 2008, 57, 1861-1869.	0.3	73
468	The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3011-3016.	3.3	357
469	The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungusHistoplasma capsulatum. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2658-2663.	3.3	107
470	PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes. Journal of Immunology, 2008, 180, 7553-7557.	0.4	52
472	Expression and Function of PDCD1 at the Human Maternal-Fetal Interface1. Biology of Reproduction, 2008, 79, 562-569.	1.2	79
473	High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. Journal of Immunology, 2008, 181, 8215-8225.	0.4	114
474	Two Quantitative Trait Loci Influence Whipworm(Trichuris trichiura)Infection in a Nepalese Population. Journal of Infectious Diseases, 2008, 197, 1198-1203.	1.9	36
475	The Programmed Death-1 and Interleukin-10 Pathways Play a Down-Modulatory Role in LP-BM5 Retrovirus-Induced Murine Immunodeficiency Syndrome. Journal of Virology, 2008, 82, 2456-2469.	1.5	16
477	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008, 111, 3635-3643.	0.6	438

#	Article	IF	Citations
478	Transplantation of NIT-1 Cells Expressing pD-L1 for Treatment of Streptozotocin-Induced Diabetes. Transplantation, 2008, 86, 1596-1602.	0.5	12
479	The Use of the Inhibitory Receptors for Modulating the Immune Responses. Current Pharmaceutical Design, 2008, 14, 2643-2650.	0.9	20
481	PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro. , 2008, 49, 2518.		105
482	Human Corneal Endothelial Cells Expressing Programmed Death-Ligand 1 (PD-L1) Suppress PD-1⁺T Helper 1 Cells by a Contact-Dependent Mechanism. , 2009, 50, 263.		65
483	B7-H3 and its relevance in cancer; immunological and non-immunological perspectives. Frontiers in Bioscience - Elite, 2009, E3, 989.	0.9	0
485	PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation. , 2009, 50, 273.		78
486	Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. Journal of Immunology, 2009, 183, 4984-4993.	0.4	83
487	Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010). Expert Review of Dermatology, 2009, 4, 199-210.	0.3	11
488	How Diverse--CD4 Effector T Cells and their Functions. Journal of Molecular Cell Biology, 2009, 1, 20-36.	1.5	152
489	Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 971-979.	3.2	725
490	Dominant Human CD8 T Cell Clonotypes Persist Simultaneously as Memory and Effector Cells in Memory Phase. Journal of Immunology, 2009, 182, 6718-6726.	0.4	18
491	B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro-Oncology, 2009, 11, 757-766.	0.6	80
492	B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2741-2746.	3.3	67
493	PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination. Journal of Immunology, 2009, 182, 980-987.	0.4	126
494	Teleost B7 Expressed on Monocytes Regulates T Cell Responses. Journal of Immunology, 2009, 182, 6799-6806.	0.4	49
496	Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. Human Reproduction, 2009, 24, 3160-3171.	0.4	63
497	Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. International Journal of Oncology, 2009, 35, 741-9.	1.4	68
498	Inhibitors of B7â€“CD28 costimulation in urologic malignancies. Immunotherapy, 2009, 1, 129-139.	1.0	10

#	Article	IF	Citations
499	Intrahepatic PD-1/PD-L1 Up-regulation Closely Correlates with Inflammation and Virus Replication in Patients with Chronic HBV Infection. Immunological Investigations, 2009, 38, 624-638.	1.0	46
500	Production of Antibodies against Multipass Membrane Proteins Expressed in Human Tumor Cells Using Dendritic Cell Immunization. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-9.	3.0	13
501	Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. Journal of Experimental Medicine, 2009, 206, 1327-1337.	4.2	764
502	PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients. Journal of Immunology, 2009, 182, 5240-5249.	0.4	158
503	T-Cell Suppression by Programmed Cell Death 1 Ligand 1 on Retinal Pigment Epithelium during Inflammatory Conditions. , 2009, 50, 2862.		77
504	Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiology of Disease, 2009, 36, 343-351.	2.1	102
505	Differentiation-Induced Post-Transcriptional Control of B7-H1 in Human Trophoblast Cells. Placenta, 2009, 30, 48-55.	0.7	16
506	Immune escape mechanisms of intraocular tumors. Progress in Retinal and Eye Research, 2009, 28, 329-347.	7.3	91
507	Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer, 2009, 9, 463.	1.1	127
508	Febrile seizures: Mechanisms and relationship to epilepsy. Brain and Development, 2009, 31, 366-371.	0.6	163
509	Register-based studies on febrile seizures in Denmark. Brain and Development, 2009, 31, 372-377.	0.6	60
510	Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. Cellular Immunology, 2009, 258, 161-171.	1.4	15
511	Interferonâ€Î³ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumorâ€associated macrophages. International Journal of Cancer, 2009, 125, 367-373.	2.3	262
512	B7â€H3 is a potent inhibitor of human Tâ€cell activation: No evidence for B7â€H3 and TREML2 interaction. European Journal of Immunology, 2009, 39, 1754-1764.	1.6	231
513	The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. European Journal of Immunology, 2009, 39, 1536-1543.	1.6	24
514	B7â€H1 and CD8⁺ Treg: The enigmatic role of B7â€H1 in peripheral tolerance. European Journal of Immunology, 2009, 39, 1448-1451.	1.6	9
515	Interaction of B7â€H1 on intrahepatic cholangiocarcinoma cells with PDâ€1 on tumorâ€infiltrating T cells as a mechanism of immune evasion. Journal of Surgical Oncology, 2009, 100, 500-504.	0.8	107
516	Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. Journal of Cancer Research and Clinical Oncology, 2009, 135, 379-386.	1.2	35

#	Article	IF	Citations
518	Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance. Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29, 77-79.	1.0	36
519	Role of ocular pigment epithelial cells in immune privilege. Archivum Immunologiae Et Therapiae Experimentalis, 2009, 57, 263-268.	1.0	78
520	Negative regulators of Tâ€cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunological Reviews, 2009, 229, 67-87.	2.8	150
521	PDâ€1 signaling in primary T cells. Immunological Reviews, 2009, 229, 114-125.	2.8	655
522	Yinâ€“Yang of costimulation: crucial controls of immune tolerance and function. Immunological Reviews, 2009, 229, 88-100.	2.8	138
523	Costimulatory and coinhibitory receptors in antiâ€tumor immunity. Immunological Reviews, 2009, 229, 126-144.	2.8	246
524	B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leukemia Research, 2009, 33, 948-957.	0.4	37
525	Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. European Journal of Cancer, 2009, 45, 1664-1672.	1.3	129
526	Human iris pigment epithelial cells suppress T-cell activation via direct cell contact. Experimental Eye Research, 2009, 89, 358-364.	1.2	9
527	Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. Journal of Molecular and Cellular Cardiology, 2009, 46, 169-176.	0.9	68
528	Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Molecular Immunology, 2009, 46, 375-383.	1.0	24
529	Immune barriers to successful gene therapy. Trends in Molecular Medicine, 2009, 15, 32-39.	3.5	48
530	Exposure of developing well-nourished and malnourished rats to environmental heating facilitates cortical spreading depression propagation at adulthood. Neuroscience Letters, 2009, 454, 218-222.	1.0	2
531	Hyperpolarization-Activated Cation Channels: From Genes to Function. Physiological Reviews, 2009, 89, 847-885.	13.1	868
532	Inhibition of TGFÎ²1 Makes Nonimmunogenic Tumor Cells Effective for Therapeutic Vaccination. Journal of Immunotherapy, 2009, 32, 232-239.	1.2	12
533	Molecular Mechanisms of Immune Suppressive Microenvironment in the Cornea. Cornea, 2009, 28, S58-S64.	0.9	3
534	Suppression of Human T-Cell Activation and Expansion of Regulatory T Cells by Pig Cells Overexpressing PD-Ligands. Transplantation, 2009, 87, 975-982.	0.5	39
535	Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. NeuroReport, 2009, 20, 1597-1602.	0.6	37

#	Article	IF	Citations
536	Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege. Transplantation, 2009, 87, 1778-1786.	0.5	60
537	Febrile Seizures: Current Views and Investigations. Canadian Journal of Neurological Sciences, 2009, 36, 679-686.	0.3	44
538	PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood, 2009, 113, 5811-5818.	0.6	179
539	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, 2009, 114, 1545-1552.	0.6	354
540	Programmed Death-1 Signaling Is Essential for the Skin Allograft Protection by Alternatively Activated Dendritic Cell Infusion in Mice. Transplantation, 2009, 88, 864-873.	0.5	22
541	Beyond IL-17: new cytokines in the pathogenesis of HIV infection. Current Opinion in HIV and AIDS, 2010, 5, 184-188.	1.5	12
542	B7-H1 Expression in Vestibular Schwannomas. Otology and Neurotology, 2010, 31, 991-997.	0.7	26
543	Interferon-Î³ and tumor necrosis factor-Î± induce an immunoinhibitory molecule, B7-H1, via nuclear factor-Î°B activation in blasts in myelodysplastic syndromes. Blood, 2010, 116, 1124-1131.	0.6	179
544	Psychotropic Effects of Anticonvulsant Drugs in Patients with Epilepsy. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S3285.	0.4	0
545	Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule. Hybridoma, 2010, 29, 153-160.	0.5	7
546	Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunology, Immunotherapy, 2010, 59, 1163-1171.	2.0	141
547	The role of dendritic cells in CNS autoimmunity. Journal of Molecular Medicine, 2010, 88, 535-544.	1.7	70
548	Receptors and ligands implicated in human T cell costimulatory processes. Immunology Letters, 2010, 128, 89-97.	1.1	59
549	HCN-related channelopathies. Pflugers Archiv European Journal of Physiology, 2010, 460, 405-415.	1.3	84
550	Effects of low-power laser irradiation on the threshold of electrically induced paroxysmal discharge in rabbit hippocampus CA1. Lasers in Medical Science, 2010, 25, 79-86.	1.0	2
551	Structural immunology of costimualtory and coinhibitory molecules. Science China Life Sciences, 2010, 53, 183-189.	2.3	8
552	Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunologic Research, 2010, 47, 216-227.	1.3	63
553	Ligation of the BT3 molecules, members of the B7 family, enhance the proinflammatory responses of human monocytes and monocyte-derived dendritic cells. Molecular Immunology, 2010, 48, 109-118.	1.0	17

#	Article	IF	Citations
554	Seizures in the developing brain result in a long-lasting decrease in GABAB inhibitory postsynaptic currents in the rat hippocampus. Neurobiology of Disease, 2010, 37, 704-710.	2.1	8
555	Lessons From the Laboratory: The Pathophysiology, and Consequences of Status Epilepticus. Seminars in Pediatric Neurology, 2010, 17, 136-143.	1.0	19
556	Febrile Status Epilepticus: Current State of Clinical and Basic Research. Seminars in Pediatric Neurology, 2010, 17, 150-154.	1.0	16
557	PD-1, gender, and autoimmunity. Autoimmunity Reviews, 2010, 9, 583-587.	2.5	79
558	Overexpression of programmed death-1 ligand-1 on NIT cells lead to negative regulation of allogeneic lymphocyte activation. Cellular Immunology, 2010, 263, 122-128.	1.4	2
559	GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. Cellular Immunology, 2010, 265, 31-36.	1.4	27
560	Programmed death-1/B7-H1 negative costimulation protects mouse liver against ischemia and reperfusion injury. Hepatology, 2010, 52, 1380-1389.	3.6	61
561	Increased PDâ€Ł1 expression and PDâ€Ł1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. Journal of Medical Virology, 2010, 82, 1152-1159.	2.5	35
562	Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver International, 2010, 30, 1379-1386.	1.9	39
563	Partial restoration of Tâ€cell function in aged mice by in vitro blockade of the PDâ€1/â€ŠPDâ€Ł1 pathway. Aging Cell, 2010, 9, 785-798.	3.0	105
564	The PDâ€1 pathway in tolerance and autoimmunity. Immunological Reviews, 2010, 236, 219-242.	2.8	1,902
565	REVIEW ARTICLE: B7 Family Molecules as Regulators of the Maternal Immune System in Pregnancy. American Journal of Reproductive Immunology, 2010, 63, 506-519.	1.2	55
566	Increased programmed death-ligand-1 expression in human gastric epithelial cells inHelicobacter pyloriinfection. Clinical and Experimental Immunology, 2010, 161, 551-559.	1.1	70
567	The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with Î³-radiation-induced T-cell lymphoblastic lymphomas. Oncogene, 2010, 29, 5265-5273.	2.6	9
568	Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. Genes and Immunity, 2010, 11, 55-66.	2.2	16
569	Prostate cancer as a model for tumour immunotherapy. Nature Reviews Immunology, 2010, 10, 580-593.	10.6	314
570	Programmed Death-1 Expression on Epstein Barr Virus Specific CD8+ T Cells Varies by Stage of Infection, Epitope Specificity, and T-Cell Receptor Usage. PLoS ONE, 2010, 5, e12926.	1.1	35
571	Suppression of Bystander T Helper 1 Cells by Iris Pigment Epithelium-Inducing Regulatory T Cells via Negative Costimulatory Signals. , 2010, 51, 2529.		16

#	Article	IF	Citations
572	Unexpected Acceleration of Type 1 Diabetes by Transgenic Expression of B7-H1 in NOD Mouse Peri-Islet Glia. Diabetes, 2010, 59, 2588-2596.	0.3	16
573	Cryptosporidium parvumInduces B7â€H1 Expression in Cholangiocytes by Downâ€Regulating MicroRNAâ€513. Journal of Infectious Diseases, 2010, 201, 160-169.	1.9	62
574	Inhibitory TCR Coreceptor PD-1 Is a Sensitive Indicator of Low-Level Replication of SIV and HIV-1. Journal of Immunology, 2010, 184, 476-487.	0.4	41
575	Th1 Cytokine Responses Fail to Effectively Control Chlamydia Lung Infection in ICOS Ligand Knockout Mice. Journal of Immunology, 2010, 184, 3780-3788.	0.4	18
576	DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells. Cancer Research, 2010, 70, 5778-5787.	0.4	61
577	Cutting Edge: Programmed Death-1 Defines CD8+CD122+ T Cells as Regulatory versus Memory T Cells. Journal of Immunology, 2010, 185, 803-807.	0.4	120
578	Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways. Current Topics in Microbiology and Immunology, 2010, 344, 245-267.	0.7	44
579	PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. International Immunology, 2010, 22, 651-660.	1.8	189
580	Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4. Journal of Immunology, 2010, 185, 7723-7730.	0.4	53
581	B7-H1â€“Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. Journal of Immunology, 2010, 185, 2747-2753.	0.4	120
582	Stimulation of B7-H1 in Hepatocarcinoma Cells by Hepatitis B virus X Antigen. Immunological Investigations, 2010, 39, 754-769.	1.0	4
583	Functional significance of B7-H1 expressed by human uveal melanoma cells. Molecular Medicine Reports, 2010, 4, 163-7.	1.1	17
584	PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunology, 2010, 3, 81-91.	2.7	157
585	Co-inhibitory molecules: Controlling the effectors or controlling the controllers?. Self/nonself, 2010, 1, 77-88.	2.0	20
586	BCL6. Advances in Immunology, 2010, 105, 193-210.	1.1	248
587	Role of PD-1 in Regulating T-Cell Immunity. Current Topics in Microbiology and Immunology, 2010, 350, 17-37.	0.7	244
588	Dominant Processes during Human Dendritic Cell Maturation Revealed by Integration of Proteome and Transcriptome at the Pathway Level. Journal of Proteome Research, 2010, 9, 1727-1737.	1.8	45
589	Preventive and therapeutic potential of placental extract in contact hypersensitivity. International Immunopharmacology, 2010, 10, 1177-1184.	1.7	23

#	Article	IF	Citations
590	Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. Journal of Clinical Neuroscience, 2010, 17, 1543-1547.	0.8	30
591	Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: Implications for specific immunotherapy. Vaccine, 2010, 28, 5075-5085.	1.7	67
592	Structure and function of programmed death (PD) molecules. Veterinary Immunology and Immunopathology, 2010, 134, 33-38.	0.5	21
593	Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Research, 2010, 12, R48.	2.2	191
594	Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Experimental Neurology, 2010, 222, 153-160.	2.0	26
595	Effects of levetiracetam on blood-brain barrier disturbances following hyperthermia-induced seizures in rats with cortical dysplasia. Life Sciences, 2010, 87, 609-619.	2.0	21
596	The Role of IL-10 in Regulating Immunity to Persistent Viral Infections. Current Topics in Microbiology and Immunology, 2010, 350, 39-65.	0.7	123
598	PI3Ks in Lymphocyte Signaling and Development. Current Topics in Microbiology and Immunology, 2010, 346, 57-85.	0.7	55
599	Mesalamineâ€induced B7â€H1 expression on hepatic stellate cells attenuates autoimmune liver injury. Hepatology Research, 2011, 41, 79-86.	1.8	4
600	The immunoregulatory mechanisms of carcinoma for its survival and development. Journal of Experimental and Clinical Cancer Research, 2011, 30, 12.	3.5	47
602	A Novel Function for Programmed Death Ligand-1. American Journal of Pathology, 2011, 178, 1922-1929.	1.9	49
603	Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine, 2011, 56, 231-238.	1.4	216
604	B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology, 2011, 216, 1302-1310.	0.8	95
605	T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends in Molecular Medicine, 2011, 17, 47-55.	3.5	44
606	Epileptogenesis after prolonged febrile seizures: Mechanisms, biomarkers and therapeutic opportunities. Neuroscience Letters, 2011, 497, 155-162.	1.0	56
607	HCN channels in behavior and neurological disease: Too hyper or not active enough?. Molecular and Cellular Neurosciences, 2011, 46, 357-367.	1.0	75
608	PD-1 and Autoimmunity. Critical Reviews in Immunology, 2011, 31, 265-295.	1.0	24
609	The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma. Korean Journal of Urology, 2011, 52, 90.	1.2	15

#	Article	IF	Citations
610	Cytotoxic T Lymphocytes and Vaccine Development 2011. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-1.	3.0	1
611	CNS Expression of B7-H1 Regulates Pro-Inflammatory Cytokine Production and Alters Severity of Theiler's Virus-Induced Demyelinating Disease. PLoS ONE, 2011, 6, e18548.	1.1	34
612	Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway. Journal of Chemotherapy, 2011, 23, 295-299.	0.7	41
613	Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. International Journal of Oncology, 2011, 38, 1219-26.	1.4	46
614	Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 155-162.	2.7	103
615	Temperature elevation increases GABAA-mediated cortical inhibition in a mouse model of genetic epilepsy. Epilepsia, 2011, 52, 179-184.	2.6	20
616	Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin. Epilepsia, 2011, 52, 541-550.	2.6	27
617	Timeline: a decade of advances in immunotherapy. Nature Medicine, 2011, 17, 296-296.	15.2	4
618	Stromal cellsâ€™ B7â€‘1 is a key stimulatory molecule for interleukinâ€‘10 production by HOZOT, a multifunctional regulatory Tâ€cell line. Immunology and Cell Biology, 2011, 89, 246-254.	1.0	2
619	The role of the PDâ€‘1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences, 2011, 1217, 45-59.	1.8	290
620	Altered TNF-Î± and IFN-Î³ levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection. Infection, Genetics and Evolution, 2011, 11, 1624-1630.	1.0	26
621	Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. Drug Discovery Today, 2011, 16, 733-740.	3.2	16
622	Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review. European Urology, 2011, 60, 644-661.	0.9	272
623	Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma. Annals of Thoracic Surgery, 2011, 91, 1025-1031.	0.7	45
624	Anti-CD3 mAb treatment cures PDL1â^'/â^'.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology, 2011, 140, 47-53.	1.4	2
625	Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. Clinical and Experimental Metastasis, 2011, 28, 661-674.	1.7	23
626	Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflammation Research, 2011, 60, 47-53.	1.6	57
627	High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical Oncology, 2011, 28, 682-688.	1.2	526

#	Article	IF	Citations
628	Recent progress of immunology research in China. Science China Life Sciences, 2011, 54, 1068-1070.	2.3	0
629	Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets. BMC Immunology, 2011, 12, 53.	0.9	42
630	Cancer immunotherapy: Progress and challenges in the clinical setting. European Journal of Immunology, 2011, 41, 1510-1515.	1.6	24
631	Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology, 2011, 54, 216-228.	3.6	37
632	Essential Role of B7-H1 in Double-Stranded RNAâ€“Induced Augmentation of an Asthma Phenotype in Mice. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 31-39.	1.4	11
633	Fighting with the Enemys Weapons? The Role of Costimulatory Molecules in HIV. Current Molecular Medicine, 2011, 11, 172-196.	0.6	4
634	Therapeutic targeting of B7-H1 in breast cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 1211-1225.	1.5	36
635	B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival. Journal of Immunology, 2011, 187, 5606-5614.	0.4	74
636	Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma. Clinical Cancer Research, 2011, 17, 1915-1923.	3.2	313
637	Host APCs Augment In Vivo Expansion of Donor Natural Regulatory T Cells via B7H1/B7.1 in Allogeneic Recipients. Journal of Immunology, 2011, 186, 2739-2749.	0.4	53
638	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.4	159
639	CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1â€“Mediated Inhibition. Journal of Immunology, 2011, 186, 1598-1607.	0.4	269
640	Phagocytosis, a Potential Mechanism for Myeloid-Derived Suppressor Cell Regulation of CD8+ T Cell Function Mediated through Programmed Cell Death-1 and Programmed Cell Death-1 Ligand Interaction. Journal of Immunology, 2011, 187, 2291-2301.	0.4	25
641	Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. Journal of Leukocyte Biology, 2011, 90, 77-86.	1.5	21
642	Hyperthermic effects on behavior. International Journal of Hyperthermia, 2011, 27, 353-373.	1.1	17
643	Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1. Infection and Immunity, 2011, 79, 1873-1881.	1.0	48
644	A Functional Polymorphism in B and T Lymphocyte Attenuator Is Associated with Susceptibility to Rheumatoid Arthritis. Clinical and Developmental Immunology, 2011, 2011, 1-8.	3.3	34
645	The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	118

#	Article	IF	Citations
646	Herpesvirus Exploitation of Host Immune Inhibitory Pathways. Viruses, 2012, 4, 1182-1201.	1.5	20
647	PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle, 2012, 11, 4305-4309.	1.3	103
648	CD28 ligation increases macrophage suppression of T-cell proliferation. Cellular and Molecular Immunology, 2012, 9, 341-349.	4.8	8
649	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	5.8	1,837
650	B7-H1 limits the entry of effector CD8⁺T cells to the memory pool by upregulating Bim. OncoImmunology, 2012, 1, 1061-1073.	2.1	38
651	Immunotherapy for Prostate Cancer Enters Its Golden Age. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7475.	0.6	6
652	Suppression of the Interferon and NF-ÎºB Responses by Severe Fever with Thrombocytopenia Syndrome Virus. Journal of Virology, 2012, 86, 8388-8401.	1.5	112
653	B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels. Journal of Immunology, 2012, 189, 181-190.	0.4	31
654	Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment. Liver Cancer, 2012, 1, 226-237.	4.2	50
655	Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction. Reviews on Recent Clinical Trials, 2012, 7, 10-23.	0.4	31
656	Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells. Molecular Medicine Reports, 2012, 6, 553-557.	1.1	5
657	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. Tumori, 2012, 98, 751-755.	0.6	192
658	PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia. Aids, 2012, 26, 1065-1071.	1.0	20
659	Pancreatic Ductal Adenocarcinoma. Journal of Investigative Medicine, 2012, 60, 643-663.	0.7	65
660	Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood, 2012, 119, 1581-1589.	0.6	87
661	Role of the PD-1 Pathway in the Immune Response. American Journal of Transplantation, 2012, 12, 2575-2587.	2.6	348
662	How type I interferons shape myeloid cell function in CNS autoimmunity. Journal of Leukocyte Biology, 2012, 92, 479-488.	1.5	15
663	Immunology beats cancer: a blueprint for successful translation. Nature Immunology, 2012, 13, 1129-1132.	7.0	148

#	Article	IF	Citations
664	The characteristic expression of B7â€H3 and B7â€H4 in liver biopsies from patients with HBVâ€related acuteâ€onâ€chronic liver failure. Pathology International, 2012, 62, 665-674.	0.6	7
665	Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives. Immunological Investigations, 2012, 41, 614-634.	1.0	238
666	The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunology, Immunotherapy, 2012, 61, 1327-1341.	2.0	72
667	Neuronal injury and cytogenesis after simple febrile seizures in the hippocampal dentate gyrus of juvenile rat. Child's Nervous System, 2012, 28, 1931-1936.	0.6	8
668	A novel zebrafish model of hyperthermia-induced seizures reveals a role for TRPV4 channels and NMDA-type glutamate receptors. Experimental Neurology, 2012, 237, 199-206.	2.0	109
669	Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice. Journal of Surgical Research, 2012, 176, e79-e87.	0.8	8
670	Tubular cell HIV-entry through apoptosed CD4 T cells: A novel pathway. Virology, 2012, 434, 68-77.	1.1	18
671	Znaczenie receptora programowanej Å›mierci 1 oraz jego ligandÃ³w w ukÅ‚adzie immunologicznym oraz nowotworach. Acta Haematologica Polonica, 2012, 43, 132-145.	0.1	11
672	Immunotherapy earns its spot in the ranks of cancer therapy. Journal of Experimental Medicine, 2012, 209, 201-209.	4.2	118
673	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. Journal of Experimental Medicine, 2012, 209, 1201-1217.	4.2	864
674	A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 624.e11-624.e22.	1.5	36
675	T-cell activation and transplantation tolerance. Transplantation Reviews, 2012, 26, 212-222.	1.2	25
676	Role of PD-L1/PD-1 in the immune response to respiratory viral infections. Microbes and Infection, 2012, 14, 495-499.	1.0	14
677	Soluble B7-H1: Differences in production between dendritic cells and T cells. Immunology Letters, 2012, 142, 78-82.	1.1	110
678	Impaired Dendritic Expression and Plasticity of h-Channels in the fmr1 Mouse Model of Fragile X Syndrome. Cell Reports, 2012, 1, 225-233.	2.9	90
679	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology, 2012, 24, 207-212.	2.4	1,186
680	The Intrahepatic Expression and Distribution of BTLA and its Ligand HVEM in patients with HBV-related acute-on-chronic liver failure. Diagnostic Pathology, 2012, 7, 142.	0.9	21
681	Experimental earlyâ€life febrile seizures induce changes in GABA_ARâ€mediated neurotransmission in the dentate gyrus. Epilepsia, 2012, 53, 1968-1977.	2.6	10

#	Article	IF	Citations
682	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leukemia and Lymphoma, 2012, 53, 2015-2023.	0.6	35
683	Computational Modeling Reveals Dendritic Origins of GABAA-Mediated Excitation in CA1 Pyramidal Neurons. PLoS ONE, 2012, 7, e47250.	1.1	20
684	Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues. Science China Life Sciences, 2012, 55, 940-947.	2.3	3
685	Safety, Activity, and Immune Correlates of Antiâ€“PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	13.9	10,727
687	Foxp3+ Regulatory T Cells among Tuberculosis Patients: Impact on Prognosis and Restoration of Antigen Specific IFN-Î³ Producing T Cells. PLoS ONE, 2012, 7, e44728.	1.1	82
688	CO-INHIBITORY MOLECULE PROGRAMMED DEATH-1 AND ITS LIGANDS: A NEW ALTERNATIVE THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION?. American Journal of Infectious Diseases, 2012, 8, 149-162.	0.1	0
689	CD28 Family and Chronic Rejection: â€œTo Belatacept...and Beyond!â€• Journal of Transplantation, 2012, 2012, 1-14.	0.3	3
690	B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World Journal of Gastroenterology, 2012, 18, 971.	1.4	46
691	The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 2012, 12, 252-264.	12.8	10,874
692	Safety and Activity of Antiâ€“PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	13.9	6,820
693	HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients. Laboratory Investigation, 2012, 92, 295-304.	1.7	33
694	Longâ€lasting enhancement of GABA_A receptor expression in newborn dentate granule cells after earlyâ€life febrile seizures. Developmental Neurobiology, 2012, 72, 1516-1527.	1.5	14
695	PDâ€1 expression on Melanâ€Aâ€reactive T cells increases during progression to metastatic disease. International Journal of Cancer, 2012, 130, 2327-2336.	2.3	34
696	Involvement of Inducible Costimulator Ligand (ICOSL) Expression in Thyroid Tissue in Hyperthyroidism of Gravesâ€™ Disease Patients. Journal of Clinical Immunology, 2012, 32, 1253-1261.	2.0	12
697	Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunology, Immunotherapy, 2012, 61, 917-926.	2.0	134
698	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 453-468.	2.0	22
699	Role of Lentivirus-Mediated Overexpression of Programmed Death-Ligand 1 on Corneal Allograft Survival. American Journal of Transplantation, 2012, 12, 1313-1322.	2.6	33
700	Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology, 2012, 51, 263-272.	1.0	158

#	Article	IF	Citations
701	A prolonged experimental febrile seizure results in motor map reorganization in adulthood. Neurobiology of Disease, 2012, 45, 692-700.	2.1	23
702	A frequent somatic mutation in CD274 3â€²-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Human Mutation, 2012, 33, 480-484.	1.1	87
703	Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunology, Immunotherapy, 2012, 61, 101-108.	2.0	75
704	The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium. Clinical Rheumatology, 2012, 31, 271-281.	1.0	21
705	Enhancement of Membrane B7-H3 Costimulatory Molecule but Reduction of Its Soluble Form in Multiple Sclerosis. Journal of Clinical Immunology, 2013, 33, 118-126.	2.0	17
706	Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumor Biology, 2013, 34, 1053-1059.	0.8	26
707	Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells. Cell Biology International, 2013, 37, 137-148.	1.4	32
708	Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer. Current Oncology Reports, 2013, 15, 98-104.	1.8	41
709	Expression and significance of B7-H1 in peripheral blood dendritic cells from patients with bladder cancer. Chinese-German Journal of Clinical Oncology, 2013, 12, 290-292.	0.1	1
710	Increased PD-1 on CD4+CD28â^' T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases. Metabolism: Clinical and Experimental, 2013, 62, 778-785.	1.5	67
712	Ivabradine (a hyperpolarization activated cyclic nucleotide-gated channel blocker) elevates the threshold for maximal electroshock-induced tonic seizures in mice. Pharmacological Reports, 2013, 65, 1407-1414.	1.5	25
713	Loss of dendritic inhibition in the hippocampus after repeated early-life hyperthermic seizures in rats. Epilepsy Research, 2013, 103, 62-72.	0.8	5
714	BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. Molecular Immunology, 2013, 56, 819-828.	1.0	34
715	Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treatment Reviews, 2013, 39, 879-885.	3.4	44
716	Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming. International Immunology, 2013, 25, 171-182.	1.8	46
717	Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic intervention. Experimental Neurology, 2013, 244, 43-50.	2.0	62
718	Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma. Journal of Immunology, 2013, 190, 5620-5628.	0.4	91
719	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmunity Reviews, 2013, 12, 1091-1100.	2.5	213

#	Article	IF	Citations
720	The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. Journal of Hematology and Oncology, 2013, 6, 74.	6.9	234
721	Mesenchymal stem cells control alloreactive CD8+CD28â^'T cells. Clinical and Experimental Immunology, 2013, 174, 449-458.	1.1	41
722	Gene Therapy Approaches to Prevent Corneal Graft Rejection: Where Do We Stand?. Ophthalmic Research, 2013, 50, 135-140.	1.0	9
723	Allogenicity of Human Cardiac Stem/Progenitor Cells Orchestrated by Programmed Death Ligand 1. Circulation Research, 2013, 112, 451-464.	2.0	71
724	Therapeutic cancer vaccines. , 2013, , 1018-1031.		2
725	Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocrine-Related Cancer, 2013, 20, 103-110.	1.6	69
726	Immunological homeostasis of the eye. Progress in Retinal and Eye Research, 2013, 33, 10-27.	7.3	137
727	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1
728	Intrahepatic Expression of Programmed Death-1 and its Ligands in Patients with HBV-Related Acute-on-Chronic Liver Failure. Inflammation, 2013, 36, 110-120.	1.7	31
729	Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients. Chinese Medical Sciences Journal, 2013, 28, 147-151.	0.2	40
730	B7-H1 as a Biomarker for Therapy Failure in Patients with Favorable Histology Wilms Tumor. Journal of Urology, 2013, 189, 1487-1492.	0.2	25
731	Strategies to reverse melanoma-induced T-cell dysfunction. Clinics in Dermatology, 2013, 31, 251-256.	0.8	8
732	Fishing for the mechanisms causing febrile seizures: Employing a novel model to uncover the physiological generators of seizures with fever. Experimental Neurology, 2013, 240, 108-111.	2.0	2
733	Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 394-399.	0.6	12
734	Advances in targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug Discovery, 2013, 12, 130-146.	21.5	229
735	Adaptive resistance: A tumor strategy to evade immune attack. European Journal of Immunology, 2013, 43, 576-579.	1.6	17
736	Other signalization targets. Targeted Oncology, 2013, 8, 69-77.	1.7	6
737	Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood, 2013, 121, 3619-3630.	0.6	47

#	Article	IF	Citations
738	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opinion on Biological Therapy, 2013, 13, 847-861.	1.4	110
739	A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Human Genetics, 2013, 132, 641-648.	1.8	134
740	At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. Journal of Leukocyte Biology, 2013, 94, 41-53.	1.5	305
741	Lack of PD-L1 Expression by iNKT Cells Improves the Course of Influenza A Infection. PLoS ONE, 2013, 8, e59599.	1.1	21
742	B7-H5 costimulates human T cells via CD28H. Nature Communications, 2013, 4, 2043.	5.8	148
743	PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients. Journal of Neuroscience, 2013, 33, 14231-14245.	1.7	121
744	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research, 2013, 19, 997-1008.	3.2	161
745	Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunology Research, 2013, 1, 85-91.	1.6	161
746	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica, 2013, 98, 1458-1466.	1.7	58
747	Vaccine-based immunotherapy for glioblastoma. CNS Oncology, 2013, 2, 331-349.	1.2	11
748	Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells. Frontiers in Immunology, 2013, 4, 481.	2.2	67
749	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. Journal of Carcinogenesis, 2013, 12, 7.	2.5	10
750	Antibodies to gp120 and PD-1 Expression on Virus-Specific CD8 ⁺ T Cells in Protection from Simian AIDS. Journal of Virology, 2013, 87, 3526-3537.	1.5	6
751	T Cells and Costimulation in Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 473-482.	1.0	22
752	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clinical Cancer Research, 2013, 19, 1021-1034.	3.2	458
753	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. Clinical Cancer Research, 2013, 19, 1363-1374.	3.2	196
754	Corticosteroids plus Long-Acting Beta₂-Agonists Prevent Double-Stranded RNA-Induced Upregulation of B7-H1 on Airway Epithelium. International Archives of Allergy and Immunology, 2013, 160, 27-36.	0.9	14
755	Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils. Journal of Leukocyte Biology, 2013, 94, 813-823.	1.5	33

#	Article	IF	Citations
756	Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages toward regulatory subsets. Advances in Bioscience and Biotechnology (Print), 2013, 04, 19-29.	0.3	14
757	HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients. Cancer Research, 2013, 73, 1764-1776.	0.4	78
758	PD-1 is a novel regulator of human B-cell activation. International Immunology, 2013, 25, 129-137.	1.8	261
759	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. Journal of Experimental Medicine, 2013, 210, 757-774.	4.2	211
760	Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S9565.	0.6	8
761	Constitutively CD40â€"Activated B Cells Regulate CD8 T Cell Inflammatory Response by IL-10 Induction. Journal of Immunology, 2013, 190, 3189-3196.	0.4	8
762	Differentiation and activation of equine monocyteâ€derived dendritic cells are not correlated with <scp>CD</scp>206 or <scp>CD</scp>83 expression. Immunology, 2013, 139, 472-483.	2.0	19
763	<scp>ITIM</scp>â€dependent negative signaling pathways for the control of cellâ€mediated xenogeneic immune responses. Xenotransplantation, 2013, 20, 397-406.	1.6	14
764	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. Cancer Immunology Research, 2013, 1, 54-63.	1.6	333
765	Increased PDâ€1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. Journal of Surgical Oncology, 2013, 107, 517-522.	0.8	75
766	<scp>PD</scp>â€1 as a potential target in cancer therapy. Cancer Medicine, 2013, 2, 662-673.	1.3	369
767	Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells. Journal of Immunology, 2013, 190, 1125-1134.	0.4	28
768	Structure and Interactions of the Human Programmed Cell Death 1 Receptor. Journal of Biological Chemistry, 2013, 288, 11771-11785.	1.6	256
769	Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2â€"Dependent Mechanisms. Cancer Research, 2013, 73, 3877-3887.	0.4	160
770	Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia, 2013, 27, 464-472.	3.3	214
771	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9879-9884.	3.3	160
772	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4⁺T cells. OncoImmunology, 2013, 2, e23991.	2.1	52
773	PD-L1 gene expression in Japanese lung cancer patients. Biomedical Reports, 2013, 1, 93-96.	0.9	12

#	Article	IF	Citations
774	The role of B7 family molecules in hematologic malignancy. Blood, 2013, 121, 734-744.	0.6	159
775	Sinomenine inhibits the expression of PD-L1 in the peripheral blood mononuclear cells of mesangial proliferative nephritis patients. Molecular Medicine Reports, 2013, 7, 1223-1228.	1.1	11
776	Current Advances in Therapy for Metastatic Melanoma. Current Cancer Therapy Reviews, 2013, 9, 8-23.	0.2	0
777	B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. Oncology Reports, 2013, 30, 2442-2448.	1.2	10
778	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. Journal of Visualized Experiments, 2013, , .	0.2	28
779	Alteration of the Thymic T Cell Repertoire by Rotavirus Infection Is Associated with Delayed Type 1 Diabetes Development in Non-Obese Diabetic Mice. PLoS ONE, 2013, 8, e59182.	1.1	7
780	B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis. PLoS ONE, 2013, 8, e70689.	1.1	119
781	B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells. PLoS ONE, 2013, 8, e76012.	1.1	150
782	Characterization of a Soluble B7-H3 (sB7-H3) Spliced from the Intron and Analysis of sB7-H3 in the Sera of Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e76965.	1.1	36
783	The nature of activatory and tolerogenic dendritic cell-derived signal II. Frontiers in Immunology, 2013, 4, 53.	2.2	91
784	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Frontiers in Immunology, 2013, 4, 417.	2.2	62
785	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. Frontiers in Oncology, 2013, 3, 54.	1.3	27
786	Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Network, 2013, 13, 184.	1.6	49
787	Immune privilege as new therapeutic strategies for success of corneal transplantation. Inflammation and Regeneration, 2013, 33, 274-282.	1.5	1
788	PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer. PLoS ONE, 2014, 9, e89350.	1.1	169
789	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Frontiers in Cellular Neuroscience, 2014, 8, 228.	1.8	11
790	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. Journal of Pigmentary Disorders, 2014, 01, .	0.2	0
791	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. , 2014, , .		4

#	Article	IF	Citations
792	Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease. Journal of Immunology, 2014, 193, 2565-2573.	0.4	67
793	Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology. Immunologic Research, 2014, 60, 156-164.	1.3	3
794	Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. Journal of Translational Medicine, 2014, 12, 347.	1.8	32
795	The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer Journal, 2014, 4, e230-e230.	2.8	30
796	An unbalanced PD-L1/CD86 ratio in CD14++CD16+ monocytes is correlated with HCV viremia during chronic HCV infection. Cellular and Molecular Immunology, 2014, 11, 294-304.	4.8	20
797	Malaria drives T cells to exhaustion. Frontiers in Microbiology, 2014, 5, 249.	1.5	70
798	The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. OncoTargets and Therapy, 2014, 7, 1465.	1.0	70
799	Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia, 2014, 28, 236-238.	3.3	37
800	The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease. Modern Rheumatology, 2014, 24, 953-960.	0.9	10
801	Epileptiform Discharges and Frontal Paroxysmal EEG Abnormality Act as Predictive Marker for Subsequent Epilepsy in Children With Complex Febrile Seizures. Clinical EEG and Neuroscience, 2014, 45, 299-303.	0.9	10
802	Association between single nucleotide polymorphism of <scp>PDâ€Ł1</scp> gene and nonâ€small cell lung cancer susceptibility in a <scp>C</scp>hinese population. Asia-Pacific Journal of Clinical Oncology, 2014, 10, e1-6.	0.7	19
803	Identification ofSrp9as a febrile seizure susceptibility gene. Annals of Clinical and Translational Neurology, 2014, 1, 239-250.	1.7	18
804	Immunological in vivo effects of B7-H1 deficiency. Immunology Letters, 2014, 162, 273-286.	1.1	5
805	PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis, 2014, 35, 424-431.	1.3	42
806	Glial cells suppress postencephalitic CD8⁺ T lymphocytes through PDâ€Ł1. Glia, 2014, 62, 1582-1594.	2.5	58
807	T cells from chronic bone infection show reduced proliferation and a high proportion of CD28â^' CD4 T cells. Clinical and Experimental Immunology, 2014, 176, 49-57.	1.1	18
808	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
809	Evolving role of tumor antigens for future melanoma therapies. Future Oncology, 2014, 10, 1457-1468.	1.1	15

#	Article	IF	Citations
810	The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. Medical Oncology, 2014, 31, 268.	1.2	22
811	Nardilysin-Dependent Proteolysis of Cell-Associated VTCN1 (B7-H4) Marks Type 1 Diabetes Development. Diabetes, 2014, 63, 3470-3482.	0.3	25
812	Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	146
813	Co-Inhibitory Pathways and Their Importance in Immune Regulation. Transplantation, 2014, 98, 3-14.	0.5	70
814	B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. Journal of Thoracic Oncology, 2014, 9, 1036-1040.	0.5	208
815	Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. Cancer Journal (Sudbury, Mass), 2014, 20, 256-261.	1.0	131
816	PD-1 as an Immune Modulatory Receptor. Cancer Journal (Sudbury, Mass), 2014, 20, 262-264.	1.0	62
817	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. Journal of Hematology and Oncology, 2014, 7, 16.	6.9	6
818	PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 1035-1042.	0.4	25
819	Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro. OncoTargets and Therapy, 2014, 7, 1389.	1.0	14
820	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2014, 20, 254-255.	1.0	6
821	Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis. Inflammation, 2014, 37, 116-121.	1.7	58
822	Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine, 2014, 65, 33-41.	1.4	50
823	Immunotherapy: It Takes a Village. Science, 2014, 344, 149-149.	6.0	13
824	Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. Journal of Translational Medicine, 2014, 12, 36.	1.8	147
825	Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Experimental Cell Research, 2014, 324, 65-74.	1.2	81
826	Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology, 2014, 89, 140-165.	2.0	148
827	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology, 2014, 27, 89-97.	2.4	111

#	Article	IF	Citations
828	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy, 2014, 6, 459-475.	1.0	88
829	Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters, 2014, 588, 368-376.	1.3	227
830	Neurophysiology of HCN channels: From cellular functions to multiple regulations. Progress in Neurobiology, 2014, 112, 1-23.	2.8	290
831	MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Human Immunology, 2014, 75, 348-353.	1.2	157
832	Influence of <scp>PD</scp>â€<scp>L</scp>1 crossâ€linking on cell death in <scp>PD</scp>â€<scp>L</scp>1â€expressing cell lines and bovine lymphocytes. Immunology, 2014, 142, 551-561.	2.0	46
833	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 1-14.	1.5	38
834	The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy. Cancer Immunology Research, 2014, 2, 926-936.	1.6	23
835	Arginine Metabolism, a Major Pathway for the Suppressive Function of Myeloid-Derived Suppressor Cells. , 2014, , 369-386.		1
836	Attenuation of IFN-Î³-induced B7-H1 expression by 15-deoxy-delta12,14-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway. Life Sciences, 2014, 112, 82-89.	2.0	19
837	PDâ€1 regulates extrathymic regulatory Tâ€cell differentiation. European Journal of Immunology, 2014, 44, 2603-2616.	1.6	87
838	Immunotherapy: Chemical tricks. Nature, 2014, 513, S10-S11.	13.7	15
839	The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity. Journal of Immunology, 2014, 193, 3835-3841.	0.4	178
840	B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation. Cancer Immunology, Immunotherapy, 2014, 63, 859-867.	2.0	13
841	PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research, 2014, 2, 361-370.	1.6	994
842	CD4+CD25+/highCD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis jointsâ€"analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Research and Therapy, 2014, 16, R97.	1.6	109
843	PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection. Cancer Immunology Research, 2014, 2, 320-331.	1.6	138
844	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Antiâ€"PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	3.2	2,050
845	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	0.8	2,015

#	Article	IF	Citations
846	Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions. Immunology Letters, 2014, 162, 248-255.	1.1	45
847	Tumor-Induced Immune Suppression. , 2014, , .		3
848	The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia, 2014, 28, 1784-1792.	3.3	77
849	Self-reactive T cells: suppressing the suppressors. Cancer Immunology, Immunotherapy, 2014, 63, 313-319.	2.0	11
850	PD-1/PD-Ls pathways between CD4+ T cells and pleural mesothelial cells in human tuberculous pleurisy. Tuberculosis, 2014, 94, 131-139.	0.8	11
851	Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?. Seminars in Oncology, 2014, 41, 126-132.	0.8	45
852	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncology, 2014, 50, 627-632.	0.8	194
853	Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. Cell Reports, 2014, 6, 625-632.	2.9	53
854	Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends in Immunology, 2014, 35, 290-298.	2.9	96
855	Long-term modifications of epileptogenesis and hippocampal rhythms after prolonged hyperthermic seizures in the mouse. Neurobiology of Disease, 2014, 69, 156-168.	2.1	11
856	Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncology Reports, 2014, 31, 1191-1198.	1.2	41
857	Aberrant expression of B7-H3 in gastric adenocarcinoma promotes cancer cell metastasis. Oncology Reports, 2014, 32, 2086-2092.	1.2	47
858	Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Nonâ€“Small Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 541-549.	0.6	171
859	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Science, 2015, 106, 945-950.	1.7	78
860	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer: Basic and Clinical Research, 2015, 9s2, BCBCR.S29425.	0.6	4
861	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers in Cancer, 2015, 7s2, BIC.S29325.	3.6	51
862	PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagnostic Pathology, 2015, 10, 189.	0.9	76
863	Ovarian Cancer Immunotherapy Using PDâ€L1 siRNA Targeted Delivery from Folic Acidâ€Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing. Advanced Healthcare Materials, 2015, 4, 1180-1189.	3.9	140

#	Article	IF	Citations
864	PD-L1 Gene Polymorphism and High Level of Plasma Soluble Pd-L1 Protein may be aSsociated with Non-Small Cell Lung Cancer. International Journal of Biological Markers, 2015, 30, 364-368.	0.7	56
865	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.1	4
866	Epitope characterization of an antiâ€PDâ€L1 antibody using orthogonal approaches. Journal of Molecular Recognition, 2015, 28, 269-276.	1.1	20
867	Pancreatitis Secondary to Antiâ€“Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, e528-e529.	0.7	62
869	Blocking of the PDâ€1/PDâ€L1 Interaction by a <scp>D</scp>â€Peptide Antagonist for Cancer Immunotherapy. Angewandte Chemie - International Edition, 2015, 54, 11760-11764.	7.2	286
870	Antiâ€“PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391.	3.9	1,112
871	Immunosuppressive Microenvironment in Head and Neck Cancer. , 2015, , .		1
872	Cancer immunotherapy: harnessing the immune system to battle cancer. Journal of Clinical Investigation, 2015, 125, 3335-3337.	3.9	1,016
873	Biomarkers of Response to Immune Modulatory Therapies in Cancer. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	1
874	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 7-17.	0.1	82
875	Neisseria gonorrhoeae Modulates Immunity by Polarizing Human Macrophages to a M2 Profile. PLoS ONE, 2015, 10, e0130713.	1.1	34
876	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS ONE, 2015, 10, e0136476.	1.1	59
877	PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment. PLoS ONE, 2015, 10, e0137646.	1.1	51
878	Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization. PLoS ONE, 2015, 10, e0142868.	1.1	21
879	Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Design, Development and Therapy, 2015, 9, 901.	2.0	150
881	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
882	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. , 0, , .		4
883	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World Journal of Hepatology, 2015, 7, 2449.	0.8	32

#	Article	IF	Citations
884	Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. Immunologic Research, 2015, 62, 316-324.	1.3	20
885	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Molecular Therapy - Nucleic Acids, 2015, 4, e237.	2.3	106
886	Introduction to Costimulation and Costimulatory Molecules. , 2015, , 1-43.		15
887	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Annals of Hematology, 2015, 94, 1545-1552.	0.8	73
888	New strategies to develop new medications for lung cancer and metastasis. Cancer and Metastasis Reviews, 2015, 34, 265-275.	2.7	10
889	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Antiâ€“PD-L1 Antibodies. Cancer Research, 2015, 75, 2928-2936.	0.4	193
890	Cancer and the Immune System: Basic Concepts and Targets for Intervention. Seminars in Oncology, 2015, 42, 523-538.	0.8	220
891	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	1.6	114
893	T Cell Fate in the Tumor Microenvironment. Cancer Drug Discovery and Development, 2015, , 53-74.	0.2	0
894	The Pekin duck programmed deathâ€ligand 1: <scp>cDNA</scp> cloning, genomic structure, molecular characterization and <scp>mRNA</scp> expression analysis. International Journal of Immunogenetics, 2015, 42, 111-120.	0.8	7
895	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncology, 2015, 51, 221-228.	0.8	256
896	Immune Checkpoint Blockade and Interferon-Î± in Melanoma. Seminars in Oncology, 2015, 42, 436-447.	0.8	34
897	Overexpression of Programmed Death Ligands in Naturally Occurring Postweaning Multisystemic Wasting Syndrome. Viral Immunology, 2015, 28, 101-106.	0.6	9
898	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. Archives of Pharmacal Research, 2015, 38, 1415-1433.	2.7	14
899	Immunology of Pregnancy. , 2015, , 1835-1874.		23
900	Gene and cell therapy for pancreatic cancer. Expert Opinion on Biological Therapy, 2015, 15, 505-516.	1.4	18
902	Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury. Journal of Immunology, 2015, 194, 325-333.	0.4	70
903	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2015, 14, 847-856.	1.9	1,787

#	Article	IF	Citations
904	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine, 2015, 13, 5.	1.8	73
905	Evaluation of Immune Restoration Potential of PD-1 Blockers. Journal of Immunoassay and Immunochemistry, 2015, 36, 567-572.	0.5	1
906	Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 97-106.	1.4	124
907	Nivolumab and Olaparib. Hospital Pharmacy, 2015, 50, 356-366.	0.4	4
908	Evolving Concepts: Immunity in Oncology from Targets to Treatments. Journal of Oncology, 2015, 2015, 1-15.	0.6	23
909	Cell-contact dependent inhibition of monocytes by airway epithelial cells and reversion by infection with Respiratory Syncytial Virus. Immunobiology, 2015, 220, 1240-1245.	0.8	6
910	T2 relaxation time post febrile status epilepticus predicts cognitive outcome. Experimental Neurology, 2015, 269, 242-252.	2.0	24
911	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical Cancer Research, 2015, 21, 3969-3976.	3.2	205
912	New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences, 2015, 36, 587-595.	4.0	158
913	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134.	3.2	27
914	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4607-4618.	3.2	271
915	IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. Journal of Neuroimmunology, 2015, 285, 129-136.	1.1	26
916	Feto-maternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy. Placenta, 2015, 36, 1153-1160.	0.7	32
917	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
918	Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 945-956.	0.5	0
919	Upregulation of PD-1 on CD4+CD25+T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis. International Immunopharmacology, 2015, 26, 357-366.	1.7	33
920	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	1.1	252
921	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€“Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	3.2	120

#	Article	IF	Citations
922	Immunotherapy for lung cancer: for whom the bell tolls?. Tumor Biology, 2015, 36, 1411-1422.	0.8	17
923	The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. European Journal of Surgical Oncology, 2015, 41, 450-456.	0.5	228
924	Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck. Surgical Oncology Clinics of North America, 2015, 24, 437-454.	0.6	11
925	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer, 2015, 16, e25-e35.	1.1	100
926	Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies. Clinical Cancer Research, 2015, 21, 1127-1138.	3.2	52
927	Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 976-984.	3.2	196
928	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology, 2015, 67, 4-17.	1.0	180
929	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clinical Cancer Research, 2015, 21, 2359-2366.	3.2	125
930	Overall Survival and Long-Term Safety of Nivolumab (Antiâ€“Programmed Death 1 Antibody, BMS-936558,) Tj ETQq0 0 0 rgBT /Overlock Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
931	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy, 2015, 23, 1380-1390.	3.7	88
932	A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clinical Cancer Research, 2015, 21, 2201-2203.	3.2	45
933	Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies. Seminars in Oncology, 2015, 42, 495-505.	0.8	44
934	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	7.7	3,266
935	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	2.9	76
936	Interferon-Î³-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. OncoImmunology, 2015, 4, e1008824.	2.1	238
937	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy, 2015, 7, 777-792.	1.0	18
938	<scp>PD</scp>â€•1/<scp>PD</scp>â€Ł1 expression on <scp>CD</scp>⁴⁺ T cells and myeloid <scp>DC</scp>s correlates with the immune pathogenesis of atrial fibrillation. Journal of Cellular and Molecular Medicine, 2015, 19, 1223-1233.	1.6	23
939	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. Drugs and Aging, 2015, 32, 821-834.	1.3	12

#	Article	IF	Citations
940	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer and Prostatic Diseases, 2015, 18, 325-332.	2.0	149
941	Immune Mechanisms Are Major Players in Cancer. Clinical Cancer Research, 2015, 21, 3581-3583.	3.2	1
942	PD-1 Blockers. Cell, 2015, 162, 937.	13.5	126
943	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 385-390.	1.1	115
944	Histamine 4 receptor promotes expression of costimulatory B7.1/B7.2 molecules, CD28 signaling and cytokine production in stress-induced immune responses. Journal of Neuroimmunology, 2015, 289, 30-42.	1.1	27
945	The PD-L1/CD86 ratio is increased in dendritic cells co-infected with porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus, and the PD-L1/PD-1 axis is associated with anergy, apoptosis, and the induction of regulatory T-cells in porcine lymphocytes. Veterinary Microbiology, 2015, 180, 223-229.	0.8	18
946	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy, 2015, 7, 1169-1186.	1.0	45
947	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treatment Reviews, 2015, 41, 868-876.	3.4	358
948	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology, 2015, 9, 1936-1965.	2.1	64
949	The role of programmed cell deathâ€1 (PDâ€1) and its ligands in pediatric cancer. Pediatric Blood and Cancer, 2015, 62, 190-197.	0.8	24
950	Clinical blockade of PD1 and LAG3 â€" potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	10.6	524
951	B7H1/CD80 Interaction Augments PD-1â€"Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. Journal of Immunology, 2015, 194, 560-574.	0.4	61
952	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. , 2015, 148, 132-153.		50
953	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015, 21, 24-33.	3.5	628
954	The presence of interleukinâ€27 during monocyteâ€derived dendritic cell differentiation promotes improved antigen processing and stimulation of <scp>T</scp> cells. Immunology, 2015, 144, 649-660.	2.0	33
955	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget, 2016, 7, 56233-56240.	0.8	48
957	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. OncoTargets and Therapy, 2016, Volume 9, 6075-6082.	1.0	47
958	Immune Checkpoint Blockade Therapy: Merits and Demerits. Journal of Clinical & Experimental Dermatology Research, 2016, 7, .	0.1	0

#	Article	IF	Citations
959	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. OncoTargets and Therapy, 2016, Volume 9, 5855-5866.	1.0	11
960	Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo. Brazilian Journal of Medical and Biological Research, 2016, 49, .	0.7	2
961	Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. Journal of Thoracic Disease, 2016, 8, 3197-3204.	0.6	39
962	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. Immune Network, 2016, 16, 134.	1.6	8
963	T cell Bim levels reflect responses to antiâ€“PD-1 cancer therapy. JCI Insight, 2016, 1, .	2.3	68
964	Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 298-308.	1.8	115
965	Immunotherapy in urothelial carcinoma: fade or future standard?. Translational Andrology and Urology, 2016, 5, 662-667.	0.6	2
966	Immune checkpoint therapy for pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 9457.	1.4	73
967	Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget, 2016, 7, 32318-32328.	0.8	141
968	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. Journal of Immunology Research, 2016, 2016, 1-12.	0.9	17
969	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. Journal of Immunology Research, 2016, 2016, 1-14.	0.9	36
970	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	2.2	409
971	Recent Advances in Immunotherapy in Metastatic NSCLC. Frontiers in Oncology, 2016, 6, 239.	1.3	29
972	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 2016, 17, 1151.	1.8	134
973	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget, 2016, 7, 74350-74361.	0.8	35
974	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Annals of Translational Medicine, 2016, 4, 215-215.	0.7	13
975	War-winning weapons. Nature Immunology, 2016, 17, S18-S18.	7.0	0
976	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016, 7, 10215-10227.	0.8	158

#	Article	IF	Citations
977	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy, 2016, 8, 907-921.	1.0	20
978	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1). American Journal of Surgical Pathology, 2016, 40, 1133-1142.	2.1	85
979	Immune Checkpoint Therapy in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 92-95.	1.0	35
980	Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Nonâ€Small Cell Lung Cancer to Receive Immunotherapy. Clinical Pharmacology and Therapeutics, 2016, 100, 220-222.	2.3	22
981	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 313-320.	1.0	4
982	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. OncoImmunology, 2016, 5, e1202391.	2.1	33
983	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open, 2016, 1, e000122.	2.0	55
984	PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. SpringerPlus, 2016, 5, 805.	1.2	61
985	Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. Cancer Immunology Research, 2016, 4, 1049-1060.	1.6	34
987	Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Scientific Reports, 2016, 6, 20090.	1.6	138
988	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduction and Targeted Therapy, 2016, 1, 16025.	7.1	35
989	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. Genes and Diseases, 2016, 3, 252-256.	1.5	17
990	Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma. Annals of Thoracic Surgery, 2016, 101, 1361-1369.	0.7	60
991	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
992	Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal of Kidney Diseases, 2016, 68, 287-291.	2.1	253
993	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	0.5	329
994	Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277.	1.1	107
995	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480

#	Article	IF	Citations
996	PD-1 Blockade Boosts Radiofrequency Ablationâ€“Elicited Adaptive Immune Responses against Tumor. Clinical Cancer Research, 2016, 22, 1173-1184.	3.2	207
997	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. Oncology Reports, 2016, 35, 699-708.	1.2	62
998	The clinical impact of ICOS signal in colorectal cancer patients. OncoImmunology, 2016, 5, e1141857.	2.1	66
999	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	12.8	2,133
1000	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
1001	Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 781-798.	1.0	29
1002	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood, 2016, 127, 3026-3034.	0.6	168
1003	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. OncoImmunology, 2016, 5, e1235107.	2.1	104
1004	Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion. Experimental and Therapeutic Medicine, 2016, 12, 2161-2168.	0.8	16
1005	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncology, 2016, 61, 152-158.	0.8	48
1006	B7â€H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukinâ€6/signal transducer and activator of transcription 3 pathway activation. Cancer Science, 2016, 107, 944-954.	1.7	36
1007	Immunotherapy for lung cancer. Respirology, 2016, 21, 821-833.	1.3	268
1008	Lymphocyteâ€activation geneâ€3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	1.7	168
1009	Generation of Febrile Seizures and Subsequent Epileptogenesis. Neuroscience Bulletin, 2016, 32, 481-492.	1.5	38
1010	Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility. Cancer Immunology Research, 2016, 4, 815-819.	1.6	8
1011	Malignant Mesothelioma Effusions Are Infiltrated byÂCD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Antiâ€PD-L1 Antibody Avelumab. Journal of Thoracic Oncology, 2016, 11, 1993-2005.	0.5	96
1012	Cancer Immunotherapy byÂCheckpoint Blockade. , 2016, , 561-580.		2
1013	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Annals of Oncology, 2016, 27, 1953-1958.	0.6	289

#	Article	IF	Citations
1014	Why Are Children With Epileptic Encephalopathies Encephalopathic?. Journal of Child Neurology, 2016, 31, 1495-1504.	0.7	12
1015	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiotherapy and Oncology, 2016, 120, 185-194.	0.3	99
1016	PD-1/PD-L and autoimmunity: A growing relationship. Cellular Immunology, 2016, 310, 27-41.	1.4	211
1017	Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. Laboratory Investigation, 2016, 96, 1156-1164.	1.7	11
1018	PD-L1 expression is associated with advanced non-small cell lung cancer. Oncology Letters, 2016, 12, 921-927.	0.8	18
1019	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy, 2016, 8, 775-784.	1.0	24
1020	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunology Research, 2016, 4, 779-788.	1.6	80
1021	Advances in the Treatment of Nonâ€“small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs, 2016, 30, 397-405.	2.2	36
1023	MERCK SHARP & DOHME LTD v ONO PHARMACEUTICAL CO. LTD. Reports of Patent Design and Trade Mark Cases, 2016, 133, 417-477.	0.0	3
1024	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
1025	Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM. Science Advances, 2016, 2, e1500637.	4.7	37
1026	Nivolumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 1247-1261.	1.1	20
1027	Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats. Journal of Immunology, 2016, 197, 3831-3840.	0.4	26
1028	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. Journal of Immunotherapy, 2016, 39, 306-315.	1.2	10
1029	Programmed cell death-1 pathway inhibitors in genitourinary malignancies. Current Opinion in Urology, 2016, 26, 548-555.	0.9	9
1030	Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. OncoImmunology, 2016, 5, e1181252.	2.1	52
1031	Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Human Vaccines and Immunotherapeutics, 2016, 12, 2232-2239.	1.4	29
1032	Temporal Coordination of Hippocampal Neurons Reflects Cognitive Outcome Post-febrile Status Epilepticus. EBioMedicine, 2016, 7, 175-190.	2.7	30

#	Article	IF	Citations
1033	Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice. Journal of Immunology, 2016, 197, 491-503.	0.4	23
1034	Autocrine Complement Inhibits IL10-Dependent T-cellâ€“Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discovery, 2016, 6, 1022-1035.	7.7	116
1035	A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. Journal of Immunology, 2016, 197, 983-993.	0.4	215
1036	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
1037	A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International Immunopharmacology, 2016, 31, 248-256.	1.7	13
1038	Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 397-406.	1.4	56
1039	Regulation of Immunity by Butyrophilins. Annual Review of Immunology, 2016, 34, 151-172.	9.5	129
1040	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. Clinical Cancer Research, 2016, 22, 2177-2182.	3.2	119
1041	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	6.3	5,456
1042	Control of PD-L1 Expression by Oncogenic Activation of the AKTâ€“mTOR Pathway in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2016, 76, 227-238.	0.4	595
1043	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathology, 2016, 47, 52-63.	1.1	284
1044	Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine and Growth Factor Reviews, 2016, 29, 109-115.	3.2	27
1045	High-Throughput Mechanobiology Screening Platform Using Micro- and Nanotopography. Nano Letters, 2016, 16, 2198-2204.	4.5	42
1046	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology, 2016, 130, 25-74.	1.1	181
1047	Basics of PD-1 in self-tolerance, infection, and cancer immunity. International Journal of Clinical Oncology, 2016, 21, 448-455.	1.0	74
1048	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. Immunity, 2016, 44, 274-286.	6.6	144
1049	Targeting the tumour microenvironment in ovarian cancer. European Journal of Cancer, 2016, 56, 131-143.	1.3	84
1050	PD-1/PD-L1 blockage in cancer treatmentâ€”from basic research to clinical application. International Journal of Clinical Oncology, 2016, 21, 447-447.	1.0	10

#	Article	IF	Citations
1051	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 511-525.	1.4	212
1052	Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 2016, 34, 539-573.	9.5	718
1053	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. Surgery Today, 2016, 46, 1341-1347.	0.7	34
1055	Cytokines and persistent viral infections. Cytokine, 2016, 82, 4-15.	1.4	33
1056	Immunotherapy of Cancer. , 2016, , .		3
1057	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
1058	Immune checkpoint pathways: perspectives on myeloid malignancies. Leukemia and Lymphoma, 2016, 57, 995-1001.	0.6	4
1059	Predictive Markers for the Efficacy of Antiâ€“PD-1/PD-L1 Antibodies in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 976-988.	0.5	197
1060	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 2016, 48, 194-202.	0.3	19
1061	Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Annals of Oncology, 2016, 27, 1135-1137.	0.6	131
1063	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology, 2016, 27, 409-416.	0.6	597
1064	PD-L1-specific T cells. Cancer Immunology, Immunotherapy, 2016, 65, 797-804.	2.0	20
1065	Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Research, 2016, 76, 472-479.	0.4	140
1066	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	3.2	170
1067	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 58-71.	3.3	49
1068	Intellectual property issues of immune checkpoint inhibitors. MAbs, 2016, 8, 10-26.	2.6	12
1069	PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients. Journal of Asthma, 2017, 54, 46-52.	0.9	6
1070	Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?. Lung Cancer, 2017, 105, 49-51.	0.9	8

#	Article	IF	Citations
1071	Adaptive Immunity to Plasmodium Blood Stages. , 2017, , 47-66.		3
1072	Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells. Immunobiology, 2017, 222, 137-147.	0.8	35
1073	A current perspective on cancer immune therapy: stepâ€byâ€step approach to constructing the magic bullet. Clinical and Translational Medicine, 2017, 6, 3.	1.7	58
1074	A special issue on cancer immunotherapy. Cell Research, 2017, 27, 1-2.	5.7	14
1075	Novel immune check point inhibiting antibodies in cancer therapyâ€"Opportunities and challenges. Drug Resistance Updates, 2017, 30, 39-47.	6.5	98
1076	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. Journal of Hematology and Oncology, 2017, 10, 34.	6.9	82
1078	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 4270-4279.	3.2	117
1079	MYC: Master Regulator of Immune Privilege. Trends in Immunology, 2017, 38, 298-305.	2.9	70
1080	Porphyromonas gingivalis activates NFÎºB and MAPK pathways in human oral epithelial cells. BMC Immunology, 2017, 18, 1.	0.9	71
1081	Virosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1725-1737.	1.7	10
1082	A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Scientific Reports, 2017, 7, 42687.	1.6	22
1083	In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. Journal of Biological Chemistry, 2017, 292, 6799-6809.	1.6	16
1084	Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discovery, 2017, 3, 17004.	3.1	147
1085	FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist, 2017, 22, 311-317.	1.9	75
1086	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clinical and Experimental Immunology, 2017, 188, 455-466.	1.1	55
1087	Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treatment Reviews, 2017, 54, 99-109.	3.4	27
1088	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood, 2017, 129, 2186-2197.	0.6	156
1089	LAG-3 Protein Expression in Nonâ€"Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	0.5	192

#	Article	IF	Citations
1090	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483
1091	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. OncoImmunology, 2017, 6, e1294296.	2.1	51
1092	Asbestos and Mesothelioma. Current Cancer Research, 2017, , .	0.2	5
1093	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2
1094	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. Journal of Controlled Release, 2017, 256, 26-45.	4.8	41
1095	Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy. Frontiers of Chemical Science and Engineering, 2017, 11, 676-684.	2.3	9
1096	Immune Characterization of the Programmed Death Receptor Pathway in High Risk ProstateÂCancer. Clinical Genitourinary Cancer, 2017, 15, 577-581.	0.9	33
1097	PD-1 regulates KLRG1+ group 2 innate lymphoid cells. Journal of Experimental Medicine, 2017, 214, 1663-1678.	4.2	163
1098	Checkpoint inhibitors in hematological malignancies. Journal of Hematology and Oncology, 2017, 10, 103.	6.9	106
1099	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunology, Immunotherapy, 2017, 66, 1113-1121.	2.0	29
1100	Role of programmed death ligand 1 and Kupffer cell in immune regulation after orthotopic liver transplantation in rats. International Immunopharmacology, 2017, 48, 8-16.	1.7	12
1101	The use of immunotherapy in the treatment of melanoma. Journal of Hematology and Oncology, 2017, 10, 88.	6.9	89
1102	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Annals of the American Thoracic Society, 2017, 14, 1248-1260.	1.5	15
1103	Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 447-453.	1.4	37
1104	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Thyroid, 2017, 27, 894-901.	2.4	123
1105	Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer, 2017, 109, 74-77.	0.9	19
1106	Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. OncoImmunology, 2017, 6, e1304337.	2.1	15
1107	Immunotherapeutic Approaches to Mesothelioma. Current Cancer Research, 2017, , 347-357.	0.2	0

#	Article	IF	Citations
1108	Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer. Oncology Letters, 2017, 13, 4818-4824.	0.8	10
1109	Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. British Journal of Pharmacology, 2017, 174, 3940-3955.	2.7	48
1110	Intergenerational Transmission of Enhanced Seizure Susceptibility after Febrile Seizures. EBioMedicine, 2017, 17, 206-215.	2.7	8
1111	Panel 3: Genetics and Precision Medicine of Otitis Media. Otolaryngology - Head and Neck Surgery, 2017, 156, S41-S50.	1.1	5
1112	Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 171-181.	1.4	52
1113	Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. Cellular Physiology and Biochemistry, 2017, 41, 907-920.	1.1	88
1114	Frequencies of PD-1- positive T CD3+CD4+, T CD3+CD8+ and BÂCD19+ lymphocytes in female patients with Graves' disease and healthy controlsâ€“ preliminary study. Molecular and Cellular Endocrinology, 2017, 448, 28-33.	1.6	12
1115	Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. Journal of Neuro-Oncology, 2017, 132, 359-372.	1.4	8
1116	PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. International Journal of Clinical Oncology, 2017, 22, 726-733.	1.0	47
1117	Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients. Cytokine, 2017, 91, 82-88.	1.4	36
1118	PD-L1 expression and tumor infiltrating PD-1+Âlymphocytes associated with outcome in HER2+Âbreast cancer patients. Breast Cancer Research and Treatment, 2017, 162, 19-30.	1.1	86
1119	Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. Journal of Biological Chemistry, 2017, 292, 20657-20668.	1.6	59
1120	Sepsis: Staging and Potential Future Therapies. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2017, 9, i-91.	0.3	0
1121	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Seminars in Immunology, 2017, 34, 114-122.	2.7	29
1122	Kaposiâ€™s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. MBio, 2017, 8, .	1.8	57
1123	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. Current Hematologic Malignancy Reports, 2017, 12, 484-494.	1.2	4
1124	Radiotherapy in combination with immune checkpoint inhibitors. Current Opinion in Oncology, 2017, 29, 105-111.	1.1	14
1125	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resistance Updates, 2017, 32, 1-15.	6.5	132

#	Article	IF	Citations
1126	Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Reports, 2017, 6, 169-174.	0.5	17
1127	PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. Cellular Physiology and Biochemistry, 2017, 42, 2267-2280.	1.1	92
1128	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. Oncology, 2017, 93, 387-394.	0.9	31
1129	Determination of PDâ€Ł1 expression in effusions from mesothelioma by immunoâ€cytochemical staining. Cancer Cytopathology, 2017, 125, 908-917.	1.4	10
1130	The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Metaâ€analysis. Scandinavian Journal of Immunology, 2017, 86, 361-367.	1.3	45
1131	Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Scientific Reports, 2017, 7, 7848.	1.6	43
1132	Role of PD-1 in Immunity and Diseases. Current Topics in Microbiology and Immunology, 2017, 410, 75-97.	0.7	136
1133	PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. Journal of Immunology, 2017, 199, 3348-3359.	0.4	54
1134	Differential regulation of PDâ€1 and its ligands in allergic asthma. Clinical and Experimental Allergy, 2017, 47, 1417-1425.	1.4	20
1135	Atezolizumab for the treatment of non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2017, 10, 935-945.	1.3	34
1136	Programmed cell deathâ€1 (PDâ€1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cellâ€“intrinsic PDâ€1. Hepatology, 2017, 66, 1920-1933.	3.6	142
1137	ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. Journal of Experimental Medicine, 2017, 214, 2507-2521.	4.2	109
1138	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure, 2017, 25, 1163-1174.	1.6	253
1139	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapyâ€”Summary of Advances and Future Directions for Studying These Drugs. Cancer Journal (Sudbury, Mass), 2017, 23, 3-9.	1.0	5
1140	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. OncoImmunology, 2017, 6, e1356146.	2.1	27
1141	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PDâ€Ł1 (CD274)â€expression: Possible roles of tumour micro environmental factors for CD274 expression. Journal of Pathology: Clinical Research, 2017, 3, 268-278.	1.3	18
1142	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	2.0	186
1143	Brachial Plexus Neuritis Associated With Antiâ€“Programmed Cell Death-1 Antibodies: Report of 2 Cases. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 192-197.	1.2	22

#	Article	IF	Citations
1144	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant PleuralÂMesothelioma. Journal of Thoracic Oncology, 2017, 12, 1421-1433.	0.5	121
1145	Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacological Research, 2017, 123, 95-102.	3.1	52
1146	PD-1 and PD-L1 expression in bone and soft tissue sarcomas. Pathology, 2017, 49, 506-513.	0.3	58
1147	Nuclear IRF-1 expression as a mechanism to assess â€œCapabilityâ€•to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
1148	Programmed Cell Death Ligand (PD-L1) Expression inÂStage II and III Lung Adenocarcinomas and NodalÂMetastases. Journal of Thoracic Oncology, 2017, 12, 458-466.	0.5	120
1149	Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells. Immunological Investigations, 2017, 46, 80-96.	1.0	18
1150	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Modern Pathology, 2017, 30, 278-285.	2.9	77
1151	Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603.	0.5	21
1152	Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo. Pathology and Oncology Research, 2017, 23, 99-110.	0.9	17
1153	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2017, 23, 454-465.	3.2	126
1154	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. Ca-A Cancer Journal for Clinicians, 2017, 67, 65-85.	157.7	344
1155	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. Molecular Diagnosis and Therapy, 2017, 21, 85-93.	1.6	28
1156	A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunology, Immunotherapy, 2017, 66, 309-318.	2.0	45
1157	Pretreatment lymphocyteâ€toâ€monocyte ratio as an independent prognostic factor for head and neck cancer. Head and Neck, 2017, 39, 247-253.	0.9	92
1158	PDâ€'L1 expression is associated with p16INK4A expression in nonâ€'oropharyngeal head and neck squamous cell carcinoma. Oncology Letters, 2017, 15, 2259-2265.	0.8	11
1159	PD-1/PD-L1 binding studies using microscale thermophoresis. Scientific Reports, 2017, 7, 17623.	1.6	56
1160	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget, 2017, 8, 58457-58468.	0.8	42
1161	Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer. International Journal of Nanomedicine, 2017, Volume 12, 5331-5343.	3.3	84

#	Article	IF	Citations
1162	Immune Checkpoint in Glioblastoma: Promising and Challenging. Frontiers in Pharmacology, 2017, 8, 242.	1.6	133
1163	Targeting Immune Cell Checkpoints during Sepsis. International Journal of Molecular Sciences, 2017, 18, 2413.	1.8	125
1164	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. International Journal of Molecular Sciences, 2017, 18, 645.	1.8	193
1165	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	2.2	225
1166	Macrophages Polarized by Expression of ToxoGRA15II Inhibit Growth of Hepatic Carcinoma. Frontiers in Immunology, 2017, 8, 137.	2.2	18
1167	Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen. Frontiers in Immunology, 2017, 8, 359.	2.2	19
1168	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Frontiers in Immunology, 2017, 8, 961.	2.2	93
1169	Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors. Frontiers in Immunology, 2017, 8, 1300.	2.2	131
1170	Differential Impact of miR-21 on Pain and Associated Affective and Cognitive Behavior after Spared Nerve Injury in B7-H1 ko Mouse. Frontiers in Molecular Neuroscience, 2017, 10, 219.	1.4	19
1171	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 67.	1.3	28
1172	A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. Journal of Immunology Research, 2017, 2017, 1-9.	0.9	34
1173	A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. ELife, 2017, 6, .	2.8	5
1174	Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. PLoS ONE, 2017, 12, e0168822.	1.1	50
1175	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618.	1.1	42
1176	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. Journal of Hematology and Oncology, 2017, 10, 174.	6.9	92
1177	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Research, 2017, 7, 57.	1.1	35
1178	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. International Journal of Molecular Sciences, 2017, 18, 1331.	1.8	60
1179	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget, 2017, 8, 90215-90224.	0.8	68

#	Article	IF	Citations
1180	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	0.5	49
1181	Clinical Significance and Therapeutic Potential of the Programmed Death Ligand-1 (PD-L1) and PD-L2 Expression in Human Colorectal Cancer. Journal of Cancer Science & Therapy, 2017, 09, .	1.7	2
1182	First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets and Therapy, 2017, Volume 6, 1-10.	2.7	26
1183	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget, 2017, 8, 110693-110707.	0.8	115
1184	PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 2017, 8, 2171-2186.	0.8	234
1185	PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders. Current Drug Delivery, 2017, 14, 791-796.	0.8	0
1186	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab. Journal of Blood Medicine, 2017, Volume 8, 41-54.	0.7	5
1187	The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy. Journal of Thoracic Disease, 2017, 9, 4226-4229.	0.6	10
1188	High-affinity human PD-L1 variants attenuate the suppression of T cell activation. Oncotarget, 2017, 8, 88360-88375.	0.8	30
1189	Immune Checkpoint Inhibition in Hodgkin Lymphoma. HemaSphere, 2018, 2, e20.	1.2	15
1190	Cyclosporin A inhibits adipogenic differentiation and regulates immunomodulatory functions of murine mesenchymal stem cells. Biochemical and Biophysical Research Communications, 2018, 498, 516-522.	1.0	6
1191	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14.	0.8	32
1192	The MYC oncogene is a global regulator of the immune response. Blood, 2018, 131, 2007-2015.	0.6	158
1193	Programmed deathâ€ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. Cancer Science, 2018, 109, 814-820.	1.7	31
1194	B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3126-3131.	3.3	35
1195	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. Digestive Diseases and Sciences, 2018, 63, 1706-1725.	1.1	13
1196	PD-L1 expression testing in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876349.	1.4	120
1197	Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes. Melanoma Research, 2018, 28, 423-434.	0.6	11

#	Article	IF	Citations
1198	Contraction of T cell richness in lung cancer brain metastases. Scientific Reports, 2018, 8, 2171.	1.6	74
1199	Immunopathogenesis and immunotherapy of multiple myeloma. International Journal of Hematology, 2018, 107, 278-285.	0.7	53
1200	PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. British Journal of Haematology, 2018, 180, 705-714.	1.2	16
1201	PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. OncoImmunology, 2018, 7, e1423170.	2.1	150
1202	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
1203	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell, 2018, 33, 187-201.e10.	7.7	381
1205	Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Clinical and Experimental Medicine, 2018, 18, 165-175.	1.9	41
1206	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 2-6.	1.0	5
1207	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E468-E477.	3.3	72
1208	Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy. Journal of Pharmaceutical Investigation, 2018, 48, 143-151.	2.7	155
1209	Inhibitors of the PD-1 Pathway in Tumor Therapy. Journal of Immunology, 2018, 200, 375-383.	0.4	112
1210	A major chromatin regulator determines resistance of tumor cells to T cellâ€“mediated killing. Science, 2018, 359, 770-775.	6.0	641
1211	The Basics of Cancer Immunotherapy. , 2018, , .		5
1212	The Basic Concepts in Cancer Immunology and Immunotherapy. , 2018, , 1-19.		3
1213	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
1214	Significance of Immune Checkpoints in Lung Cancer. , 2018, , 59-77.		0
1215	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. Targeted Oncology, 2018, 13, 125-140.	1.7	19
1216	Association of genetic variants of <scp>PD</scp>1 with recurrent pregnancy loss. Reproductive Medicine and Biology, 2018, 17, 195-202.	1.0	5

#	Article	IF	Citations
1217	Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin Î²4/SNAI1/SIRT3 signaling pathway. Oncogene, 2018, 37, 4164-4180.	2.6	91
1218	The Pekin duck programmed death ligand-2: cDNA cloning, genomic structure, molecular characterization and expression analysis. Biochemistry and Biophysics Reports, 2018, 13, 116-122.	0.7	1
1219	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	6.6	1,437
1220	Nivolumab in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy, 2018, 18, 409-420.	1.1	9
1221	PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics, 2018, 70, 73-86.	1.2	100
1222	The emerging world of breast cancer immunotherapy. Breast, 2018, 37, 200-206.	0.9	39
1223	Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2018, 437, 13-36.	1.4	29
1224	Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Nonâ€“Small Cell Lung Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 83-93.	0.6	124
1225	Combination therapy strategies for improving PDâ€1 blockade efficacy: a new era in cancer immunotherapy. Journal of Internal Medicine, 2018, 283, 110-120.	2.7	162
1226	The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18, 153-167.	10.6	1,210
1227	The application and mechanism of PD pathway blockade for cancer therapy. Postgraduate Medical Journal, 2018, 94, 53-60.	0.9	10
1228	Programmed cell death ligand 1 (PDâ€L1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood and Cancer, 2018, 65, e26719.	0.8	39
1229	Humoral and Cellular Immune Dysregulation and Lung Cancer. , 2018, , 137-142.e3.		1
1230	Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5.		0
1231	Immune Checkpoint PDâ€1/PDâ€L1: Is There Life Beyond Antibodies?. Angewandte Chemie - International Edition, 2018, 57, 4840-4848.	7.2	109
1232	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Seminars in Cancer Biology, 2018, 52, 53-65.	4.3	58
1233	Der Immuncheckpoint PDâ€1/PDâ€L1: Gibt es Therapieoptionen jenseits der AntikÃ¶rper?. Angewandte Chemie, 2018, 130, 4932-4940.	1.6	4
1234	Immune checkpoint molecules soluble program death ligand 1 and galectinâ€9 are increased in pregnancy. American Journal of Reproductive Immunology, 2018, 79, e12795.	1.2	89

#	Article	IF	Citations
1235	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 1562-1573.	3.2	150
1236	PD-L1. Journal of Clinical Pathology, 2018, 71, 189-194.	1.0	218
1237	Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1. Molecular Cancer Research, 2018, 16, 243-255.	1.5	117
1238	Hepatocellular carcinoma in the era of immunotherapy. Current Problems in Cancer, 2018, 42, 40-48.	1.0	135
1239	Humanized mice in studying efficacy and mechanisms of PDâ€1â€targeted cancer immunotherapy. FASEB Journal, 2018, 32, 1537-1549.	0.2	260
1240	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood, 2018, 131, 68-83.	0.6	311
1241	Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. Human Pathology, 2018, 71, 1-7.	1.1	46
1242	Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells. Critical Reviews in Immunology, 2018, 38, 379-401.	1.0	58
1243	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	0.8	55
1244	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. Journal of Thoracic Disease, 2018, 10, S3162-S3165.	0.6	0
1245	Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2018, 10, 4433-4444.	0.6	24
1247	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4082-S4084.	0.6	1
1248	Selective Targeting of 4SO4-N-Acetyl-Galactosamine Functionalized Mycobacterium tuberculosis Protein Loaded Chitosan Nanoparticle to Macrophages: Correlation With Activation of Immune System. Frontiers in Microbiology, 2018, 9, 2469.	1.5	4
1249	Tumor microenvironment classification based on Tâ€‘cell infiltration and PDâ€‘L1 in patients with mismatch repairâ€‘proficient and â€‘deficient colorectal cancer. Oncology Letters, 2018, 17, 2335-2343.	0.8	8
1250	A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1â€“insensitive models of triple-negative breast cancer. JCI Insight, 2018, 3, .	2.3	175
1251	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	0.7	40
1252	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. Frontiers in Immunology, 2018, 9, 3061.	2.2	28
1253	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Frontiers in Immunology, 2018, 9, 3081.	2.2	116

#	Article	IF	Citations
1254	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. Ochsner Journal, 2018, 18, 370-376.	0.5	33
1255	Putting the Immunologic Brakes on Cancer. Cell, 2018, 175, 1452-1454.	13.5	75
1256	PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule. Rhinology, 2018, 56, 255-260.	0.7	1
1257	HDAC is indispensable for IFN-Î³-induced B7-H1 expression in gastric cancer. Clinical Epigenetics, 2018, 10, 153.	1.8	38
1258	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Scientific Reports, 2018, 8, 17812.	1.6	39
1259	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon, 2018, 4, e01039.	1.4	37
1260	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Management and Research, 2018, Volume 10, 6457-6468.	0.9	23
1261	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	38
1262	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. Journal of Hematology and Oncology, 2018, 11, 142.	6.9	95
1263	Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317.	0.7	101
1264	2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade â€“ A personal account. Genes and Diseases, 2018, 5, 302-303.	1.5	32
1265	A CD300c-Fc Fusion Protein Inhibits T Cell Immunity. Frontiers in Immunology, 2018, 9, 2657.	2.2	9
1266	An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or Medicine. Science Bulletin, 2018, 63, 1608-1610.	4.3	5
1267	Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis. Frontiers in Immunology, 2018, 9, 2077.	2.2	36
1268	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry, 2018, 29, 3937-3966.	1.8	23
1270	The intracellular signalosome of PD-L1 in cancer cells. Signal Transduction and Targeted Therapy, 2018, 3, 26.	7.1	174
1271	EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity. Journal of Immunology, 2018, 201, 2824-2831.	0.4	13
1272	On the Road to Immunotherapyâ€"Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. Frontiers in Immunology, 2018, 9, 2182.	2.2	15

#	Article	IF	Citations
1273	Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. Biochemical and Biophysical Research Communications, 2018, 505, 830-836.	1.0	10
1274	Predictive biomarkers for tumor immune checkpoint blockade. Cancer Management and Research, 2018, Volume 10, 4501-4507.	0.9	18
1275	Expression of PDâ€'L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion. Oncology Letters, 2018, 16, 5761-5768.	0.8	7
1276	Antigen in theÂAbsence of DAMPs Promotes Immune Tolerance: The Role of Dendritic Cells and Regulatory T Cells. , 2018, , 791-827.		1
1277	Radiopharmacology and molecular imaging of PD-L1 expression in cancer. Clinical and Translational Imaging, 2018, 6, 429-439.	1.1	7
1278	Nobel goes to immune checkpointâ€"Innovative cancer treatment by immunotherapy. Science China Life Sciences, 2018, 61, 1445-1450.	2.3	3
1279	Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2018, 24, 193-204.	1.0	144
1280	New developments in immunotherapy for lymphoma. Cancer Biology and Medicine, 2018, 15, 189.	1.4	24
1281	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	2.2	127
1282	Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. Frontiers in Immunology, 2018, 9, 1822.	2.2	46
1283	Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunology, Immunotherapy, 2018, 67, 1777-1788.	2.0	67
1284	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends in Immunology, 2018, 39, 624-631.	2.9	153
1285	Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins. Cancer Letters, 2018, 431, 73-84.	3.2	33
1286	Emerging biomarkers for immune checkpoint inhibition in lung cancer. Seminars in Cancer Biology, 2018, 52, 269-277.	4.3	67
1287	Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer. Annals of Surgical Oncology, 2018, 25, 2498-2499.	0.7	5
1288	Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance. Journal of Immunology Research, 2018, 2018, 1-14.	0.9	21
1289	Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Modern Pathology, 2018, 31, 1630-1644.	2.9	33
1290	Cancer Vaccines. , 2018, , 161-184.e6.		2

#	Article	IF	Citations
1291	Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. Clinical and Experimental Medicine, 2018, 18, 487-494.	1.9	15
1292	B7-H1 Expression Is Required for Human Endometrial Regenerative Cells in the Prevention of Transplant Vasculopathy in Mice. Stem Cells International, 2018, 2018, 1-12.	1.2	11
1293	Activation of phagocytosis by immune checkpoint blockade. Frontiers of Medicine, 2018, 12, 473-480.	1.5	15
1294	Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Frontiers in Immunology, 2018, 9, 1614.	2.2	23
1295	Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virotherapy, 2018, Volume 7, 65-77.	6.0	57
1296	Construction of an antiâ€programmed deathâ€ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. Oncology Letters, 2018, 16, 157-166.	0.8	9
1297	Stress and Corticosteroids Aggravate Morphological Changes in the Dentate Gyrus after Early-Life Experimental Febrile Seizures in Mice. Frontiers in Endocrinology, 2018, 9, 3.	1.5	18
1298	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. Frontiers in Immunology, 2018, 9, 374.	2.2	51
1299	Emerging Concepts of Adaptive Immunity in Leprosy. Frontiers in Immunology, 2018, 9, 604.	2.2	28
1300	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. Frontiers in Immunology, 2018, 9, 1370.	2.2	49
1301	Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins. Frontiers in Microbiology, 2018, 9, 380.	1.5	6
1302	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. Frontiers in Molecular Neuroscience, 2018, 11, 82.	1.4	61
1303	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. Frontiers in Oncology, 2018, 8, 54.	1.3	62
1304	Melanoma Immunotherapy: Next-Generation Biomarkers. Frontiers in Oncology, 2018, 8, 178.	1.3	53
1305	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
1306	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 2018, 6, 26.	1.4	16
1307	Programmed cell deathâ€1 3â€²â€untranslated region polymorphism is associated with spontaneous clearance of hepatitis B virus infection. Journal of Medical Virology, 2018, 90, 1730-1738.	2.5	11
1308	Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Reports, 2018, 24, 379-390.e6.	2.9	140

#	Article	IF	Citations
1309	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica, 2018, 39, 1693-1698.	2.8	39
1310	Microbial biomarkers for immune checkpoint blockade therapy against cancer. Journal of Gastroenterology, 2018, 53, 999-1005.	2.3	15
1311	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Clinical and Experimental Metastasis, 2018, 35, 503-520.	1.7	9
1312	Structureâ€"Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy. Journal of Medicinal Chemistry, 2018, 61, 10957-10975.	2.9	30
1313	Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNÎ³ secretion. Cancer Letters, 2018, 430, 47-56.	3.2	117
1314	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. British Journal of Cancer, 2018, 119, 538-545.	2.9	111
1315	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). Oncology Letters, 2018, 15, 7497-7505.	0.8	50
1316	PD-L1 expression in malignant salivary gland tumors. BMC Cancer, 2018, 18, 156.	1.1	38
1317	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
1318	B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells. OncoImmunology, 2018, 7, e1504156.	2.1	0
1319	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 104.	6.9	303
1320	Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with antiâ€"PD-L1 to eliminate melanoma in mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8698-E8706.	3.3	77
1321	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 2018, 8, 1069-1086.	7.7	2,128
1322	The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Design, Development and Therapy, 2018, Volume 12, 981-986.	2.0	27
1323	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings, 2018, 93, 917-936.	1.4	4
1324	Principles of Protein Recognition by Small T-Cell Adhesion Proteins and Costimulatory Receptors. , 2018, , 39-80.		0
1325	Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 497-509.	1.4	8
1326	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treatment Reviews, 2019, 74, 49-60.	3.4	38

#	Article	IF	Citations
1327	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene, 2019, 38, 390-405.	2.6	149
1328	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 389-397.	0.5	20
1329	Cancer immunotherapy for metastasis: past, present and future. Briefings in Functional Genomics, 2019, 18, 140-146.	1.3	10
1330	Lentivirusâ€'mediated RNA interference targeting programmed death receptor ligandï¿½1 increases the immunologic antiâ€'tumor effect of dendritic cell vaccination against pancreatic cancer in SCIDâ€'hu mice. Oncology Letters, 2019, 18, 1539-1547.	0.8	6
1331	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity, 2019, 52, 144-160.	1.2	10
1332	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
1333	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€"Review. Frontiers in Immunology, 2019, 10, 2043.	2.2	7
1334	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. Metabolic Brain Disease, 2019, 34, 1705-1712.	1.4	8
1335	BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene, 2019, 38, 6752-6766.	2.6	52
1336	Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. Physiological Reviews, 2019, 99, 1765-1817.	13.1	550
1337	Effect and biomarker of Nivolumab for nonâ€"small-cell lung cancer. Biomedicine and Pharmacotherapy, 2019, 117, 109199.	2.5	22
1338	Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy. Pharmaceutical Patent Analyst, 2019, 8, 87-90.	0.4	20
1339	Considering B7-CD28 as a family through sequence and structure. Experimental Biology and Medicine, 2019, 244, 1577-1583.	1.1	7
1340	Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract. Marine Drugs, 2019, 17, 421.	2.2	13
1341	Immune checkpoint blockade in glioma. , 2019, , 387-396.		0
1342	Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma. Journal of Cancer, 2019, 10, 2578-2587.	1.2	22
1343	The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Molecular Cancer, 2019, 18, 115.	7.9	192
1344	Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 962.	1.6	29

#	Article	IF	Citations
1345	Programmed death ligandâ€1/programmed deathâ€1 inhibition therapy and programmed death ligandâ€1 expression in urothelial bladder carcinoma. Chronic Diseases and Translational Medicine, 2019, 5, 170-177.	0.9	3
1346	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. Cells, 2019, 8, 1213.	1.8	14
1347	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. Seminars in Immunology, 2019, 42, 101295.	2.7	16
1348	PD-L1/PD-1 Axis in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2019, 20, 5347.	1.8	115
1349	Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy. Journal of Clinical Medicine, 2019, 8, 1864.	1.0	13
1350	Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing. Frontiers in Oncology, 2019, 9, 1115.	1.3	21
1351	Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Frontiers in Oncology, 2019, 9, 1111.	1.3	15
1352	Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers, 2019, 11, 1756.	1.7	92
1353	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. Journal of Clinical Medicine, 2019, 8, 1833.	1.0	19
1354	Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. International Immunopharmacology, 2019, 77, 105999.	1.7	43
1355	Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 18-32.	2.7	7
1356	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines, 2019, 7, 100.	2.1	30
1357	Role of PDL1 as a prognostic marker in renal cell carcinoma: a prospective observational study in eastern India. Therapeutic Advances in Urology, 2019, 11, 175628721986885.	0.9	7
1358	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
1359	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology and Oncology, 2019, 12, 92.	6.9	485
1360	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. Russian Journal of Bioorganic Chemistry, 2019, 45, 225-240.	0.3	6
1361	The role of immune regulatory molecules in multiple sclerosis. Journal of Neuroimmunology, 2019, 337, 577061.	1.1	27
1362	Paradox-driven adventures in the development of cancer immunology and immunotherapy. Genes and Diseases, 2019, 6, 224-231.	1.5	3

#	Article	IF	Citations
1363	Pro-Cellular Exhaustion Markers are Associated with Splenic Microarchitecture Disorganization and Parasite Load in Dogs with Visceral Leishmaniasis. Scientific Reports, 2019, 9, 12962.	1.6	11
1364	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Frontiers in Immunology, 2019, 10, 2298.	2.2	244
1365	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Translational Gastroenterology and Hepatology, 2019, 4, 63-63.	1.5	12
1366	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	1.0	41
1367	Unbalanced Expression of ICOS and PD-1 in Patients with Neuromyelitis Optica Spectrum Disorder. Scientific Reports, 2019, 9, 14130.	1.6	9
1368	Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLoS ONE, 2019, 14, e0223325.	1.1	32
1369	Differential Modulation of Human Innate Lymphoid Cell (ILC) Subsets by IL-10 and TGF-Î². Scientific Reports, 2019, 9, 14305.	1.6	28
1370	B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. International Journal of Biochemistry and Cell Biology, 2019, 108, 84-91.	1.2	20
1371	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	2.9	39
1372	Programmed cell death protein receptor and ligands in haematological malignancies â€“ Current status. Critical Reviews in Oncology/Hematology, 2019, 135, 47-58.	2.0	4
1373	The evolving role of immunoâ€oncology for the treatment of head and neck cancer. Laryngoscope Investigative Otolaryngology, 2019, 4, 62-69.	0.6	3
1374	The Prognostic and Therapeutic Value of PD-L1 in Glioma. Frontiers in Pharmacology, 2018, 9, 1503.	1.6	85
1375	Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 47.	3.5	63
1376	Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis . OncoTargets and Therapy, 2019, Volume 12, 3671-3682.	1.0	40
1377	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
1378	Silencing of PD-L2/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity. Journal of Investigative Dermatology, 2019, 139, 2164-2173.e1.	0.3	9
1379	Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 661-674.	1.9	333
1380	Skint8, a Novel B7 Familyâ€“Related Molecule, Negatively Regulates T Cell Responses. Journal of Immunology, 2019, 203, 400-407.	0.4	6

#	Article	IF	Citations
1381	Challenge of immune-mediated adverse reactions in the emergency department. Emergency Medicine Journal, 2019, 36, 369-377.	0.4	10
1382	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258.	3.1	115
1383	Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254.	4.2	125
1384	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends in Cancer, 2019, 5, 208-232.	3.8	54
1385	Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Immunotherapy, 2019, 11, 725-735.	1.0	25
1386	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
1387	Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy. Cytotechnology, 2019, 71, 705-722.	0.7	7
1388	Immune privilege in corneal transplantation. Progress in Retinal and Eye Research, 2019, 72, 100758.	7.3	103
1389	Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes. Journal of Diabetes Research, 2019, 2019, 1-8.	1.0	16
1390	The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology, 2019, 10, 204062071984159.	1.1	23
1391	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Molecular Cell, 2019, 74, 1215-1226.e4.	4.5	144
1392	The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Journal of Gastroenterology, 2019, 54, 1019-1028.	2.3	6
1394	Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma. International Journal of Molecular Sciences, 2019, 20, 1326.	1.8	43
1395	Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report. Oncology Letters, 2019, 17, 4011-4015.	0.8	8
1396	Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Frontiers in Oncology, 2019, 9, 52.	1.3	36
1397	Programmed cell death ligand 1 <scp>d</scp>isruption by <scp>clustered regularly interspaced short palindromic repeats</scp>/Cas9â€genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Science, 2019, 110, 1279-1292.	1.7	31
1398	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. Annals of Surgical Oncology, 2019, 26, 1925-1933.	0.7	23
1399	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist, 2019, 24, S31-S41.	1.9	239

#	Article	IF	Citations
1400	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Frontiers of Medicine, 2019, 13, 438-450.	1.5	32
1401	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 2019, 25, 656-666.	15.2	461
1402	Molecular cloning, expression and characterization of Pekin duck programmed death-1. Gene, 2019, 702, 182-193.	1.0	0
1403	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nature Communications, 2019, 10, 1125.	5.8	131
1404	Construction of a Recombinant Lactococcus lactis Strain Expressing a Variant Porcine Epidemic Diarrhea Virus S1 Gene and Its Immunogenicity Analysis in Mice. Viral Immunology, 2019, 32, 144-150.	0.6	10
1405	Prognostic value of PD-L1 expression in patients with pancreatic cancer. Medicine (United States), 2019, 98, e14006.	0.4	30
1406	NK cell expression of Tim-3: First impressions matter. Immunobiology, 2019, 224, 362-370.	0.8	38
1407	BTNL2â€Ig Protein Attenuates Type 1 Diabetes in Nonâ€Obese Diabetic (NOD) Mice. Advanced Healthcare Materials, 2019, 8, 1800987.	3.9	5
1408	Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. Current Pharmaceutical Design, 2019, 24, 4911-4920.	0.9	27
1409	PD-1 Tumor Suppressor Signaling in T Cell Lymphomas. Trends in Immunology, 2019, 40, 403-414.	2.9	24
1410	YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistance Updates, 2019, 43, 10-28.	6.5	81
1411	High expression of B7â€H2 or B7â€H3 is associated with poor prognosis in hepatocellular carcinoma. Molecular Medicine Reports, 2019, 19, 4315-4325.	1.1	18
1412	Affective and cognitive behavior is not altered by chronic constriction injury in B7-H1 deficient and wildtype mice. BMC Neuroscience, 2019, 20, 16.	0.8	8
1413	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
1414	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1651-1660.	1.2	31
1415	PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 179-187.	1.0	4
1416	PDâ€L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. Oncology Reports, 2019, 41, 2833-2843.	1.2	15
1417	Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biology and Therapy, 2019, 20, 1105-1112.	1.5	22

#	Article	IF	Citations
1418	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. Structure, 2019, 27, 829-836.e3.	1.6	13
1419	A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelialâ€“Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clinical Cancer Research, 2019, 25, 3630-3642.	3.2	46
1420	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integrative Cancer Therapies, 2019, 18, 153473541982709.	0.8	2
1421	Met inhibition revokes IFNÎ³-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer, 2019, 120, 527-536.	2.9	34
1422	Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell International, 2019, 19, 22.	1.8	26
1423	Oral Mucosal Epithelial Cells. Frontiers in Immunology, 2019, 10, 208.	2.2	225
1424	FcÎ³R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 292.	2.2	111
1425	Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy. Archives of Pharmacal Research, 2019, 42, 150-158.	2.7	28
1426	Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. British Journal of Cancer, 2019, 120, 547-554.	2.9	42
1427	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	1.6	106
1428	Is it true that gut microbiota is considered as panacea in cancer therapy?. Journal of Cellular Physiology, 2019, 234, 14941-14950.	2.0	27
1429	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. Cancer Reports, 2019, 2, e1160.	0.6	26
1430	PDâ€L1 expression levels on tumor cells affect their immunosuppressive activity. Oncology Letters, 2019, 18, 5399-5407.	0.8	54
1431	Immunologic treatment strategies in mantle cell lymphoma: checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engager (BiTE) molecules. Annals of Lymphoma, 0, 3, 6-6.	4.5	1
1432	A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24500-24506.	3.3	43
1433	PD-L1 regulation by SDH5 via Î²-catenin/ZEB1 signaling. OncoImmunology, 2019, 8, 1655361.	2.1	14
1434	Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer. Nano Today, 2019, 29, 100801.	6.2	48
1435	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity, 2019, 51, 1059-1073.e9.	6.6	229

#	Article	IF	Citations
1436	Immunotherapy for Multiple Myeloma. Cancers, 2019, 11, 2009.	1.7	20
1437	Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load. Scientific Reports, 2019, 9, 20275.	1.6	27
1438	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	2.6	26
1439	PD-L1 Detectionâ€"Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. American Journal of Dermatopathology, 2019, 41, 539-565.	0.3	8
1440	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714.	0.6	36
1441	Basis of PD1/PD-L1 Therapies. Journal of Clinical Medicine, 2019, 8, 2168.	1.0	85
1442	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 879.	1.3	6
1443	Immunotherapy for Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030627.	2.9	41
1444	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
1445	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
1446	PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer. Anticancer Research, 2019, 39, 443-448.	0.5	18
1447	Loss of <scp>VGLL</scp> 4 suppresses tumor <scp>PD</scp> â€L1 expression and immune evasion. EMBO Journal, 2019, 38, .	3.5	42
1448	Immunotherapy in advanced gastric cancer, is it the future?. Critical Reviews in Oncology/Hematology, 2019, 133, 25-32.	2.0	97
1449	Monocytes show immunoregulatory capacity on CD4+ T cells in a human in-vitro model of extracorporeal photopheresis. Clinical and Experimental Immunology, 2019, 195, 369-380.	1.1	8
1450	High PDâ€L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A metaâ€analysis of the literature. Cell Proliferation, 2019, 52, e12537.	2.4	43
1451	Epithelial-Stromal Interactions in Pancreatic Cancer. Annual Review of Physiology, 2019, 81, 211-233.	5.6	33
1452	Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular Cancer, 2019, 18, 10.	7.9	810
1453	Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research. Cancer Investigation, 2019, 37, 1-7.	0.6	6

#	Article	IF	Citations
1454	Cutting Edge: ICOS-Deficient Regulatory T Cells Display Normal Induction of Il10 but Readily Downregulate Expression of Foxp3. Journal of Immunology, 2019, 202, 1039-1044.	0.4	43
1455	A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 2019, 20, 1.	1.0	63
1456	A prognostic index for colorectal cancer based on preoperative absolute lymphocyte, monocyte, and neutrophil counts. Surgery Today, 2019, 49, 245-253.	0.7	20
1457	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. Annual Review of Cancer Biology, 2019, 3, 385-408.	2.3	17
1458	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-Î²B Activation and PD-L1 Expression. Molecular Cell, 2019, 73, 22-35.e6.	4.5	174
1459	The role and clinical significance of programmed cell death- ligand 1 expressed on CD19+B-cells and subsets in systemic lupus erythematosus. Clinical Immunology, 2019, 198, 89-99.	1.4	12
1460	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. Clinical Colorectal Cancer, 2019, 18, e20-e38.	1.0	62
1461	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
1462	Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study. Archives of Oral Biology, 2019, 98, 99-107.	0.8	11
1463	RNA In Situ Hybridization for Epstein-Barr Virus and Cytomegalovirus: Comparison With In Situ Hybridization and Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 155-159.	0.6	17
1464	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. Journal of Drug Targeting, 2019, 27, 244-256.	2.1	86
1465	Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. Journal of Cranio-Maxillo-Facial Surgery, 2019, 47, 33-40.	0.7	28
1466	Cancer Immunology. , 2020, , 84-96.e5.		0
1467	An update of knowledge on PDâ€L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. Oral Diseases, 2020, 26, 511-526.	1.5	44
1468	Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Modern Pathology, 2020, 33, 518-530.	2.9	61
1469	PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma. Clinical and Experimental Medicine, 2020, 20, 51-62.	1.9	15
1470	Gene networks and toxicity/detoxification pathways in juvenile largemouth bass (Micropterus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	1.3	13
1471	Targeting B7â€1 in immunotherapy. Medicinal Research Reviews, 2020, 40, 654-682.	5.0	44

#	Article	IF	Citations
1472	B7-H4, a promising target for immunotherapy. Cellular Immunology, 2020, 347, 104008.	1.4	56
1473	CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. Journal of Pathology, 2020, 250, 205-216.	2.1	34
1474	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncology, 2020, 16, 4439-4453.	1.1	29
1475	Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Science China Life Sciences, 2020, 63, 180-205.	2.3	40
1476	Combination of C-reactive Protein and Monocyte Count Is a Useful Prognostic Indicator for Patients With Colorectal Cancer. In Vivo, 2020, 34, 299-305.	0.6	7
1477	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomedicine and Pharmacotherapy, 2020, 121, 109625.	2.5	92
1478	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. European Journal of Medicinal Chemistry, 2020, 186, 111876.	2.6	98
1479	Programmed death-ligand 1 triggers PASMCs pyroptosis and pulmonary vascular fibrosis in pulmonary hypertension. Journal of Molecular and Cellular Cardiology, 2020, 138, 23-33.	0.9	48
1480	Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PDâ€L1 into extracellular vesicles. FASEB Journal, 2020, 34, 2213-2226.	0.2	55
1481	SnapshotDx Quiz: January 2020. Journal of Investigative Dermatology, 2020, 140, e1-e6.	0.3	0
1482	CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. International Journal of Cancer, 2020, 146, 1730-1740.	2.3	51
1483	Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. Pathology and Oncology Research, 2020, 26, 651-663.	0.9	18
1484	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics, 2020, 10, 1033-1045.	4.6	27
1485	Advances of immune checkpoints in colorectal cancer treatment. Biomedicine and Pharmacotherapy, 2020, 123, 109745.	2.5	21
1486	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
1487	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. Cancers, 2020, 12, 2794.	1.7	17
1488	Escherichia coli K12 Upregulates Programmed Cell Death Ligand 1 (PD-L1) Expression in Gamma Interferon-Sensitized Intestinal Epithelial Cells via the NF-ÎºB Pathway. Infection and Immunity, 2020, 89, .	1.0	10
1489	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132.	2.2	27

#	Article	IF	Citations
1490	Antibody and antibody fragments for cancer immunotherapy. Journal of Controlled Release, 2020, 328, 395-406.	4.8	63
1491	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
1492	The Immunotherapy Revolution in Kidney Cancer Treatment. Cancer Journal (Sudbury, Mass), 2020, 26, 419-431.	1.0	17
1493	T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors. International Journal of Molecular Sciences, 2020, 21, 7424.	1.8	9
1494	Using phage-assisted continuous evolution (PACE) to evolve human PD1. Experimental Cell Research, 2020, 396, 112244.	1.2	3
1495	The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Frontiers in Immunology, 2020, 11, 1721.	2.2	61
1496	Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction. Journal of Materials Chemistry B, 2020, 8, 10162-10171.	2.9	0
1497	PD-1 expression on uveal melanoma induces tumor proliferation and predicts poor patient survival. International Journal of Biological Markers, 2020, 35, 50-58.	0.7	11
1498	The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Communication and Signaling, 2020, 18, 112.	2.7	62
1499	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663.	2.0	24
1500	Development of a fluorescent probe for the detection of hPD-L1. Journal of Bioscience and Bioengineering, 2020, 130, 431-436.	1.1	6
1501	PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia. IScience, 2020, 23, 101570.	1.9	23
1502	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. Frontiers in Oncology, 2020, 10, 559596.	1.3	9
1503	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. Seminars in Cancer Biology, 2022, 86, 1033-1057.	4.3	14
1504	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers, 2020, 12, 3285.	1.7	85
1505	Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma. Journal of Immunology Research, 2020, 2020, 1-18.	0.9	12
1506	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 36.	1.0	26
1507	PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. Biomarker Research, 2020, 8, 57.	2.8	13

#	Article	IF	Citations
1508	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€"Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508.	2.2	60
1509	B7-H1 Promotes the Functional Effect of Human Gingiva-Derived Mesenchymal Stem Cells on Collagen-Induced Arthritis Murine Model. Molecular Therapy, 2020, 28, 2417-2429.	3.7	17
1510	Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). Expert Opinion on Therapeutic Patents, 2020, 30, 677-694.	2.4	6
1511	Targeting immune checkpoints in hematological malignancies. Journal of Hematology and Oncology, 2020, 13, 111.	6.9	66
1512	Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. , 2020, 8, e001247.		18
1513	Ambulatory blood pressure in patients with systemic lupus erythematosus: Association with markers of immune activation. Lupus, 2020, 29, 1683-1690.	0.8	8
1514	Cancer immunotherapy harnessing Î³Î´ T cells and programmed deathâ€1. Immunological Reviews, 2020, 298, 237-253.	2.8	16
1515	Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22910-22919.	3.3	32
1516	Gated Resonance Energy Transfer (gRET) Controlled by Programmed Death Protein Ligand 1. Nanomaterials, 2020, 10, 1592.	1.9	17
1517	Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. Light: Science and Applications, 2020, 9, 161.	7.7	145
1518	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers, 2020, 12, 2592.	1.7	8
1519	Retinal Pigment Epithelial Cells Derived from Induced Pluripotent Stem (iPS) Cells Suppress or Activate T Cells via Costimulatory Signals. International Journal of Molecular Sciences, 2020, 21, 6507.	1.8	10
1520	PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. OncoImmunology, 2020, 9, 1844403.	2.1	18
1521	Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment. ACS Nano, 2020, 14, 17524-17534.	7.3	26
1522	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers, 2020, 12, 3173.	1.7	36
1523	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2020, 8, 569219.	1.8	59
1524	Clinical significance of the combined measurement of serum B7-H1 and interleukin-10 in colorectal cancer patients. Medicine (United States), 2020, 99, e20044.	0.4	3
1525	Cardiotoxicity danger in immunotherapy. IUBMB Life, 2020, 72, 1160-1167.	1.5	4

#	Article	IF	Citations
1526	How microRNAs affect the PD-L1 and its synthetic pathway in cancer. International Immunopharmacology, 2020, 84, 106594.	1.7	19
1527	Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Human Cell, 2020, 33, 1099-1111.	1.2	9
1528	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomedicine and Pharmacotherapy, 2020, 127, 109996.	2.5	35
1529	Highâ€dimensional analyses reveal a distinct role of Tâ€cell subsets in the immune microenvironment of gastric cancer. Clinical and Translational Immunology, 2020, 9, e1127.	1.7	21
1530	Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. Translational Gastroenterology and Hepatology, 2020, 5, 55-55.	1.5	29
1531	Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 3962.	1.8	18
1532	Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 1075.	2.2	36
1533	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 739-753.	1.9	2
1534	The roles of programmed death ligand 1 in virus-associated cancers. Infection, Genetics and Evolution, 2020, 84, 104368.	1.0	16
1535	Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy. Cancers, 2020, 12, 1316.	1.7	4
1536	Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics. Cell, 2020, 182, 85-97.e16.	13.5	115
1537	Development of bispecific antibodies in China: overview and prospects. Antibody Therapeutics, 2020, 3, 126-145.	1.2	20
1538	Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics, 2020, 10, 6231-6244.	4.6	20
1539	Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer. Molecular Therapy - Oncolytics, 2020, 17, 571-585.	2.0	42
1540	Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. Diagnostics, 2020, 10, 394.	1.3	4
1541	HK3 is correlated with immune infiltrates and predicts response to immunotherapy in nonâ€small cell lung cancer. Clinical and Translational Medicine, 2020, 10, 319-330.	1.7	27
1542	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 364.	2.2	50
1543	Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Research Notes, 2020, 13, 139.	0.6	5

#	Article	IF	Citations
1544	Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neuro-Oncology Practice, 2020, 7, 465-476.	1.0	10
1545	Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nature Immunology, 2020, 21, 365-366.	7.0	14
1546	Immunomodulators in Lymphoma. Current Treatment Options in Oncology, 2020, 21, 28.	1.3	4
1547	Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma. Anticancer Research, 2020, 40, 1487-1494.	0.5	16
1548	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, 1.	0.5	24
1549	Programmed cell death ligandâ€1: A dynamic immune checkpoint in cancer therapy. Chemical Biology and Drug Design, 2020, 95, 552-566.	1.5	13
1550	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology, 2020, 11, 159.	2.2	73
1551	Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Seminars in Nephrology, 2020, 40, 76-85.	0.6	18
1552	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
1553	ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses. Cellular and Molecular Immunology, 2020, 18, 1920-1933.	4.8	8
1554	BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody. Viruses, 2020, 12, 684.	1.5	9
1555	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43.	4.3	35
1556	Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors. Experimental Biology and Medicine, 2020, 245, 1104-1114.	1.1	13
1557	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. Cytokine and Growth Factor Reviews, 2020, 52, 1-14.	3.2	18
1558	Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. Journal of Clinical Oncology, 2020, 38, 1138-1145.	0.8	32
1559	Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142.	0.3	13
1560	Prognostic Biomarkers for Melanoma Immunotherapy. Current Oncology Reports, 2020, 22, 25.	1.8	13
1561	Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells, 2020, 9, 263.	1.8	43

#	Article	IF	Citations
1562	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular Cancer, 2020, 19, 19.	7.9	180
1563	Functional tumor specific CD8Â+ÂT cells in spleen express a high level of PD-1. International Immunopharmacology, 2020, 80, 106242.	1.7	8
1564	Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. BMC Cancer, 2020, 20, 59.	1.1	8
1565	Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model. ACS Omega, 2020, 5, 8474-8482.	1.6	10
1566	TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiformeâ€"Future Perspectives. International Journal of Molecular Sciences, 2020, 21, 3114.	1.8	27
1567	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head and Neck Pathology, 2020, 14, 951-965.	1.3	11
1568	Roles of lncRNAs in cancer: Focusing on angiogenesis. Life Sciences, 2020, 252, 117647.	2.0	54
1569	Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Journal of Cardiovascular Translational Research, 2020, 13, 402-416.	1.1	16
1570	Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sciences, 2020, 254, 117580.	2.0	91
1571	PD-L1â€"PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers, 2020, 12, 924.	1.7	41
1572	Natural Killer Cells: Tumor Surveillance and Signaling. Cancers, 2020, 12, 952.	1.7	56
1573	Talkinâ€™ Toxins: From Coleyâ€™s to Modern Cancer Immunotherapy. Toxins, 2020, 12, 241.	1.5	47
1574	CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. FEBS Open Bio, 2020, 10, 1162-1170.	1.0	3
1575	Co-immunizing with PD-L1 induces CD8+ DCs-mediated anti-tumor immunity in multiple myeloma. International Immunopharmacology, 2020, 84, 106516.	1.7	9
1576	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. Frontiers in Pharmacology, 2020, 11, 441.	1.6	48
1577	The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Translational Andrology and Urology, 2020, 9, 367-381.	0.6	8
1578	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. Cells, 2020, 9, 940.	1.8	8
1579	Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. Archives of Oral Biology, 2020, 114, 104717.	0.8	17

#	Article	IF	Citations
1580	Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer. Annals of Translational Medicine, 2020, 8, 244-244.	0.7	14
1581	Verteporfin Inhibits PD-L1 through Autophagy and the STAT1â€“IRF1â€“TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunology Research, 2020, 8, 952-965.	1.6	63
1582	A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients. Cancer Cell International, 2020, 20, 96.	1.8	21
1583	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
1584	A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy . Cancer Management and Research, 2020, Volume 12, 1981-1990.	0.9	3
1585	The Role of B7 Family Molecules in Maternalâ€“Fetal Immunity. Frontiers in Immunology, 2020, 11, 458.	2.2	33
1586	Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. International Journal of Molecular Sciences, 2020, 21, 2399.	1.8	29
1587	The PD-1/PD-L pathway in rheumatic diseases. Journal of the Formosan Medical Association, 2021, 120, 48-59.	0.8	26
1588	Patients with systemic lupus erythematosus show increased proportions of CD19+CD20â^' B cells and secretion of related autoantibodies. Clinical Rheumatology, 2021, 40, 151-165.	1.0	7
1589	Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cellular and Molecular Life Sciences, 2021, 78, 173-193.	2.4	72
1590	Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biology, 2021, 38, 101780.	3.9	42
1591	Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology, 2021, 73, 104-114.	3.6	54
1592	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. Journal of Advanced Research, 2021, 29, 45-54.	4.4	31
1593	Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer. Translational Research, 2021, 230, 21-33.	2.2	5
1594	Targeting <scp>CTLA</scp>â€4 in cancer: Is it the ideal companion for <scp>PD</scp>â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	2.3	23
1595	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	2.0	26
1596	The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis. Frontiers in Oncology, 2020, 10, 608609.	1.3	18
1597	How wide is the application of genetic big data in biomedicine. Biomedicine and Pharmacotherapy, 2021, 133, 111074.	2.5	5

#	Article	IF	Citations
1598	The role of B7 family members in the generation of Immunoglobulin. Journal of Leukocyte Biology, 2021, 109, 377-382.	1.5	0
1599	Immune checkpoint: The novel target for antitumor therapy. Genes and Diseases, 2021, 8, 25-37.	1.5	27
1600	Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics, 2021, 11, 5955-5969.	4.6	23
1601	The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. Cancer Management and Research, 2021, Volume 13, 757-764.	0.9	0
1602	Biosensors: Homogeneous Detection. , 2021, , .		2
1603	Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. Endocrine Journal, 2021, 68, 613-620.	0.7	8
1604	Molecules in Signal Pathways. , 2021, , 139-154.		0
1605	PDâ€L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. Cancer Science, 2021, 112, 1173-1183.	1.7	27
1606	A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer, 2021, 12, 2735-2746.	1.2	105
1607	Development of a Non-IgG PD-1/PD-L1 Inhibitor by in Silico Mutagenesis and an In-Cell Proteinâ€“Protein Interaction Assay. ACS Chemical Biology, 2021, 16, 316-323.	1.6	7
1608	Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. Frontiers in Immunology, 2020, 11, 563258.	2.2	24
1609	PD-L1 in Breast Cancers and its Prognostic Significance. The Journal of Bahria University Medical and Dental College, 2021, 11, 40-43.	0.0	0
1610	Immune Checkpoint Moleculesâ€”Inherited Variations as Markers for Cancer Risk. Frontiers in Immunology, 2020, 11, 606721.	2.2	28
1611	PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation. Biomaterials Science, 2021, 9, 1246-1255.	2.6	9
1612	PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging. Analyst, The, 2021, 146, 2910-2918.	1.7	11
1613	Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nature Communications, 2021, 12, 1222.	5.8	62
1614	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 619650.	1.1	17
1615	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21

#	Article	IF	Citations
1616	Clinical significance of checkpoint regulator â€œProgrammed death ligand-1 (PD-L1)â€•expression in meningioma: review of the current status. Journal of Neuro-Oncology, 2021, 151, 443-449.	1.4	13
1617	Programmed cell deathâ€1/programmed cell deathâ€ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages. Experimental and Therapeutic Medicine, 2021, 21, 400.	0.8	5
1618	Immune function of miR-214 and its application prospects as molecular marker. PeerJ, 2021, 9, e10924.	0.9	4
1619	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers, 2021, 13, 651.	1.7	7
1620	Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression. Frontiers in Immunology, 2020, 11, 624272.	2.2	43
1622	An in vivo method for diversifying the functions of therapeutic antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	3
1623	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. Pharmaceuticals, 2021, 14, 288.	1.7	21
1624	The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. European Journal of Pharmacology, 2021, 895, 173867.	1.7	21
1625	Identification ACTA2 and KDR as key proteins for prognosis of PDâ€1/PDâ€L1 blockade therapy in melanoma. Animal Models and Experimental Medicine, 2021, 4, 138-150.	1.3	4
1626	T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). Anticancer Research, 2021, 41, 1123-1141.	0.5	6
1627	Immunological Prognostic Factors in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 3587.	1.8	16
1629	The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Frontiers in Oncology, 2021, 11, 573547.	1.3	11
1630	CDKN2A Deletion in Melanoma Excludes T Cell Infiltration by Repressing Chemokine Expression in a Cell Cycle-Dependent Manner. Frontiers in Oncology, 2021, 11, 641077.	1.3	7
1631	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. Cancers, 2021, 13, 1256.	1.7	6
1632	A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery, 2021, 11, 1700-1715.	7.7	86
1633	PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia. Acibadem Universitesi Saglik Bilimleri Dergisi, 2021, 12, .	0.0	0
1634	The synergistic strategies for the <scp>immunoâ€oncotherapy</scp> with photothermal nanoagents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1717.	3.3	9
1635	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	1.0	8

#	Article	IF	Citations
1636	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 2021, 50, 100832.	2.8	5
1637	Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. Neuroscience Bulletin, 2021, 37, 1188-1202.	1.5	30
1638	ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nature Communications, 2021, 12, 2346.	5.8	52
1640	Current and emerging therapies for primary central nervous system lymphoma. Biomarker Research, 2021, 9, 32.	2.8	20
1641	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines, 2021, 9, 509.	2.1	14
1642	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients, 2021, 13, 1718.	1.7	10
1643	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Scientific Reports, 2021, 11, 10264.	1.6	0
1644	Emerging concepts in PD-1 checkpoint biology. Seminars in Immunology, 2021, 52, 101480.	2.7	84
1645	VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses. Immunology Letters, 2021, 233, 42-47.	1.1	6
1646	Porphyromonas gingivalis induced upâ€regulation of PDâ€L1 in colon carcinoma cells. Molecular Oral Microbiology, 2021, 36, 172-181.	1.3	13
1647	Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents. Journal of Personalized Medicine, 2021, 11, 460.	1.1	5
1648	Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas. Frontiers in Immunology, 2021, 12, 669964.	2.2	1
1649	Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. International Journal of Molecular Sciences, 2021, 22, 5383.	1.8	10
1650	Identification of TAPBPL as a novel negative regulator of Tâ€cell function. EMBO Molecular Medicine, 2021, 13, e13404.	3.3	6
1651	The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. Seminars in Cancer Biology, 2022, 86, 1045-1055.	4.3	17
1652	Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. International Journal of Molecular Sciences, 2021, 22, 5158.	1.8	3
1653	Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. Acta Pharmaceutica Sinica B, 2021, 11, 1365-1378.	5.7	38
1654	The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 1132-1140.	0.6	5

#	Article	IF	Citations
1655	Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. International Immunopharmacology, 2021, 95, 107508.	1.7	19
1656	Expression of PD-L1 in EBV-associated malignancies. International Immunopharmacology, 2021, 95, 107553.	1.7	16
1657	Leishmania Parasites Drive PD-L1 Expression in Mice and Human Neutrophils With Suppressor Capacity. Frontiers in Immunology, 2021, 12, 598943.	2.2	13
1658	Advancing to the era of cancer immunotherapy. Cancer Communications, 2021, 41, 803-829.	3.7	90
1659	Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. Oncogene, 2021, 40, 5105-5115.	2.6	7
1661	Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	71
1662	Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Aging, 2021, 13, 18827-18838.	1.4	3
1663	Ecology of Fear: Spines, Armor and Noxious Chemicals Deter Predators in Cancer and in Nature. Frontiers in Ecology and Evolution, 2021, 9, .	1.1	4
1664	Prostasin regulates PD-L1 expression in human lung cancer cells. Bioscience Reports, 2021, 41, .	1.1	2
1665	Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses. Journal of Investigative Dermatology, 2022, 142, 145-154.e8.	0.3	12
1666	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
1667	Contributions of PDâ€L1 reverse signaling to dendritic cell trafficking. FEBS Journal, 2021, , .	2.2	3
1669	A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma. Translational Oncology, 2021, 14, 101085.	1.7	21
1670	Immune checkpoints and cancer development: Therapeutic implications and future directions. Pathology Research and Practice, 2021, 223, 153485.	1.0	29
1671	Sialidase-Conjugated â€œNanoNicheâ€•for Efficient Immune Checkpoint Blockade Therapy. ACS Applied Bio Materials, 2021, 4, 5735-5741.	2.3	8
1672	PDâ€1â€induced proliferating T cells exhibit a distinct transcriptional signature. Immunology, 2021, 164, 555-568.	2.0	5
1674	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews, 2021, 40, 949-982.	2.7	72
1675	Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. Frontiers in Pharmacology, 2021, 12, 670900.	1.6	9

#	Article	IF	Citations
1676	Autophagy controls programmed deathâ€ligandÂ1 expression on cancer cells (Review). Biomedical Reports, 2021, 15, 84.	0.9	12
1677	CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 132, 202-209.	0.2	11
1678	PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions. Pancreatology, 2021, 21, 920-927.	0.5	9
1679	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World Journal of Gastroenterology, 2021, 27, 5362-5375.	1.4	17
1680	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells, 2021, 10, 2250.	1.8	6
1681	Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors. International Journal of Molecular Sciences, 2021, 22, 8355.	1.8	5
1682	Platelets stimulate programmed deathâ€ligand 1 expression by cancer cells: Inhibition by antiâ€platelet drugs. Journal of Thrombosis and Haemostasis, 2021, 19, 2862-2872.	1.9	8
1683	Tumor Microenvironment in Breast Cancerâ€”Updates on Therapeutic Implications and Pathologic Assessment. Cancers, 2021, 13, 4233.	1.7	72
1684	PDâ€1/PDâ€L1 inhibitorsâ€based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Medicine, 2021, 10, 6384-6401.	1.3	10
1685	PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity. Journal of Allergy and Clinical Immunology, 2021, 148, 563-573.e7.	1.5	19
1686	PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression. Clinica Chimica Acta, 2021, 519, 70-75.	0.5	8
1687	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews, 2021, 99, 102253.	3.4	26
1688	The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines. Anesthesia and Analgesia, 2021, Publish Ahead of Print, 1321-1330.	1.1	2
1689	Expression, prognostic significance and therapeutic implications of PDâ€L1 in gliomas. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	8
1690	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. Current Treatment Options in Oncology, 2021, 22, 100.	1.3	11
1692	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037895.	2.9	24
1693	The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. Cancers, 2021, 13, 4426.	1.7	15
1694	InÂvivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell, 2021, 184, 5357-5374.e22.	13.5	79

#	Article	IF	Citations
1695	PD-1 and PD-L1 expression in cardiac transplantation. Cardiovascular Pathology, 2021, 54, 107331.	0.7	9
1696	The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Molecular Cancer, 2021, 20, 116.	7.9	76
1697	Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends in Cancer, 2021, 7, 837-846.	3.8	45
1698	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. International Immunopharmacology, 2021, 98, 107876.	1.7	15
1699	Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nuclear Medicine and Biology, 2021, 100-101, 4-11.	0.3	6
1700	An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam University Journal of Medicine, 2021, 38, 308-317.	0.7	1
1701	Immune Tolerance of the Human Decidua. Journal of Clinical Medicine, 2021, 10, 351.	1.0	37
1702	Cancer Immunotherapy. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 1-41.	0.1	0
1703	Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4. Infectious Disease Reports, 2021, 13, 72-81.	1.5	0
1704	Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy. , 2021, , 193-212.		1
1705	Immune-Checkpoint Inhibitors in B-Cell Lymphoma. Cancers, 2021, 13, 214.	1.7	29
1706	Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors. Cancer Medicine, 2021, 10, 1141-1154.	1.3	34
1707	Inhibitory B7 Family Members in Human Ovarian Carcinoma. , 2008, 622, 261-271.		5
1708	The Endocannabinoid System as a Therapeutic Target in Epilepsy. , 2008, , 407-422.		3
1709	Melanoma and Nonmelanoma Skin Cancers and the Immune System. Advances in Experimental Medicine and Biology, 2008, 624, 187-202.	0.8	9
1710	Febrile Seizures and Mechanisms of Epileptogenesis: Insights from an Animal Model. Advances in Experimental Medicine and Biology, 2004, 548, 213-225.	0.8	69
1711	The Tetanus Toxin Model of Chronic Epilepsy. Advances in Experimental Medicine and Biology, 2004, 548, 226-238.	0.8	27
1713	Immunology of Cryptosporidiosis. , 2014, , 423-454.		8

#	Article	IF	Citations
1714	Neurobiology of Epileptogenesis in the Temporal Lobe. Advances and Technical Standards in Neurosurgery, 2002, , 3-22.	0.2	22
1715	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 2020, 1248, 33-59.	0.8	232
1716	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
1717	Co-signal Molecules in T-Cell Activation. Advances in Experimental Medicine and Biology, 2019, 1189, 3-23.	0.8	45
1718	Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors. Advances in Experimental Medicine and Biology, 2019, 1189, 85-133.	0.8	14
1720	Cancer Immunology. , 2014, , 78-97.e5.		3
1721	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
1722	Checkpoint inhibitor immunotherapy in kidney cancer. Nature Reviews Urology, 2020, 17, 137-150.	1.9	162
1723	p110Î´ PI3K as a therapeutic target of solid tumours. Clinical Science, 2020, 134, 1377-1397.	1.8	15
1724	COADMINISTRATION OF EITHER CYCLOSPORINE OR STEROIDS WITH HUMANIZED MONOCLONAL ANTIBODIES AGAINST CD80 AND CD86 SUCCESSFULLY PROLONG ALLOGRAFT SURVIVAL AFTER LIFE SUPPORTING RENAL TRANSPLANTATION IN CYNOMOLGUS MONKEYS1. Transplantation, 2001, 72, 1128-1137.	0.5	45
1725	Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 258-264.	0.6	21
1726	Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes and Development, 2000, 14, 1693-1711.	2.7	497
1727	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Journal of Clinical Investigation, 2020, 130, 51-61.	3.9	66
1728	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. Journal of Clinical Investigation, 2020, 130, 5380-5396.	3.9	185
1729	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. Journal of Clinical Investigation, 2003, 111, 363-370.	3.9	164
1730	Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. Journal of Clinical Investigation, 2004, 113, 694-700.	3.9	146
1731	The role of herpesvirus entry mediator as a negative regulator of T cellâ€“mediated responses. Journal of Clinical Investigation, 2005, 115, 711-717.	3.9	169
1732	The role of herpesvirus entry mediator as a negative regulator of T cellâ€“mediated responses. Journal of Clinical Investigation, 2005, 115, 711-717.	3.9	85

#	Article	IF	Citations
1733	VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. Journal of Clinical Investigation, 2006, 116, 2817-2826.	3.9	218
1734	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. Journal of Clinical Investigation, 2017, 127, 1960-1977.	3.9	88
1735	PD-L1 serves as a double agent in separating GVL from GVHD. Journal of Clinical Investigation, 2017, 127, 1627-1630.	3.9	9
1736	Costimulation ofâ€‰ T cells by B7-H2, a B7-like molecule that binds ICOS. Blood, 2000, 96, 2808-2813.	0.6	14
1737	Porphyromonas gingivalisand digestive system cancers. World Journal of Clinical Cases, 2019, 7, 819-829.	0.3	19
1738	Reciprocity between Regulatory T Cells and Th17 Cells: Relevance to Polarized Immunity in Leprosy. PLoS Neglected Tropical Diseases, 2016, 10, e0004338.	1.3	62
1739	Homeostatic Plasticity Studied Using In Vivo Hippocampal Activity-Blockade: Synaptic Scaling, Intrinsic Plasticity and Age-Dependence. PLoS ONE, 2007, 2, e700.	1.1	123
1740	B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells. PLoS ONE, 2010, 5, e10800.	1.1	24
1741	Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations. PLoS ONE, 2013, 8, e78367.	1.1	19
1742	Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas. PLoS ONE, 2013, 8, e82870.	1.1	246
1743	Helicobacter pylori cag Pathogenicity Island's Role in B7-H1 Induction and Immune Evasion. PLoS ONE, 2015, 10, e0121841.	1.1	32
1744	PD-L1 Expression on Circulating CD34ï¼‹ Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients. International Journal of Stem Cells, 2018, 11, 78-86.	0.8	10
1745	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer, 2019, 26, R157-R179.	1.6	34
1746	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
1747	The Inflammatory Microenvironment in Wilms Tumors. , 0, , 189-207.		6
1748	Modern approaches to kidney cancer immunotherapy. Onkourologiya, 2018, 14, 54-67.	0.1	15
1749	The influence of aranoza drug formulations and Â«emptyÂ» liposomes on the expression of PD-L1 Ð¸ PD-L2 in human melanoma cell lines. , 2017, 16, 74-81.	0.3	2
1750	The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. Sultan Qaboos University Medical Journal, 2019, 19, 277.	0.3	3

#	Article	IF	Citations
1751	The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. Aging, 2021, 13, 2279-2293.	1.4	4
1752	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 47252-47264.	0.8	79
1753	KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget, 2016, 7, 82104-82111.	0.8	30
1754	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget, 2017, 8, 14416-14427.	0.8	70
1755	Hypoxia enhances indoleamine 2,3-dioxygenase production in dendritic cells. Oncotarget, 2018, 9, 11572-11580.	0.8	30
1756	Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget, 2018, 9, 37439-37457.	0.8	96
1757	B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget, 2015, 6, 3452-3461.	0.8	108
1758	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget, 2016, 7, 33350-33362.	0.8	56
1759	Costimulation and Pancreatic Autoimmunity: The PD-1/PD-L Conundrum. Review of Diabetic Studies, 2006, 3, 6-6.	0.5	10
1760	Decoding cancerâ€™s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
1761	Melanoma immunotherapy dominates the field. Annals of Translational Medicine, 2016, 4, 269-269.	0.7	19
1762	Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry, 2019, 26, 3009-3025.	1.2	286
1763	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry, 2020, 27, 2402-2448.	1.2	12
1764	Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer. Current Pharmaceutical Design, 2019, 24, 4605-4610.	0.9	28
1765	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Current Drug Targets, 2017, 18, 315-331.	1.0	39
1766	Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. Current Cancer Drug Targets, 2019, 19, 896-905.	0.8	34
1767	Stimulation of Human CD4+ T Lymphocytes via TLR3, TLR5 and TLR7/8 Up-Regulates Expression of Costimulatory and Modulates Proliferation. Open Microbiology Journal, 2009, 3, 1-8.	0.2	17
1768	PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. Anticancer Research, 2017, 37, 1433-1442.	0.5	30

#	Article	IF	Citations
1769	Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. Anticancer Research, 2018, 38, 107-112.	0.5	31
1771	Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2951-2957.	0.5	8
1772	Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions. International Journal of Molecular Sciences, 2020, 21, 3639.	1.8	8
1773	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells. World Journal of Gastroenterology, 2008, 14, 6853.	1.4	11
1774	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. World Journal of Gastroenterology, 2009, 15, 5129.	1.4	18
1775	B7molecule mRNA expression in colorectal carcinoma. World Journal of Gastroenterology, 2005, 11, 5655.	1.4	11
1776	Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World Journal of Gastroenterology, 2006, 12, 457.	1.4	133
1777	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2016, 22, 8389.	1.4	22
1778	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World Journal of Gastroenterology, 2018, 24, 2686-2697.	1.4	23
1779	Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World Journal of Gastroenterology, 2019, 25, 1684-1696.	1.4	29
1780	In situexpression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. World Journal of Gastroenterology, 2003, 9, 1370.	1.4	24
1782	Downregulation of PDâ€'L1 via amide analogues of brefelamide: Alternatives to antibodyâ€'based cancer immunotherapy. Experimental and Therapeutic Medicine, 2020, 19, 3150-3158.	0.8	5
1783	Clinical significance of CD38 and CD101 expression in PDâ€'1+CD8+ TÂcells in patients with epithelial ovarian cancer. Oncology Letters, 2020, 20, 724-732.	0.8	10
1784	Immunotherapy a New Hope for Cancer Treatment: A Review. Pakistan Journal of Biological Sciences, 2018, 21, 135-150.	0.2	21
1785	Novel Approaches to Pediatric Cancer: Immunotherapy. AIMS Medical Science, 2015, 2, 104-117.	0.2	1
1786	Immunotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 2-14.	1.3	53
1787	PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2015, 4, 203-8.	1.3	43
1788	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Translational Lung Cancer Research, 2015, 4, 728-42.	1.3	48

#	Article	IF	Citations
1789	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational Lung Cancer Research, 2015, 4, 743-51.	1.3	31
1790	Predictive factors for immunotherapy in melanoma. Annals of Translational Medicine, 2015, 3, 208.	0.7	27
1791	Targeted therapies in development for non-small cell lung cancer. Journal of Carcinogenesis, 2013, 12, 22.	2.5	67
1792	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1167-1175.	0.3	51
1793	PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. Journal of Clinical & Cellular Immunology, 2013, 04, 143.	1.5	58
1794	Cancer immunotherapy by targeting immune checkpoint receptors. World Journal of Immunology, 2018, 8, 1-11.	0.5	4
1795	IL-12 Regulates B7-H1 Expression in Ovarian Cancer-associated Macrophages by Effects on NF-Î¹B Signalling. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5767-5772.	0.5	28
1796	Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biology and Medicine, 2015, 12, 87-95.	1.4	35
1797	Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research. Cureus, 2018, 10, e2130.	0.2	4
1798	The Adrenergic Nerve Network in Cancer. Advances in Experimental Medicine and Biology, 2021, 1329, 271-294.	0.8	5
1799	Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110464.	0.8	0
1800	Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer. Cancers, 2021, 13, 5225.	1.7	8
1801	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. Frontiers in Cell and Developmental Biology, 2021, 9, 760211.	1.8	9
1802	Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma. Bioengineered, 2021, 12, 9520-9530.	1.4	8
1803	Metabolic regulation of the cancer-immunity cycle. Trends in Immunology, 2021, 42, 975-993.	2.9	28
1804	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. Acta Biomedica Scientifica, 2021, 6, 146-159.	0.1	0
1805	Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer. Cancer Research, 2021, 81, 5141-5143.	0.4	8
1806	Do Effects of Febrile Seizures Differ in Normal and Abnormal Brain?. , 2002, , 139-151.		0

#	Article	IF	Citations
1807	Physiology of Limbic Hyperexcitability after Experimental Complex Febrile Seizures. , 2002, , 203-213.		2
1808	The Genomic Biology of the Human Chromosome 2q33 Costimulatory Receptor Region. , 2002, , 81-102.		0
1809	Mast Cells. Annual Review of Immunology, 0, , .	9.5	0
1811	Co-stimulation Regulation of Immune Tolerance and Autoimmunity. , 2007, , 121-138.		0
1812	Ocular Immune Privilege. Journal of the Society of Japanese Women Scientists, 2007, 8, 13-18.	0.0	1
1813	Adaptative Immune Responses in HIV-1 Infection. , 2007, , 333-378.		0
1814	The Double-Hit Hypothesis: Is It Clinically Relevant?. , 2008, , 385-395.		0
1815	Cancer-Specific Vaccines. , 2008, , 649-669.		1
1816	T-cell Unresponsiveness in Renal Cell Carcinoma Patients. , 2008, , 115-130.		0
1817	Therapeutic cancer vaccines. , 2008, , 1135-1145.		0
1818	Cancer Immunology. , 2008, , 77-93.		1
1819	New Approaches for Optimizing Melanoma Vaccines. Translational Medicine Series, 2008, , 143-160.	0.0	1
1820	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. , 2009, , 367-403.		0
1821	Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. , 2009, , 575-590.		0
1823	Vaccine-Primed Lymph Node Cells in the Adoptive Immunotherapy of Cancer: Presence of Host Immune Suppression Induced by Established Cancer. , 2009, , 425-432.		0
1824	Transplantation Immunobiology. , 2009, , 1835-1866.		1
1825	Molecular Markers for Predicting Prognosis of Renal Cell Carcinoma. , 2009, , 449-471.		1
1826	Expression of mouse PD-1/PD-L1 recombinant protein in prokaryotic cells. Academic Journal of Second Military Medical University, 2010, 30, 385-389.	0.0	0

#	Article	IF	Citations
1827	Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. , 2012, , 319-334.		0
1828	Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity. , 2012, , 251-266.		0
1829	Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints. IOSR Journal of Pharmacy, 2012, 2, 01-08.	0.1	0
1830	Preconditioning for Epilepsy. , 2013, , 521-539.		0
1831	Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. , 2013, , 315-333.		1
1834	Renal tumors: evaluation of prognostic factors in 98 cases from a reference hospital in Porto Alegre, Brazil. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2014, 50, 57-63.	0.3	0
1835	Immunology of Pediatric Renal Transplantation. , 2015, , 1-51.		0
1836	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. Cancer Drug Discovery and Development, 2015, , 231-244.	0.2	0
1837	Immunology of Pediatric Renal Transplantation. , 2016, , 2457-2500.		0
1838	Inhibitory Immune Checkpoints and T-Cell Exhaustion in Lymphoma. Journal of Blood Disorders and Medicine, 2016, 1, .	0.0	0
1839	Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.		0
1840	Multipl miyelomâ€™da CD4+ regÃ¼latÃ¶r T hÃ¼crelerin rolÃ¼. Ã‡ukurova Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 2017, 42, 546-551.	0.0	0
1841	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
1842	Multifactorial regulators of tumor programmed death-ligand 1 (PD-L1) response. Translational Cancer Research, 2017, 6, S1451-S1454.	0.4	1
1843	Cellular Automata (CA) Model for Protein. , 2018, , 291-325.		1
1844	Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in chronic apical periodontitis. European Endodontic Journal, 2018, 4, 3-8.	0.4	3
1845	New Progress in Breast Cancer Immunotherapy. Advances in Clinical Medicine, 2018, 08, 47-52.	0.0	0
1846	New Development of Cancer Immunotherapy : History of Immunity Check Inhibitors Focusing on Programmed Death-1 (PD-1). Japanese Journal of Neurosurgery, 2018, 27, 712-722.	0.0	0

#	Article	IF	Citations
1847	Construction and Identification of Eukaryotic Expression Vector of Human Programmed Death Receptor 1. Bioprocess, 2018, 08, 55-60.	0.1	0
1848	Gut Microbiome and the Response to Immunotherapy in Cancer. Discoveries, 2018, 6, e84.	1.5	4
1849	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
1850	Immunology of Melanoma. , 2019, , 1-32.		0
1852	Expression of PDCD1 (PD-1) Gene among Non-small Cell Lung Cancer (NSCLC) Patients with Real-Time PCR Application. Asian Journal of Biochemistry Genetics and Molecular Biology, 0, , 1-9.	0.0	1
1854	Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. , 2020, , 437-452.		0
1855	Overview of theÂImmune System and Its Pharmacological Targets. , 2020, , 1-42.		1
1857	In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligandâ€1 inhibitor in anaplastic lymphoma kinaseâ€rearranged nonâ€smallâ€cell lung cancer. Cancer Science, 2020, 111, 1887-1898.	1.7	8
1860	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 770561.	1.3	51
1861	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
1862	Immunology of Melanoma. , 2020, , 41-72.		0
1864	Expression features of antigens involved in the formation of immunological synapse in splenic marginal zone lymphoma. Oncogematologiya, 2020, 15, 18-28.	0.1	0
1866	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
1867	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
1868	Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity. SSRN Electronic Journal, 0, , .	0.4	0
1869	Immunotherapy for Glioblastomas. , 0, , .		0
1870	Advances in systemic therapy for non-small cell lung cancer. BMJ, The, 2021, 375, n2363.	3.0	134
1871	Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives. Advanced Drug Delivery Reviews, 2021, 179, 114035.	6.6	23

#	Article	IF	Citations
1872	The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis. Scientific Reports, 2021, 11, 21504.	1.6	21
1873	Programmed Cell Death Ligand 1 Is Enriched in Mammary Stem Cells and Promotes Mammary Development and Regeneration. Frontiers in Cell and Developmental Biology, 2021, 9, 772669.	1.8	4
1874	New Insights into the Role of PD-1 and Its Ligands in Allergic Disease. International Journal of Molecular Sciences, 2021, 22, 11898.	1.8	13
1875	NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 565-575.	1.2	4
1877	Co-Receptors in the Positive and Negative Regulation of T-Cell Immunity. , 2008, , 221-245.		0
1879	Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. , 2008, , 29-40.		0
1880	Pathological significance of abnormal recepteur dâ€™origine nantais and programmed death ligand 1 expression in colorectal cancer. World Journal of Gastrointestinal Oncology, 2020, 12, 1216-1236.	0.8	1
1881	Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cellular and Molecular Immunology, 2006, 3, 179-87.	4.8	65
1882	T cell costimulation and coinhibition: genetics and disease. Discovery Medicine, 2011, 12, 119-28.	0.5	21
1883	Role of biphasic changes in splenic dendritic cell activity in a mouse model of multiple organ dysfunction syndrome. International Journal of Clinical and Experimental Pathology, 2014, 7, 4720-33.	0.5	1
1884	B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 6015-23.	0.5	75
1885	Reflections on immune checkpoint inhibition in non-small cell lung cancer. Translational Lung Cancer Research, 2014, 3, 411-3.	1.3	9
1886	Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. American Journal of Cancer Research, 2015, 5, 2277-84.	1.4	5
1887	Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 9351-9.	0.5	22
1888	Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. International Journal of Clinical and Experimental Pathology, 2015, 8, 11084-91.	0.5	66
1889	Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population. International Journal of Clinical and Experimental Medicine, 2015, 8, 16585-91.	1.3	28
1890	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. American Journal of Clinical and Experimental Urology, 2016, 4, 1-8.	0.4	22
1892	Immune reaction by cytoreductive prostatectomy. American Journal of Clinical and Experimental Urology, 2019, 7, 64-79.	0.4	2

#	Article	IF	Citations
1893	Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. Oncology Letters, 2019, 18, 2661-2669.	0.8	4
1894	Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. International Journal of Clinical and Experimental Pathology, 2019, 12, 123-132.	0.5	4
1895	Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis. International Journal of Clinical and Experimental Pathology, 2018, 11, 1256-1264.	0.5	2
1896	Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features. International Journal of Clinical and Experimental Pathology, 2017, 10, 10565-10570.	0.5	0
1898	The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population. International Journal of Clinical and Experimental Pathology, 2020, 13, 2130-2136.	0.5	2
1899	Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy. Biochemistry (Moscow), 2021, 86, 1461-1468.	0.7	2
1900	PD-L1 sustains chronic, cancer cellâ€“intrinsic responses to type I interferon, enhancing resistance to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
1901	ÐŸÐ°ÑŠÐ°Ð¼ÐµÑ‚Ñ€Ñ‹ Ð¼Ð¸ÐºÑ€Ð¾Ñ•Ð¾Ñ€ÑƒÐ¶ÐµÐ½Ð¸Ñ•Ð¾Ð¿ÑƒÑ…Ð¾Ð»Ð¸ Ð¾Ð¿Ñ€ÐµÐ´ÐµÐ»ÑÑŽÑ‚ ÑÑ„Ñ„ÐµÐºÑ‚Ð¸Ð²Ð½Ð¾ÑÑ‚ÑŒ Ð°Ð½Ñ‚Ð¸-PD-1/PD-L1 Ñ‚ÐµÑ€Ð°Ð¿Ð¸Ð¸. Ð‘Ð¸Ð¾Ñ…Ð¸Ð¼Ð¸Ñ•, 2021, 86, 1461-1468.	0.7	2
1902	Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Frontiers in Oncology, 2021, 11, 749064.	1.3	17
1903	Immune Checkpoints and Innate Lymphoid Cellsâ€”New Avenues for Cancer Immunotherapy. Cancers, 2021, 13, 5967.	1.7	11
1904	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
1905	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight, 2022, 7, .	2.3	20
1906	Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. Cancer Letters, 2022, 527, 127-139.	3.2	18
1907	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. International Immunopharmacology, 2022, 103, 108484.	1.7	2
1908	The potential role of vitamin C in empowering cancer immunotherapy. Biomedicine and Pharmacotherapy, 2022, 146, 112553.	2.5	24
1909	The role of A Disintegrin and Metalloproteinase (ADAM)-10 in T helper cell biology. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119192.	1.9	5
1910	Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Frontiers in Pharmacology, 2021, 12, 790963.	1.6	17
1911	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022, 11, 320.	1.8	43

#	Article	IF	Citations
1912	The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems. Frontiers in Oncology, 2021, 11, 704999.	1.3	8
1913	CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patientsâ€™ Survival. Cancer Investigation, 2022, 40, 228-233.	0.6	4
1914	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergology International, 2022, 71, 169-178.	1.4	34
1915	B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview. International Journal of Rheumatic Diseases, 2022, 25, 259-271.	0.9	4
1916	Programmed death ligand 1 signals in cancer cells. Nature Reviews Cancer, 2022, 22, 174-189.	12.8	133
1917	Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. Cell Communication and Signaling, 2022, 20, 14.	2.7	23
1918	A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Frontiers in Pharmacology, 2021, 12, 820446.	1.6	6
1919	PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-Î² receptor I versus II. Cell Reports, 2022, 38, 110349.	2.9	15
1920	Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms. Journal of Gastrointestinal Surgery, 2022, 26, 1213-1223.	0.9	0
1921	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury. Journal of Neuroinflammation, 2022, 19, 43.	3.1	21
1922	Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. International Journal of Hyperthermia, 2022, 39, 278-286.	1.1	19
1923	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduction and Targeted Therapy, 2021, 6, 422.	7.1	57
1924	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, .	0.5	6
1925	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	1.6	53
1926	RAS pathway regulation in melanoma. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	11
1927	Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. Journal of Clinical Medicine, 2022, 11, 1257.	1.0	5
1928	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology and Oncology, 2022, 15, 24.	6.9	136
1929	Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer. OncoImmunology, 2022, 11, 2043037.	2.1	1

#	Article	IF	Citations
1930	LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Molecular Cancer, 2022, 21, 75.	7.9	54
1931	Impact of Cannabinoid Compounds on Skin Cancer. Cancers, 2022, 14, 1769.	1.7	9
1932	Hostâ€“Pathogen Interaction in Leishmaniasis: Immune Response and Vaccination Strategies. Immuno, 2022, 2, 218-254.	0.6	21
1933	Overexpression of PDâ€Ł1 causes germ cells to slough from mouse seminiferous tubules via the PDâ€Ł1/PDâ€Ł1 interaction. Journal of Cellular and Molecular Medicine, 2022, , .	1.6	3
1934	Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis. Cureus, 2022, 14, e23845.	0.2	6
1935	Current methods and emerging approaches for detection of programmed death ligand 1. Biosensors and Bioelectronics, 2022, 208, 114179.	5.3	3
1936	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. International Journal of Molecular Sciences, 2022, 23, 245.	1.8	6
1937	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research, 2022, 40, 109-124.	4.4	10
1938	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528.	21.5	201
1939	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. Frontiers in Immunology, 2021, 12, 794226.	2.2	2
1940	The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma. Annals of Translational Medicine, 2021, 9, 1727-1727.	0.7	1
1941	Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. Cancer Research, 2005, 65, 1089-1096.	0.4	819
1942	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Frontiers in Pharmacology, 2022, 13, 835510.	1.6	10
1943	Therapeutic approaches for the treatment of head and neck squamous cell carcinomaâ€“An update on clinical trials. Translational Oncology, 2022, 21, 101426.	1.7	33
1970	The combination of PD-1 blockade with interferon-Î± has a synergistic effect on hepatocellular carcinoma. , 2022, 19, 726-737.		28
1971	Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype. Histology and Histopathology, 2021, 36, 77-89.	0.5	0
1976	Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. Advances in Clinical Medicine, 2022, 12, 3079-3086.	0.0	0
1977	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. Frontiers in Pharmacology, 2022, 13, 869488.	1.6	8

#	Article	IF	Citations
1978	Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 2022, 29, 3044-3060.	0.9	239
1979	Over-expression of Programmed Death Ligand 1 (PD-L1) in Refractory Inflammatory Bowel Disease (IBD). Human Pathology, 2022, , .	1.1	3
1980	Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. OncoTargets and Therapy, 2022, Volume 15, 437-468.	1.0	11
1981	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review of Immunology, 2022, 40, 45-74.	9.5	122
1982	Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma. Genes and Immunity, 2022, 23, 129-140.	2.2	6
1983	Transcriptomic characterization of Atlantic salmon (Salmo salar) head kidney following administration of Aeromonas salmonicida subsp. masoucida vaccine. Fish and Shellfish Immunology, 2022, , .	1.6	0
1984	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. Cancers, 2022, 14, 2450.	1.7	4
1985	Extrafollicular Plasmablasts Present in the Acute Phase of Infections Express High Levels of PD-L1 and Are Able to Limit T Cell Response. Frontiers in Immunology, 2022, 13, .	2.2	1
1986	Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research, 2022, 28, 3917-3928.	3.2	31
1987	Cell-based therapies for rheumatoid arthritis: opportunities and challenges. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211002.	1.2	13
1988	The CD8Î±â€“PILRÎ± interaction maintains CD8 ⁺ T cell quiescence. Science, 2022, 376, 996-1001.	6.0	9
1989	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Frontiers in Immunology, 0, 13, .	2.2	3
1990	Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. Molecules, 2022, 27, 3545.	1.7	1
1991	PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. International Journal of Molecular Sciences, 2022, 23, 5837.	1.8	7
1992	Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Frontiers of Medicine, 2022, 16, 307-321.	1.5	6
1994	L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression. , 2022, 10, e003957.		5
1995	Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome. Immunologic Research, 2022, 70, 698-707.	1.3	9
1996	Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma. Neuroscience Bulletin, 2022, 38, 1069-1084.	1.5	6

#	Article	IF	Citations
1997	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	21.5	134
1998	Research Progress of Chemokine and Costimulatory Molecules in the Pathogenesis of Mycoplasma pneumoniae Pneumonia in Children. Advances in Clinical Medicine, 2022, 12, 5937-5945.	0.0	0
1999	Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1. BMC Chemistry, 2022, 16, .	1.6	3
2000	Screening and Identification of a Novel Antiâ€“Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity. Molecular Pharmacology, 2022, 102, 161-171.	1.0	1
2001	Application of PDâ€L1 blockade in refractory histiocytic sarcoma: A case report. Molecular and Clinical Oncology, 2022, 17, .	0.4	3
2002	Research progress of <scp>PDâ€L1</scp> nonâ€glycosylation in cancer immunotherapy. Scandinavian Journal of Immunology, 2022, 96, .	1.3	2
2003	Association of PD-1/PD-L1 expression and Epstein-â€“Barr virus infection in patients with invasive breast cancer. Diagnostic Pathology, 2022, 17, .	0.9	7
2004	Identification and characterization of novel CD274 (PDâ€L1) regulating microRNAs and their functional relevance in melanoma. Clinical and Translational Medicine, 2022, 12, .	1.7	4
2005	Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	5
2006	EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. International Immunopharmacology, 2022, 110, 109031.	1.7	4
2007	The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis. Journal of Investigative Dermatology, 2022, 142, 3167-3174.e9.	0.3	8
2008	PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway. Scientific Reports, 2022, 12, .	1.6	18
2009	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	2
2010	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers in Oncology, 0, 12, .	1.3	32
2011	Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes and Diseases, 2023, 10, 1318-1350.	1.5	11
2012	PD-L1 testing by immunohistochemistry in Immuno-Oncology. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	6
2013	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. Current Medicinal Chemistry, 2023, 30, 3215-3237.	1.2	3
2014	Preclinical antibody-PET imaging of PD-L1. Frontiers in Nuclear Medicine, 0, 2, .	0.7	0

#	Article	IF	Citations
2015	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. International Journal of Molecular Sciences, 2022, 23, 8599.	1.8	10
2016	Myc inhibition tips the immune balance to promote antitumor immunity. , 2022, 19, 1030-1041.		4
2017	Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. Biomedicine and Pharmacotherapy, 2022, 154, 113618.	2.5	11
2018	Successes and failures of immunotherapy for gastric cancer. Drug Discovery Today, 2022, 27, 103343.	3.2	3
2019	The tumor microenvironment. , 2022, , 31-58.		7
2020	Tumor Microenvironment and Inflammatory Markers. , 2022, , 35-43.		0
2021	Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. Communications Biology, 2022, 5, .	2.0	7
2022	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after â€œIFN-Î³ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerâ€. British Journal of Cancer, 2023, 128, 461-467.	2.9	9
2023	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	97
2024	<scp>PDâ€L1</scp>/<scp>PDâ€L1</scp> signalling promotes colorectal cancer cell migration ability through <scp>RAS</scp>/<scp>MEK</scp>/<scp>ERK</scp>. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 1281-1293.	0.9	7
2026	miR-aculous new avenues for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
2027	PD-L1 enhances migration and invasion of trophoblasts by upregulating ARHGDIB via transcription factor PU.1. Cell Death Discovery, 2022, 8, .	2.0	4
2028	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	0
2029	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
2030	PD-L1 Status in Tenosynovial Giant Cell Tumors. Medicina (Lithuania), 2022, 58, 1270.	0.8	1
2031	Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. Frontiers in Genetics, 0, 13, .	1.1	1
2032	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	33
2033	Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective. Cancer Letters, 2022, 550, 215945.	3.2	15

#	Article	IF	Citations
2034	Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody. Frontiers in Immunology, 0, 13, .	2.2	2
2035	Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences, 2022, 23, 12067.	1.8	15
2036	Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. Metabolites, 2022, 12, 966.	1.3	2
2037	FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	21
2038	Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. , 2022, 10, e005573.		11
2039	PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients. Medicina (Lithuania), 2022, 58, 1399.	0.8	2
2040	Tumor immune microenvironment in therapyâ€naive esophageal adenocarcinoma could predict the nodal status. Cancer Medicine, 2023, 12, 5526-5535.	1.3	4
2041	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
2042	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. Animals, 2022, 12, 2661.	1.0	2
2043	Expression profile of immunoregulatory factors in canine tumors. Veterinary Immunology and Immunopathology, 2022, 253, 110505.	0.5	0
2044	Autoimmunity: Are we asking the right question?. Frontiers in Immunology, 0, 13, .	2.2	6
2045	Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. International Journal of Molecular Sciences, 2022, 23, 13356.	1.8	3
2046	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. Medicina (Lithuania), 2022, 58, 1572.	0.8	5
2047	Role of non-coding RNA in immune microenvironment and anticancer therapy of gastric cancer. Journal of Molecular Medicine, 2022, 100, 1703-1719.	1.7	6
2048	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	2.0	14
2049	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
2050	Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 0, , .		0
2052	Preclinical models for development of immuneâ€“oncology therapies. Immuno-oncology Insights, 2022, 03, 396-398.	0.0	2

#	Article	IF	Citations
2053	Expression and T cell regulatory action of the PDâ€1 immune checkpoint in the ovary and fallopian tube. American Journal of Reproductive Immunology, 2023, 89, .	1.2	1
2054	Diesel exhaust particle exposure accelerates oxidative DNA damage and cytotoxicity in normal human bronchial epithelial cells through PD-L1. Environmental Pollution, 2023, 317, 120705.	3.7	3
2055	Selective enrichment and detection of PD-L1 positive extracellular vesicles derived from human plasma and patient derived tumor cells. Sensors and Actuators B: Chemical, 2023, 377, 133086.	4.0	0
2057	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. , 2022, , 1-16.		0
2058	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology, 2023, 20, 133-157.	1.9	46
2059	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. Immuno, 2022, 2, 671-691.	0.6	2
2060	Divergent roles of PD-L1 in immune regulation during ischemiaâ€“reperfusion injury. Frontiers in Immunology, 0, 13, .	2.2	1
2061	B7 family protein glycosylation: Promising novel targets in tumor treatment. Frontiers in Immunology, 0, 13, .	2.2	4
2062	Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. International Journal of Molecular Sciences, 2022, 23, 15384.	1.8	12
2063	Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma. Frontiers in Genetics, 0, 13, .	1.1	2
2064	Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective. Biomedicines, 2022, 10, 3277.	1.4	4
2065	Importance of lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs) in cancer cells. Health Science Reports, 2023, 6, .	0.6	5
2066	PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection (TUM2P.881). Journal of Immunology, 2014, 192, 71.5-71.5.	0.4	0
2067	PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 16, 1-8.	0.8	0
2068	CD8 and CD4 Positive NKT Subpopulations and Immune-Checkpoint Pathways in Early-Onset Preeclampsia and Healthy Pregnancy. International Journal of Molecular Sciences, 2023, 24, 1390.	1.8	0
2069	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell International, 2023, 23, .	1.8	5
2070	Strahlentherapie und Immuntherapie. Springer Reference Medizin, 2023, , 1-20.	0.0	0
2071	Real-time detection of T cell activation by visualizing TCR nanoclusters with a cholesterol derived aggregation-induced emission probe. European Journal of Medicinal Chemistry, 2023, 247, 115073.	2.6	1

#	Article	IF	Citations
2072	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. PLoS ONE, 2023, 18, e0281143.	1.1	4
2073	A Look at Emerging Therapeutic Targets for Gallbladder Cancer: A Multi-Omics Approach. , 2023, , 161-175.		0
2074	PD-L1: expression regulation. Blood Science, 2023, 5, 77-91.	0.4	5
2075	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. Pathology Research and Practice, 2023, 244, 154338.	1.0	3
2076	Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. Journal of Immunology Research, 2023, 2023, 1-17.	0.9	0
2077	Role of Monocyte-Derived Dendritic Cells (MoDCs) in Tumor Immune Response. , 2023, , 1-18.		0
2078	Immunotherapy: Targeting Cancer Cells. Biological and Medical Physics Series, 2023, , 179-217.	0.3	0
2079	Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	5
2081	The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases. , 2023, 245, 108399.		8
2082	Interferon-Î±2a induces CD4+ T cell apoptosis and suppresses Th1/Th17 responses via upregulating IRF1-mediated PDL1 expression in dendritic cells from Behcetâ€™s uveitis. Clinical Immunology, 2023, 250, 109303.	1.4	2
2083	The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. Biomedicine and Pharmacotherapy, 2023, 162, 114646.	2.5	7
2084	Association of B7H3 and B7H4 gene polymorphisms and protein expression with the development and prognosis of autoimmune thyroid diseases. Clinical Endocrinology, 2023, 99, 103-112.	1.2	1
2085	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0
2086	<scp>CD70</scp> and <scp>PDâ€L1</scp> (<scp>CD274</scp>) coâ€expression predicts poor clinical outcomes in patients with pleural mesothelioma. Journal of Pathology: Clinical Research, 2023, 9, 195-207.	1.3	2
2087	The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics. Processes, 2023, 11, 538.	1.3	0
2088	Novel Potential Mechanisms of Regulatory B Cell-Mediated Immunosuppression. Biochemistry (Moscow), 2023, 88, 13-21.	0.7	0
2089	Blocking CD47-SIRPÎ± Signal Axis as Promising Immunotherapy in Ovarian Cancer. Cancer Control, 2023, 30, 107327482311597.	0.7	5
2090	Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	32

#	Article	IF	Citations
2091	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics, 2023, 13, 1520-1544.	4.6	19
2092	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). International Journal of Cancer Care and Delivery, 2023, 3, .	0.0	0
2093	Effect of triple therapy with low-dose total body irradiation and hypo-fractionated radiation plus anti-programmed cell death protein 1 blockade on abscopal antitumor immune responses in breast cancer. International Immunopharmacology, 2023, 117, 110026.	1.7	1
2094	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
2095	Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. Journal of Thoracic Oncology, 2023, 18, 869-881.	0.5	14
2096	Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Molecular Cancer, 2023, 22, .	7.9	32
2097	Immunotherapy for Primary Cancers of Central Nervous System. , 2023, , 1-21.		0
2098	Guest Editorial: what can be done to improve cancer immunotherapies?. International Journal of Hematology, 2023, 117, 631-633.	0.7	0
2099	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. Cardio-Oncology, 2023, 9, .	0.8	1
2100	Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells. Cell Communication and Signaling, 2023, 21, .	2.7	1
2101	Novel technologies for applying immune checkpoint blockers. International Review of Cell and Molecular Biology, 2024, , 1-101.	1.6	2
2102	Dimerization of Transmembrane Proteins in Cancer Immunotherapy. Membranes, 2023, 13, 393.	1.4	1
2103	Immune checkpoint therapyâ€"current perspectives and future directions. Cell, 2023, 186, 1652-1669.	13.5	114
2104	Current Medicinal Insights on Synthetic Small Molecules and Natural Origin Products as PD-1/PD-L1 Inhibitors. Current Topics in Medicinal Chemistry, 2023, 23, .	1.0	0
2105	Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2106	The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. , 2023, , 173-192.		0
2123	Research progression of PD-1/PD-L1 in non-small cell lung cancer. , 2017, 3, 111-115.		0
2131	Predictive genomic biomarkers of therapeutic effects in renal cell carcinoma. Cellular Oncology (Dordrecht), 0, , .	2.1	0

#	Article	IF	Citations
2157	Immunotherapy for Melanoma. , 2023, , 1693-1712.		0
2161	Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies. Frontiers of Medicine, 2023, 17, 805-822.	1.5	1
2163	Molecular insight into renal cancer and latest therapeutic approaches to tackle it: anÂupdatedÂreview. , 2023, 40, .		0
2164	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. 3 Biotech, 2023, 13, .	1.1	0
2174	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. British Journal of Cancer, 2023, 129, 1409-1416.	2.9	4
2178	Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death and Disease, 2024, 15, .	2.7	0
2198	Immune-oncological drug atezolizumab. , 2024, , 89-101.		0